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This study aimed at evaluating the antimalarial, toxicity and phytochemical profile of Cucumis 
metuliferus and Lippia kituiensis used for treatment of malaria in Tanzania. Pulverised plant 
materials were sequentially extracted in chloroform, ethyl acetate and methanol, the solvent 
was removed using a rotary evaporator. This extracts were evaluated for antimalarial activity 
using animal model infected with Plasmodium berghei. The negative and positive controls 
were treated with 1% DMSO and chloroquine (CQ) respectively. Cucumis metuliferus 
percentage suppression was 98.55%, 88.89% and 84.39% for chloroform, methanolic, and 
ethyl acetate extract respectively. For L. kituiensis the percentage suppression was 95.19%, 
93.88% and 74.83%, for ethyl acetate, chloroform and methanolic extracts respectively at a 
dose of 1500, 600 and 300 mg/kg respectively. Phytochemical profile of C. metuliferus and L. 
kituiensis methanolic, ethyl acetate and chloroform leaf extract were also determined by GC-
MS technique. The analysis revealed the presence of 11 major compounds. Moreover, the 
extracts were evaluated for acute and sub-acute toxicity. In acute toxicity test, the result showed 
no significant difference was observed in behavior, body weight and hematology parameters.  
The LD50 of the C. metuliferus and L. kituiensis extracts in mice was determined to be not 
greater than 2000 mg/kg body weight. In sub acute toxicity the rats were orally treated with 
doses of 150 mg/kg, 300 mg/kg and 500 mg/kg body weight. The results revealed a significant 
change in body weight, organ weight, hematological and biochemical parameters of rats 
administered with 300 mg/kg and 500 mg/kg body weight. Histopathological examination 
revealed the distraction of glomerula and bowman’s capsule, distraction of tubules and 
inflammation of kidneys and bile duct hyperplasia, hepatic necrosis and vacuolation of the liver 
while the lung showed thickened alveolar wall in a dose of 300 mg/kg and 500 mg/kg body 
weight. These findings suggest that C. metuliferus and L. kituiensis have demonstrated 
antimalarial activities, but with toxicity. To reduce their toxicity and improve their 
pharmacologic properties, the study suggests that isolation, characterization, structural 
elucidation of different types of bioactive compound with high potency may serve as candidate 
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1.1 Background of the study 
Malaria is a vector-borne disease caused by protozoan plasmodia parasites namely Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malaria and Plasmodium ovale and the most 
severe form of malaria is caused by P. falciparum (Kantele et al., 2011), that accounts for over 
96% of all malarial infections in sub-Saharan Africa (Galshir et al., 2001; Marsh et al., 1995). 
Malaria can be transmitted by infective bites from a female Anopheline mosquito or, rarely, 
through transfusion of infected blood products or in utero from the mother to the newborn 
through the placenta and during delivery (Malhotra et al., 2006). This parasite targets the 
erythrocytes by shuttling its own proteins into the surface of the erythrocytes, as a result, the 
erythrocytes stick to the blood vessels (Bhattacharjee et al., 2012). The stickiness of the 
erythrocytes with the veins is the key factor that leads to hemorrhagic problems of malaria 
(Adm, 2002). However, the management of malaria is complicated because the parasites that 
cause the disease are resistant to most of the safest and cheapest first line treatments developed 
so far.  
1.1.1 Global burden of Malaria 
Malaria is an important disease that has a global distribution and a significant health burden. 
In 2016, there were an estimated 445 000 deaths from malaria globally, compared to 446 000 
estimated deaths in 2015 as reported by World Health Organization (WHO, 2017). The WHO 
African Region accounted for 91% of all malaria deaths in 2016, followed by the WHO South- 
East Asia Region (6%). Fifteen countries accounted for 80% of global malaria deaths in 2016, 
all of these countries are in sub-Saharan Africa, except for India (WHO, 2017). According to 
the world health report, about 214 million cases of malaria were reported worldwide in 2015, 
and an estimated 446 000 deaths (WHO, 2015), 92% of all malaria deaths occur in Africa 
region (WHO, 2016). Most malaria cases in 2016 were in the WHO African Region 90%, 
followed by the WHO South-East Asia Region 7% and the WHO Eastern Mediterranean 
Region 2% (WHO, 2017). As shown in Fig. 1, in Sub-saharan Africa, malaria remains a major 
public health hazard owing to its high morbidity and mortality despite being the focus of 
significant financial support and research. It is estimated that malaria costs Africa USD 12 
billion per year in direct costs and reduces GDP growth by 1.3% annually (WHO, 2014). The 
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burden is carried mostly by poor, rural families that have less access to current prevention and 
treatment services. The reduction of malaria occurrence and transmission of parasites from 
humans to mosquitoes have been achieved largely through the use of insecticide treated 
mosquito nets (ITNs) and indoor residual spraying (IRS). The burden has been reduced by an 
estimate of 55% in children by the use of ITN whereas about 116 million people worldwide 
reported to be protected by IRS in 2014 (WHO, 2015). In addition, Artemisinin-based 
combination therapies (ACTs) are highly effective against P. falciparum, the most prevalent 
and lethal malaria parasite affecting humans. Globally, the number of Artemisini-based 
Combination Therapy treatment produced by manufacturers estimated to be 409 million 
treatment courses of Artemisinin-based Combination Therapy (ACT) in 2016, an increase from 
311 million in 2015. Over 69% of these procurements were reported to have been made for the 
public sector. The African Region accounted for most (99%) manufacturer deliveries of ACTs 
in 2017. Despite such efforts, malaria still represents a major health burden, particularly in 
Africa. Therefore, more effort in many Africa countries is needed to address these challenges. 
 





1.1.2 Malaria in Tanzania 
Malaria remains a major public health problem in sub-Saharan Africa, with approximately 1 
million deaths and more than 400 million cases a year. Over 93 % of the Tanzania mainland 
populations live in areas where malaria is endemic. In Tanzania, there is great variation in the 
risk of malaria transmission and prevalence ranging from 1–33 %, with an average of about 
10 % as reported by The Tanzania Commission for AIDS (TACAIDS, 2012). Malaria risk in 
Tanzania is diverse with malaria prevalence rates, parasite densities and entomological 
inoculation rates varying from one area to another. The prevalence rates usually vary by region 
from <1% in Northern parts to >30% along the Lake Victoria shores. In Tanzania Mainland, it 
is estimated that more than 90% of the 44 million people are at risk of contracting malaria and 
about 10-12 million malaria cases cost their lives annually as reported by Ministry of Health 
and Social Welfare (MOHSW, 2015). Plasmodium falciparum accounts for 96% of malaria 
infection in Tanzania, with the remaining 4% due to P. malariae and P. ovale as reported by 
The United States Agency for International Development (USAID, 2013). The principal 
vectors of malaria in Tanzania are mosquitoes of the Anopheles gambiae complex (USAID, 
2013). Contrary to that, morbidity and mortality have been substantially reduced, with a 
decrease of ≥75% in the numbers of malaria cases, in-patient malaria cases and deaths in recent 
years (WHO, 2016). The decline of malaria burden in many parts of the country attributed to 
the deployment of malaria interventions including mass distribution of insecticide treated nets 
(ITNs), Indoor residue sprays (IRS) and treatment with antimalarials (Jacobson et al., 2014). 
Additionally, changes in malaria treatment policy in 2006 from Sulphadoxine/pyrimethamine 
to Artemisinin-based Combination Therapy (ACTs) as first line drug for malaria treatment in 
Tanzania National Malaria Control Programme (NMCP, 2006). Despite such reduction, 
residual malaria is still observed in many parts which still cause morbidity and mortality both 
in rural and urban areas (Russell et al., 2015). Therefore, efforts are still needed to maintain an 
effective surveillance system to prevent and to treat malaria properly as the risk of Plasmodium 
falciparum resistance to available drugs and insecticides is still high. In this context, the search 
for new anti-malarial agents remains a priority. 
1.1.3 Malaria and life cycle of plasmodium species 
There are numerous transitions and stages, which comprises the life cycle of the malaria 
parasites and these can be divided into three main stages as shown in Fig. 2. 
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(i) Mosquito stage: This is also referred to as the sexual stage from gametocytes to 
sporozoites in the female Anopheles mosquito.  
(ii) Human liver stage: This is the asexual exo-erythrocytic schizogony (tissue schizogony 
or the multiple fission of a trophozoite or schizont into merozoites) in the liver cells of 
the primate host.  
(iii) Human blood stage: This is the asexual erythrocytic schizogony in the red blood cells. 
When an infected female Anopheles mosquito bites a person, elongated motile 
sporozoites in her saliva are injected into the human blood circulation (step 1). The 
parasites rapidly leave the blood circulation and are taken up into the liver, where they 
pass through the Kupffer cells and infect the hepatocytes to initiate the human liver stage 
infection (step 2). This asymptomatic tissue stage of infection lasts for 5 to 16 days, 
depending on the species of Plasmodium. However, in all species of Plasmodium, these 
parasites multiply and develop to form exo-erythrocytic (tissue) schizonts from which 
several thousand merozoites develop (step 3). In Plasmodium vivax and Plasmodium 
ovale only, a proportion of the liver stage parasites remain in the hepatocytes as a 
dormant form or hypnozoite (Hemmer, 2006). 
This stage of the parasite can remain dormant for a few weeks or up to several years and can, 
therefore, start a life cycle of asexual reproduction without the need for further mosquito bites. 
Hence, the P. vivax infection is also referred to as relapsing malaria. However, in P. falciparum 
and P. malariae infections, the tissue schizonts rupture more or less simultaneously leaving no 
form of the parasites in the liver. The infected hepatocytes rupture and release these merozoites 
into the bloodstream as aggregates called merosomes that allow the merozoites to evade 
antibodies and rapidly invade red blood cells (step 4). This initiates the human blood stage or 
the erythrocytic cycle of infection. The intra-erythrocytic parasites undergo asexual 
development from young ring forms to trophozoites and finally to mature schizonts. Asexual 
blood stage parasites produce 8-20 new merozoites every 48 hours (or 72 hours for P. 
malariae), causing the parasite number to rise rapidly to higher levels in the human host. The 
P. falciparum is also distinguished by its ability to bind to end othelium during this blood stage 
of the infection and sequester in organs, including the brain. Antibodies that blocks (step 5) 
binding of P. falciparum-infected erythrocytes to end othelium might prevent disease and 
control parasitemi. The asexual stages are pathogenic whereas the sexual stage parasites are 
non-pathogenic but transmissible to the Anopheles vector (Aravind et al., 2003). The parasites 
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replicate synchronously to release more merozoites into the blood stream leading to the 
classical cycle of fever that is observed as afebrile clinical attack. The released merozoites then 
invade more erythrocytes to continue the cycle, which proceeds until the death of the host or 
modulation by drug treatment or acquired immunity (step 6). At a certain stage of malaria, 
some merozoites infecting red blood cells differentiate into sexual forms known as male and 
female gametocytes (step 7). In P. falciparum, these are formed in the later stages of infection. 
By contrast, they are formed at the same time as the asexual stages in P. vivax. Gametocytes 
are taken up into the female Anopheles mosquito gut during a blood meal to initiate the 
mosquito stage of infection (step 8). The male gametocytes are activated (ex- flagellation) 
followed by male gametogenesis to form gametes which fuse with the female gametes 
(fertilization) in the gut of the insect to form diploid ookinetes. These ookinetes migrate to the 
midgut of the insect and the resulting zygote develops in the gut wall to form the oocysts (step 
9). These eventually give rise to the infective sporozoites by meiotic division and then migrate 
to the salivary gland of the mosquito (Fidock et al., 2004). The periodicity of parasitaemia and 
febrile clinical manifestations in tertian or quartan malaria thus depends on the timing of 
schizogony of a generation of erythrocytic parasites (Goodman & Gilman, 1992). 
 





1.1.4 Malaria and natural products drug development 
Natural compounds have been the source antimalarial drug known to date. Recent surveys have 
identified many extracts of various organisms (mostly plants) as having antiplasmodial activity. 
Huge libraries of fractionated natural compounds have been screened with impressive hit rates. 
Natural products are the sources of the two most important drugs currently available to treat 
severe falciparum malaria, that is, quinine and artemisinin derivatives. In the case of 
artemisinin, relatively simple chemical modification of the natural product parent compound 
has led to a series of highly potent antimalarials that are playing an increasingly important role 
in the treatment of malaria (Meshnick, 2002). With the current spread of drug resistance and 
the emergence of artemisinin-resistant parasites, new drugs for the treatment of malaria are 
urgently needed. However, the challenge facing malaria chemotherapy today is to find safe and 
selective agents whose potencies are not compromised by malaria parasite resistance and thus 
promote more efforts to discover lead compounds providing valuable bioactive scaffolds, 
which could be further adjusted by semi-synthetic approaches to obtain effective antimalarials. 
1.1.5 Screening of traditional medicinal plants for antimalarial activities 
In sub-Saharan Africa and other parts of the world where malaria is endemic, herbal remedies 
are commonly used to treat the disease. The understanding is that traditional medicinal plants 
that are employed for the treatment of malaria represent a potential for discovery of lead 
molecules for development into potential antimalarial drugs (Rukunga et al., 2007). In most 
African, about 80% of the population rely on medicinal plants for primary health care (WHO, 
2008b), and since the discovery of artemisinin as an effective antimalarial isolated from the 
herb plant Artemisia annua a lot of interests have shifted to plant sources as antimalarial agents 
Klayman et al., (1985). The screening of plants known to cure malaria in ethno medicine is 
therefore, an important strategy in the treatment and control of malaria. Cucumis metuliferus 
and Lippia kituiensis are some of the medicinal plants traditionally used to treat malaria in 
Tanzania. Cucumis metuliferus (Cucurbitaceae) also called ‘African horned cucumber’ is a 
monoecious, climbing annual herb, with staminate flowers typically appearing several days 
before pistillate flowers (Morton et al., 1987). The fruits are ovoid berries of between 8 and 
10-centimeter-long, 4 and 5 cm in diameter, reddish orange at maturity, hanging, and covered 
with strong spiny out-growth (Benzioni et al., 1993). It occurs in tropical Africa, especially 
Nigeria, Botswana, South Africa, Namibia, Zimbabwe, Malawi and Tanzania (Morton et al., 
1987). In some areas this plant has been used by traditional healers for the management of 
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various ailments including peptic ulcer disease, diabetes mellitus, hypertension and HIV/AIDS 
(Personal communication, 2006). The fruit pulp was found to possess alkaloids, flavonoids, 
glycosides, which are known to produce biological activity. Information on toxicological 
studies done on the plant material is not much however, Wannang et al. (2007) demonstrated 
that the extract altered serum enzymes in laboratory animals. 
Lippia is a genus of flowering plants in the verbena family, Verbenaceae. The genus contains 
roughly 200 species of tropical shrubs that are found around the world. Plants are fragrant due 
to their essential oils, which vary between species but may include estragole, carvacrol, 
linalool, or limonene. The leaves of certain species, such as L. graveolens, can be used as a 
culinary herb similar to oregano. Lippia species are also used traditionally for the treatment of 
a variety of ailments such as gastrointestinal, respiratory complaints and for relaxation and 
sedation (Joubert et al., 2011). Other studies also linked the use of Lippia kituiensis and C. 
metuliferus multiflora to the treatment of blood pressure, malaria, diarrhea and mild 
hypertension (Arthur et al., 2011). 
However, little scientific information about their antimalarial activities against Plasmodium 
species and safety for use are available. It is important, therefore, to investigate the antimalarial 
activities of these plants to determine their potentials as new antimalarial compounds 
1.2 Problem statement 
Malaria is a major public health problem that is currently complicated by the increasing 
resistance of P. falciparum against the mainstay drugs (Batista et al., 2009; Nguta et al., 2011). 
Despite extensive efforts to control malaria, the disease remains a major public health threat 
throughout the tropics, with persistent severe malarial morbidity and increasing resistance to 
malaria drugs, including new artemisinin-based combination therapy (ACT). There is a 
compelling need for new and improved treatments for malaria. Discovery of the lead 
compounds against malaria parasites is a crucial step to ensure a sustainable global pipeline for 
effective antimalarial drugs. 
Considering important roles for natural products in the treatment of malaria, the screening of 
medicinal plants that are traditionally used to treat malaria is a credible approach to discover 
new antimalarial leads. In view of the increasing use of medicinal plants, it is necessary to carry 
out toxicity studies to determine lethality and the safest and effective dose that is appropriate 
for human consumption with a view to validate and document the safety of these medicinal 
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plants with antimalarial properties to the society. This study, therefore, focused on the 
antimalarial activity, toxicity and phytochemical analysis of two medicinal plants namely 
Lippia kituiensis and Cucumis metuliferus growing in Tanzania. These plants were selected on 
the basis of the literature reviews and verbal information collected from local traditional healers 
in Ugweno ward within Mwanga District, Kilimanjaro Region in Tanzania. 
1.3 Rationale of the study 
About 80% of the World’s people rely on Traditional medicine (UNEP, 2010). Plants have 
always been considered to be an alternative source of new drugs and some of the antimalarial 
drugs in use today such as artemisinin were derived directly from medicinal plants or structures 
modeled on plant derived compounds (Nguta et al., 2010). The important advantages for 
therapeutic uses of medicinal plants in various ailments are their safety, economical, effective 
and easy availability. Increased side effects of conventional drugs/development of resistance 
by parasites that cause malaria has become a global concern and thus highlights the need to 
develop novel antimalarial drugs that are not only active against drug resistant parasites, but 
more importantly, kill persistent parasites and shorten the length of treatment. 
1.4 Objectives 
1.4.1 General objectives 
The general objective of this study was to evaluate antimalarial activity, toxicity and 
phytochemical analysis of L. Kituiensis and C. metuliferus used for management of malaria in 
Tanzania. 
1.4.2 Specific objectives 
(i) To evaluate in-vivo ant plasmodium activity of L. kituensis, and C.metuliferus species 
found in Tanzania. 
(ii) To screen for phytochemical compound present in L. kituiensis and C. metuliferus extract 
by using Gas Chromatography-Mass Spectrometry (GC-MS).  
(iii) To evaluate in-vivo acute and sub acute toxicity of L. kituiensis and C. metuliferus extract 
in mice and rats’ models respectively. 
1.5 Research questions 
The study sought to answer the following questions 
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(i) What are the ant-plasmodium potentials of crude extract of leaves from Lippia kintuensis 
and Cucumis metuliferus species? 
(ii) What are the phytochemical constituents present in Lippia kintuensis and Cucumis 
metuliferus of methanol, ethyl acetate and chloroform extracts? 
(iii) What are the acute and sub acute toxicity effects in albino rats of crude extracts of Lippia 
kintuensis and Cucumis metuliferus species? 
1.6 Significance of the study 
This study opens up the search for novel antimalarial ‘leads’ from L. kituiensis and C. 
metuliferus the medicinal plants with reported antimalarial efficacy and locally used to treat 
malaria in Tanzania. This study also illustrates secondary metabolites that can be associated 
with their antimalarial efficacy. In this study, the compounds associated with antimalarial 
efficacy of plant extract are highlighted, paving the way for further research to be done to 
isolate the identified compound(s). 
The in vivo toxicity profiles from L. kituiensis and C. metuliferus have been made evidenced 
in this study. The study has shown that the toxicity of the extracts from the plant exceeded the 
therapeutic levels hence these plants should be used with care. This research adds to the current 
knowledge on the effectiveness of the plant and thus validates its ethnobotanical value for local 
communities. This data can extensively contribute to policy development towards the 
channeling of safe and efficacious medicinal plants to primary healthcare, particularly in 
Malaria management. In addition, with the increasing interests in medicinal plants, the present 
study revealed the possibility of developing plant-based antimalarial agents for the treatment 
of malarial diseases. Furthermore, the study provided scientific evidence on the toxic effects 
of these plants in animal models. 
1.7 Delineation of the study 
This research is concerned with evaluatig antimalarial activity and its compounds of two 
medicinal plants namely C. metuliferus and L. kituiensis used traditionally to treat malaria in 
Tanzania. Furthermore, the study provided scientific evidence of the efficacy of these plants 
through in vivo-acute and Sub-acute toxicity in an animal model, that all plant materials 
entailed for medical purposes should be thoroughly tested for their efficacy and safety before 
being approved for human consumption. The antimalarial activity of these two plants was 
expressed by counting the number of parasites in a given volume of the blood. The study aimed 
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to use the mice model to test the activity of these plants against Plasmodium berghei. This 
result has established the rationale for the traditional use of the plants in the treatment of 
malaria. 
The study uses GC-MS to reveal unique chemical classes present in the L. kituiensis and C. 
metuliferus that might be responsible for the antiplasmodial effect against Plasmodium berghei. 
The study identified unique chemical classes present in the C. metuliferus and L. kituiensis that 
the antimalarial effects observed may be attributed to these compounds observed. The study 
went far on evaluating adverse effects or safety of a substance that result either from a single 
and multiple exposures within 14 and 28 day to determine the toxicity of the substance. The 
study uses a mice model to test toxicity for single exposure and rat’s model for everyday doses 
the plants showed severe toxic to animals. Since malaria is a major public health problem that 
presently is complicated by the increasing resistance of P. falciparum against the current drugs, 






2.1 Historical background 
Effective malaria treatment originated in the 17th century with quinine, extracted from the back 
of the cinchona tree (Cinchona officinalis) (PATH, 1990). For more than three centuries 
quinine and other alkaloids of cinchona trees, such as quinidine, cinchonine and cinchonidine 
were the only effective drugs available for the treatment of malaria (Brautbar et al., 1985). In 
recent times, however, synthetic antimalarials were introduced as they were found to be 
superior to quinine and also less toxic (Brautbar et al., 1985). These include 8-amino quinolines 
e.g. primaquine; 4-aminoquinolines e.g. chloroquine and amodiaquine; biguanides e.g 
proguanil, diamino Pyrimidine e.g. pyrimethamine, sulfones and sulfonamides and antibiotics 
e.g. tetracycline. For these synthetic antimalarials, chloroquine was found to be excellent both 
as curative and preventive, with a very wide range of other useful qualities. It is non-toxic safe, 
reliable, inexpensive and highly effective and a rapid blood schizontocide against all forms of 
malaria parasites. Therefore, at that time it was adopted as the first line drug of choice (PATH, 
1990; Bruce-Chwatt et al., 1985). In the 1960’s, however, resistant strains of P. falciparum 
began to emerge in South – East Asia and Latin America (PATH, 1990). In Africa, resistant P. 
falcipanum malaria was first reported in Kenya by Jepsen et al. (1979) and since then it has 
spread throughout the continent, with resistance first recorded in Nigeria (Olorunnisola et al., 
1989; Daniel et al., 1989). The widespread resistance to chloroquine and other synthetic 
antimalarials necessitated the development of alternative second line drugs such as 
Sulphadoxine/Pyrimethamine, Pyrimethamine/Sulphaline, sadly cases of resistance to these 
second line drugs became widespread and persistent. It is creditable to note that the emergence 
of widespread resistance of P. falciparum to chloroquine, the drug of choice, led to additional 
studies that produced new recent and effective antimalarial drugs the artemisinin derivatives 
(Ozer et al., 2007). These artemisinin based compounds which were developed first in China 
fortunately happened to arrive on the market just at a time when resistance to earlier drugs was 
becoming a very serious issue (Anderson et al., 2007). The World Health Organisation 
recommended that all countries experiencing resistance to monotherapies such as chloroquine, 
primaquine should use artemisinin-based combination therapies in order to ensure a high cure 
rate of P. falciparum malaria and to reduce the spread of resistance (WHO, 2006). As a result, 
the majority of falciparum malaria endemic countries have adopted Artemisinin-based 
Combination Therapy (ACT) as first line treatment and the deployment of ACTS in the public 
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sector has increased exponentially in recent times (WHO, 2006). In order to delay eminent 
emergence of resistance, artemisinins are now combined with long-acting drugs, especially 
with amodiaquine, mefloquine, lumefantrine or sulfadoxine-pyrimethamine (Gotep et al., 
2009). Currently four artemisinin combination therapies (ACTs) are recommended for 
treatment of malaria: Artemether-lumefantrine, artesunate-amodiaquine, artesunate-
mefloquine and artesunate –sulfadoxine – pyrimethamine (WHO, 2015). 
2.2 Resistance to antimalarial drugs and the use of artemisinin combination therapy 
(ACT) 
Resistance is defined as ‘the ability of a parasite strain to survive and/ or multiply despite the 
administration and absorption of a drug in doses equal to or higher than those usually 
recommended but within limits of tolerance of the subject’ (WHO, 1973). The development 
and spread of P. falciparum resistance to most commonly used antimalarial drugs is a major 
challenge in the control of malaria since it hinders our capacity to roll back malaria (Olliaro et 
al., 2005). Some scientists such as Kochurova et al. (2009) pointed out that parasite resistance 
has caused some of the least expensive traditional antimalarial drugs to be ineffective. 
Additionally, they said that, because there is a concern that resistance will emerge against the 
current first-line drugs such as the ACTs, there is currently great interest in discovering the 
next generation of antimalarial drugs. A strategy that has received much attention recently to 
combat drug resistance is the use of a combination of antimalarial drugs, such as mefloquine, 
sulfadoxine/pyrimethamine (SP), or amodiaquine, with an artemisinin derivative (Vasu et al., 
2006). Currently, four artemisinin combination therapies (ACTs) are recommended for 
treatment of malaria: Artemether-lumefantrine, artesunate-amodiaquine, artesunate-
mefloquine and artesunate - sulfadoxine – pyrimethamine (WHO, 2009). Balogun (2003) 
seems to have somehow a contrary view of malaria therapy using ACT in Africa. He said that 
while ACT unquestionably holds wonderful promise as a malaria treatment, the reality of ACT 
today is somewhat problematic. One problem he noted was availability; that substantial 
quantities of quality artemisinin drugs are actually hard to come by. The second problem is the 
cost. Artemisinin combination therapies are far more expensive than currently used treatments 
and more than most African economies can sustain. Be that as it may, ACTs are being used as 
first- line drugs for malaria treatment in most African countries (WHO, 2009). However, there 
is the fear among scientists that the most common and most debilitating malaria parasite in the 
tropics, P. falciparum, might soon develop resistance to artemisinin-based combination drugs. 
Bantie et al. (2007) pointed out that although the artemisinin derivatives retain excellent 
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efficacy, the selection of resistance to the artemisinin is a matter of time. He observed that since 
treatment courses are generally short, the artemisinin component is dependent upon the partner 
drug for adequate clinical efficacy. Furthermore, when resistance to the partner drug reaches 
critical level, the efficacy of ACTs would fall and would no longer be suitable for malaria 
treatment. 
2.3 Medicinal plants as alternative sources of antimalarial compounds 
Alsllami et al. (2007) pointed out that the problem created by drug-resistant strains of malaria 
especially P. falciparum in malaria therapy has accelerated antimalarial drug research over the 
last two decades. While synthetic therapeutic agents continue to dominate research, attention 
has increasingly been directed to natural products. Similarly, Grover et al. (2008) said that drug 
resistant strain of P. falciparum has compromised malaria therapy and has led to the search for 
new lead compounds in medicinal plants used in folk medicine for the treatment of the diseases. 
In search of new, safe, affordable and effective antimalarial drugs, phytochemical screening of 
extracts of plants used in traditional medicine becomes necessary as pointed out by Tchouankeu 
et al. (2007). Medicinal plants have been part of African cultures for centuries, therefore, the 
search for newer, more effective anti-malaria drugs is a major challenge (Jimam et al., 2007) 
and a very welcome development, and it is believed that traditional plants which have been 
used to cure malaria are bound to give us effective antimalarial compounds (Anderson et al., 
2007). Additionally, plants commonly used in traditional medicine are assumed to be safe due 
to their long usage in the treatment of diseases according to knowledge accumulated over 
centuries (Ajaiyeoba et al., 2006).  
2.4 Current status of drug discovery from plant sources 
Many medicines used against different diseases including malaria, cancer, diabetes, 
hypertension, neurodegenerative disorders and infectious diseases have been sourced from a 
plant or designed based on scaffolds of compounds isolated from plants. The latest of these 
include artemether (antimalarial), galantamine (for Alzheimer’s disease), nitisinone (for 
tyrosine-associated metabolic disorder) and tiotropium (anticholinergic), which have all 
recently been introduced in the United States or are currently involved in late-phase clinical 
trials (Balunas et al., 2005). Drug discovery from medicinal plants involves a multi-thronged 
approach that includes, but is not limited to traditional medicine practitioners, botanists, 
medicinal chemists, pharmacologists and molecular biologists. Conventionally, plants are 
selected either randomly or based on their claimed historical medicinal relevance and subjected 
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to sequential extraction and purification steps. This can be very tedious and time-consuming 
and more effective methods for identifying new lead molecules from plants have been 
explored. These include chemoinformatics and bioinformatics as tools for in silico drug 
discovery (Lagunin et al., 2014), systems/polypharmacology approach which integrates oral 
bioavailability tests, druggability, blood-brain barrier permeation, target identification and 
network analysis owing to the complex composition of medicinal plant extracts and their 
diverse physiological effects (Liu et al., 2013). High throughput pharmacological screens and 
genetic manipulation have also been applied to discover new drug leads from plants, in which 
plants extracts are screened against an array of receptors with or without gene manipulation 
and compared to existing drugs (Litteleton et al., 2005). 
2.5 Approaches in antimalarial drug discovery 
Six major approaches to antimalarial drug discovery have been identified and reviewed, 
including the investigation of natural products (Rosenthal et al., 2003). A plant-based approach 
is particularly useful in resource-poor, malaria-endemic areas where nearly one-fifth of patients 
rely on herbal remedies to treat malaria and febrile illnesses (Willex et al., 2004). The choice 
of plants for antimalarial drug discovery maybe based on both random and empirical methods 
to explore biodiversity or through studies guided by the traditional use of the plant in the 
treatment of fever. The latter ethnopharmacological approach has been recognized to give 
higher success rates for finding active compounds, as over 50% of extracts from ethno 
medicinal plants were active in vivo and/or in vitro (Cawalho et al., 1998). 
2.6 Ethnopharmacology-based plant selection and extraction 
Herbal medicines have played a pivotal role in health and disease management for many 
centuries. Different ancient civilizations, including Mesopotamian, Indian ayurveda, ancient 
traditional Chinese medicine and Greek unani medicine, show documented evidence for the 
use of herbs in the treatment of different ailments. In Africa, knowledge of traditional medicine 
constitutes part of a holistic system, passed through generations by oral communication and 
indigenous practices (Romero-Daza et al., 2002). The scientific exploitation of herbs used 
ethno medicinally for pain relief, wound healing and abolishing fevers has resulted in the 
identification of a wide range of compounds that have been developed as new therapeutics 
(Harvey et al., 2008). The major role of ethnopharmacology is to discover new plant-derived 
compounds based on the traditional use of medicinal plants. The knowledge on the use of plants 
for fevers and other symptoms of malaria are used to guide the selection of plants to be 
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subjected to antimalarial screening and isolation of active constituents. This is a favored and 
conservative approach in drug discovery as historical use of a plant as medicine increases the 
possibility that safe and pharmacologically active compounds would be isolated from it. 
2.7 In vivo and in vitro antimalarial activities of medicinal plants reputed to treat malaria 
The literature on researches conducted in the tropics and sub-tropics on the in vitro and in vivo 
antimalarial activities of plants traditionally used in the treatment of malaria and related fevers 
are vast. Screening of medicinal plants for antimalarial activities is a strategy employed by 
scientists in the malarious regions of the world to validate or justify or support the use of such 
plant remedies in malaria therapy. These researches are also efforts to produce the next 
effective, affordable and safe antimalarial drugs (Anderson et al., 2007).  
In vitro antiplasmodial evaluation studies involve the use of micro-test well plates for the 
assessment of the response of fresh isolates of Plasmodium species obtained from malaria 
patients (Berzins et al., 1997; WHO, 2001b; Basco & Ringwald, 2007) or from continues 
cultures of chloroquine sensitive or resistant strains of P. falciparum (O’Neil et al., 1986; 
Ngemenya et al., 2006; Omar et al., 2007). On the other hand, the evaluation of in vivo 
plasmodial activity normally involves the inoculation of experimental animals (mice or rats) 
with Plamodium berghei followed by administration of drug or extract to observe therapeutic 
effects (Abosi et al., 2003; Okokon et al., 2006; Bickii et al., 2007; Ogbunufagor et al., 2008).  
Jenett-Siems et al. (1999) studied the in vitro antiplasmodial activity of Central American 
medicinal plants. Their result revealed antiplasmodial activity in vitro of some of the remedies 
tested and concluded that selection of plants by ethnobotanical criteria may provide promising 
sources of potential antimalarial lead compounds. The antimalarial activity of Swartziamada 
scariensis, Cumbretum glutunosum and Tinosporabakis, Burkina Faso medicinal plants was 
evaluated by Ouattara et al. (2006). They reported that the extracts of S. madagascariensis, C. 
glutunosumand T. bakis possess some measure of antimalarial activity. The in vitro 
antiplasmodial activity of Enicostemmalittorale, a plant traditionally used for malaria treatment 
in India, was evaluated by Soni et al. (2009). Their report demonstrated the antiplasmodial 
activity of E. littorale against P. falciparum and the potential antimalarial action of the plant 
and its active phytoconstituents. Moreover Ngemenya et al. (2006) screened some products of 
Turreanthus africanus, a plant used in traditional medicine to treat malaria in Southwest 
Cameroon. Their result showed that T. africanus has weak antiplasmodial activity, which 
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probably when combined with other antiplasmodial plants results in enhanced antimalarial 
effect. Kayembe et al. (2010) investigated the in vitro antimalarial activity of 20 quinones 
isolated from 4 plants used by traditional healers in the Democratic Republic of Congo. They 
reported that quinones isolated from Cassia alata, C. occidentalis, Garcinia kola and Ocimum 
basilicum have interesting antimalarial activities IC50 < 1 μg/ml for 12 of them. In the same 
vein, Bero et al. (2009) evaluated the in vitro antiplasmodial activity of crude extracts of 12 
plant species traditionally used in Benin for the treatment of malaria in order to validate their 
use. Their study justified the traditional use of some of the investigated plants to treat malaria 
in Benin. They concluded that the dichloromethane extracts of Acanthospermum 
hispidumaerial parts, Keetialeucantha (leaves and twigs), Carpolobia lutea aerial parts and 
Strychnos spinosa leaves showed promising antiplasmodial activities. Ademowo et al. (2007) 
also investigated the in vitro antimalarial activity of methylene blue (MB) against field isolates 
of P. falciparum from children in Southwest Nigeria. Their preliminary study showed that MB 
has a potential to be used as schizonticidal antimalarial. The in vivo antimalarial activity of root 
bark and leaves of Vernonia amygdalina (bitter leaf) was evaluated by Abosi et al. (2003). The 
leaf extract produced 67% suppression of parasitemia while the rootbark produced 53% 
suppression, justifying the use of the plant parts for malaria treatment in herbal medicine. 
Ogbunogafor et al. (2008) also studied the tolerance and antiplasmodial activity of 
Ritchealongipedicellatain Plasmodium berghei. Their result revealed a dose dependent 
therapeutic activity, which means a higher dose is required to clear the parasites from the blood 
stream once infection has been established. The result also justifies the use of R. 
longipedicellata as an antimalarial in herbal medicine in Nigeria. Okokon et al. (2006) studied 
the in vivo antimalarial activity of stem bark of Mammea africana, a plant used traditionally by 
the Ibibios of the Niger Delta region of Nigeria for the treatment of malaria and related fever. 
They reported that M. Africana possesses antimalarial activity and therefore justifies its 
folkloric use as an antimalarial. Innocent et al. (2009) screened traditionally used plants in 
Tanzania for in vivo antimalarial activity in mice to establish the validity of their claims. Their 
work revealed that the extracts of six plants used in traditional medicine exhibited in vivo 
antimalarial activity, but three had very weak activity. They concluded that Caesalpinia 
bonducella root and Cassia abbreviate leaf ethanol extracts were the most promising.  
2.8 Toxicity studies 
Toxicity is the degree to which a substance can harm humans or animals. It can be measured 
by its effects on the target organism, organ, tissue or cells (Kifayatullah et al., 2014). The toxic 
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effects of a substance on animal physiology can range from minor changes such as reduced 
weight gain, small physiological alteration or change in the levels of circulating hormones, to 
severe effects in organ functional loss leading to death. Intermediate levels of toxicity may 
cause pain and suffering (Home office, 2004). During toxicity studies, five major aspects are 
put into consideration. These include organs affected by the chemical, relevance of 
quantification effect, concentration of the chemical to be tested, in vitro markers of toxicity 
that is relevant to the chemical and how to use the data from in vitro test for risk assessment 
(Said et al., 2000). 
Toxicological studies in the pharmaceutical field have been growing exponentially. These 
developments have been prompted by the discovery of teratogenic effects of drugs such as 
thalidomide, exposure of chemicals to the environment and employees and by conduct and 
assessment of toxicity studies as part of good manufacturing practice (Traina et al., 2006). In 
the study of herbal remedies, it has been found that toxicity may result from inadvertent 
substitution of one plant species another. For example, rapidly progressive renal failure 
resulting in end-stage renal disease has been reported in women who have taken weight-
reducing pills containing the Chinese herbs Stephania tetrandra and Magnolia officinalis. This 
so called Chinese–herb nephropathy is characterized by a pattern of interstitial fibrosis (Kripa 
et al., 2011). The cause of the disease was later noted to be due to inadvertent inclusion of 
Stephania fangchi containing the nephrotoxic and carcinogenic aristolochic acids instead of S. 
tetrandra that contains weight reducing tetrandrine (Nortier et al., 2000; Rotblatt et al., 2002). 
Another reported case on herbal toxicity involved patients using a dietary supplement 
containing herbal constituents yohimbine in addition to norephendrine, sodium usiniate and 3,5 
diiodothyronine. All patients developed hepatotoxicity within 3 months, recovering 
spontaneously on withdrawal of the supplement (Flavreau et al., 2002). Another study carried 
out in Zimbabwe confirmed an increase in incidences of poisoning by herbal remedy since 
1971 (Nyanzema et al., 1986). These facts support the need to have toxicity profiling of all 
herbal remedies. Qualitative toxicity assessment of a chemical substance in laboratory animals 
or in vitro toxicity testing gives information on its potential to cause toxic effects in humans or 
animals (Descote et al., 1996). To succeed in this exercise, an appropriate choice of control 
group must be selected, a sufficient number of laboratory animals used and a good selection of 
rigorous experimental protocols. Furthermore, the severity of the effect described on major 
organs and the relevance of the mechanisms involved including the variations in different 
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species assist in the extrapolation of toxicological findings from laboratory animals to man 
(Descote et al., 1996).  
During the study, the target organ of toxicity in laboratory animals are identified, the 
mechanism of induced changes is noted and compared to the properties of the target site in 
man. Determination of the toxic potential of new compounds constitutes a major part in drug 
development and it involves both in vivo and in vitro toxicological tests. These tests are very 
critical in the assessment of the safety of all pharmaceutical products before they are released 
for general use. Animal models are used in in vivo studies as indicators of human toxicity 
(Magna et al., 2007). Toxicity testing on herbal extracts is carried out on the same principles 
as conventional medicine. In vitro toxicity testing employs the use of models such as the brine 
shrimp lethality test (BST) whereas in in vivo methods, animals such as mice or rats are used. 
The advantage of the brine shrimp in toxicity testing is that the shrimp has a lot of homogeneity 
in eggs and in newly born nauplii which are highly sensitive to chemicals. The eggs are easily 
available and hatch with ease within 16-24 hours to the nauplii. The nauplii are utilized within 
24-48 hours post hatching. At 24 hours post exposure of nauplii to the test chemical, the 
concentration causing 50 % lethality (LC50) is determined. The BST method is used to screen 
for bioactivity, anticancer, cytotoxicity, toxicity, pesticidal activity or gastro protective action 
among other pharmacological effects of plant extracts. Brine shrimp lethality is a rapid method 
that is reliable, inexpensive and convenient as an in-house general bio-assay tool (Meyer et al., 
1982).  
This method is basically used to predict toxicity and the results obtained are compared with 
oral acute toxicity in rodents (Amenya et al., 2011). In vivo toxicity testing mainly employs the 
use of rats although other rodents may be used. Dogs and monkeys are restricted to advanced 
stages of testing (Amenya et al., 2011). Organization for Economic Cooperation and 
Development (OECD) guidelines are used during acute and sub-acute oral toxicity testing 
(Diener et al., 1995). It is important to optimize the information obtained by using the smallest 
number of animals to comply with animal welfare regulations. Further, it is important to avoid 
excessive pain or tissue damage in the animals, pharmaceuticals with irritant or corrosive 
characteristics should not be administered in concentrations that produce severe toxicity after 
administration. During toxicity studies, all the animals must be checked for morbidity, 
mortality and specific signs of toxicological relevance. For example, neuro functional and 
neurobehavioral, pharmacological observation, bodyweight and food/water intake. The key 
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hematological parameters investigated are mean corpuscular volume (MCV), mean 
corpuscular hemoglobin concentration (MCHC), haemoglobin levels, hematocrit levels, 
packed cell volume (PCV) total and differential leukocytes, erythrocytes and platelet counts. 
Clinical biochemistry is crucial to investigate major toxic effects on organs especially the 
kidney and the liver. Some of the parameters include total protein, albumin, major electrolytes, 
total cholesterol, alanine aminotransferase, aspartate aminotransferase, creatinine and alkaline 
phosphatase that aid in hepatocellular evaluation. All long-term studies such as chronic toxicity 
must include urinalysis (urine output, color, protein and osmolarity). Pathological studies and 
gross necropsy are done by examining the body, orifices, abdominal cavity, body weight and 
organ weight changes among others. In addition, histopathological studies are done on 
adrenals, lung, liver, kidney, testis, ovaries among others (OECD 407, 2008).  
These organs are considered to be the most important during toxicity studies in rodents and 
non-rodents (Michael et al., 2007). Taking the weights of organs is necessary because organ to 
body weight ratios or organ weight index (OWI) is commonly calculated and are considered 
more useful when body weights are affected (Michael et al., 2007). By carrying out toxicity 
tests, the effects of an increase in dose on the mortality and other effects of the lethal dose that 
kills are determined. Estimating different levels of toxicity by use of LD50 for instance can help 
in estimating the probabilities of an outcome for a given individual in a population. The 
determination of acute, sub-acute, subchronic and chronic toxic effects of the test compounds 
is therefore crucial (Traina, 2006). 
2.8.1 Acute toxicity 
Acute toxicity is caused by an agent when it is administered in one or more doses over a period 
not exceeding 24 hours and involves harmful effects to the organism through a single or short 
term exposure. Acute toxicity studies have also been used during the selection of starting doses 
for phase-I human and animal studies and provide information relevant to acute overdosing in 
humans and animals. The testing is based on the route of substance administration to the animal 
and therefore, it is classified from Class-1 to Class-5 for oral, dermal, gas inhalation, 
vapor/dust/mist inhalation and injection. Dosing can be repeated during the administration of 
test material by a variety of routes of exposure, including gaveling which involves stomach 
intubation or forced feeding, injection, skin, painting and inhalation. The acute toxic class 
method, a stepwise procedure, involves the use of three animals of a single sex per step. 
Depending on the mortality and/or moribund status of the animals, on average 2 to 4 steps may 
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be necessary to allow judgment on the acute toxicity of the substance. The OECD Guideline 
423 (2001) provides a reproducible method that uses few animals. 
2.8.2 Sub-acute toxicity 
The sub-acute toxicity test in the study was based on OECD guideline 407 (2008), repeated 
dose 28-day oral toxicity study in rodents. In this form of toxicity, adverse effects occur as a 
result of repeated daily dosing of a chemical or exposure to the chemical, for part of an 
organism's lifespan usually not exceeding 10 % of the animals’ lifespan. With experimental 
animals, the period of exposure may range from a few days to 6 months. Exposure for 28 days 
provides a first-hand indicator of potential sub acute toxicity. The test is intended to investigate 
effects on a very broad variety of potential targets of toxicity. It provides information on the 
possible health hazards likely to arise from repeated exposure over a relatively limited period 
of time, including effects on nervous, immune and endocrine systems. The duration of exposure 
is normally 28 days in rodents where results are used for hazard identification and risk 
assessment (OECD, 2008). All the knowledge gathered from the studies is used in selecting 
doses for repeat-dose studies as a source of preliminary identification of target organs of 
toxicity and may also reveal delayed toxicity. Sub-acute toxicity studies in animals are essential 
for any pharmaceutical product especially those intended for human use. 
2.8.3 Sub-chronic toxicity 
This is the ability of a toxic substance to cause effects for more than one year but less than the 
lifetime of the exposed organism. This form of toxicity is studied for at least 90 days in animal 
models notably rodents. The test is carried out after getting initial information on toxicity from 
acute or 28-day sub-acute toxicity studies. It provides information on possible hazards likely 
to arise from repeated exposures over a prolonged period of time covering post-weaning 
maturation and growth well into adulthood. The study provides information on the major toxic 
effects, indicates target organs and the possibility of accumulation. It can also provide an 
estimate of a non-observed-adverse effects level (NOAEL) of exposure which can be used in 
selecting dose levels for chronic studies and to establish safety criteria for human studies 





2.8.4 Chronic toxicity 
This is the ability of a substance or mixture of substances to cause harmful effects over an 
extended period, usually upon repeated or continuous exposure, sometimes lasting for the 
entire life of the exposed organism. The three main routes for chronic study include oral, dermal 
and inhalation depending on the characteristic of the test substance and the predominant route 
of exposure in humans. The objectives of chronic toxicity studies include identification of the 
hazard properties of a chemical, identification of target organs, characteristic of dose-response 
relationship and identification of NOAEL or point of departure of Benchmark Dose (BMD). It 
also helps in the identification of chronic toxic effects in human exposure levels and provision 
of data to test hypotheses regarding the mode of action (OECD 452, 2008). 
2.9 Future perspective of medicinal plants as antimalarial agents 
The importance of plants is becoming clear from the fact that more than 80% of the world 
population fulfills its medical needs from medicinal plants (Jimma et al., 2015). In some 
African countries such as Tanzania, about 60% of the people especially in rural areas rely on 
traditional medicines for their healthcare needs (Magano et al., 2001). Demand for these herbal 
medicines for therapeutic purposes is increasing and will continue in the future mainly because 
of less toxicity and side effects of these medicines (Balkema et al., 2007). Since the demand of 
such plants as antimalarial agents is highly increasing in both developed and developing 
countries, many of these plant species are at greater risk of being extinct (Martinez et al., 2013). 
According to the International Union for Conservation of Nature, there are many plant species 
that are used for medicinal purposes worldwide (IUCN, 2007). Among these species, few of 
them are threatened with extinction from overharvesting, especially in China, India, Nepal, 
Tanzania, Kenya and Uganda (Nalawade et al., 2003; Heywood et al., 2003; Zerabruk et al., 
2012). In order to alleviate this concern and to meet public demands, sustainable use of 
medicinal plants should be highly considered. Similarly, herbal medicines should be brought 
under legal control in all countries where they are used for therapeutic purposes and more 
efforts should be made to raise public awareness about the benefits and risk of extinction of 
these herbal medicines (Ramanan et al., 2007). Additionally, the development of genetic 
engineering and advancement in tissue culture can also be a promising alternative for the 






ANTIMALARIAL ACTIVITY OF Cucumis metuliferus AND Lippiakituiensis 
AGAINST Plasmodium berghei INFECTION IN MICE1 
Abstract 
The search for new antimalarial drugs has become progressively urgent due to plasmodial 
resistance to most of the commercially available antimalarial drugs. As part of this effort, the 
study evaluated the antimalarial activity of C. metuliferus and L. kituiensis, which are 
traditionally used in Tanzania for the treatment of malaria. In vivo antimalarial activity was 
assessed using the 4-day suppressive antimalarial assay. Mice were infected through an 
intraperitoneal route with 1 × 107 erythrocytes infected with Plasmodium berghei. Extracts 
were administered orally Chloroquine (10 mg/kg/day) and 1% of dimethylsulfoxide (5 
mL/kg/day) were used as positive and negative controls, respectively. The level of parasitemia, 
survival time, packed cell volume and variation in body weight of mice were used to determine 
the antimalarial activity of the extract. The chloroform, ethyl acetate and methanolic extracts 
of C. metuliferus and L. kituiensis significantly (p < 0.05) suppressed parasitemia in a dose-
dependent manner. The highest suppression was recorded at dose level of 1500 mg/kg. At this 
dose, C. metuliferus had percentage suppression of 98.55%, 88.89% and 84.39% of chloroform, 
methanolic, and ethyl acetate extracts respectively whereas L. kituiensis exhibited suppression 
of the pathogens of 95.19%, 93.88% and 74.83% ethyl acetate, chloroform and methanolic 
extracts respectively. The extracts prevented loss of body weight at a dose of 600 mg/kg and 
1500 mg/kg in all solvent’s extracts. In addition, the extracts prolonged the mean survival time 
of P. berghei-infected mice compared to the non-treated control. The significant reduction of 
packed cell volume was observed at a dose of 300mg/kg body weight. From this study, it can 
be concluded that the leaves extract of C. metuliferus and L. kituiensis showed good chemo 
suppressive thus supporting further studies of the plant for its active components 
Keywords: Malaria, Cucumis metuliferus, Lippia kituiensis, Plasmodium berghei, Crude 
extracts. 
                                                          




Substantial progress has been made in fighting malaria since the year 2000 (WHO, 2016). 
Estimates between 2000 and 2015 indicated that malaria case incidence has been reduced by 
41% and malaria mortality rates by 62% (WHO, 2016). At the beginning of 2016, malaria was 
considered endemic in 91 countries and territories down from 108 in 2000 (WHO, 2016). This 
progress is associated with the wide-scale deployment of malaria control interventions. Despite 
this remarkable progress, malaria continues to have a devastating impact on people’s health 
and livelihoods. It is estimated that 214 million cases occurred globally in 2015, leading to 446 
000 deaths, most of which were children aged under 5 years (WHO, 2016). The burden of the 
disease is heaviest in Africa, where 82 and 90 % of all global cases and deaths occurred, the 
report further indicates that 90% of all malaria deaths occur in African regions; 78% of all 
deaths occur in children under five years of age. Increased side effects of conventional drugs 
and the development of resistance by malaria parasites have become a global concern and thus 
call for continued efforts to search for antimalarial agents and plants. There fore; medicinal 
plants have made and continue to make a great contribution to antimalarial chemotherapy as 
they contain molecules with a great variety of structures and biological activities.  
Lippia kituiensis and C. metuliferus have been utilized by rural communities in Tanzania for 
the management of malaria. L. kituiensis belongs to the verbena families (Verbenaceae) which 
are aromatic due to their essential oils (Arthur et al., 2011). Apart from its use for the 
management of malaria, leaves are used as a culinary herb (Tucker et al., 2009). Camphor 
isolated from L. kituiensis essential oil was found to have a strong repellent activity against 
maize weevil compared with NN-diethyl toluamide (DEET) (Mwangi et al., 1992). It also used 
for the treatment of chronic joint pains, such as osteoarthritis and/or rheumatoid arthritis, but 
also in different farms, they use L. kituiensis for milk treatments in animals (Wambugu et al., 
2011). Cucumis metuliferus (Cucurbitaceae) is a monoecious annual herb with staminate 
flowers that grows wild (Wannang et al., 2007). The family is commonly referred to as African 
horned cucumber, jelly melon in English. Cucumis metuliferus is an annual climbing or rarely 
trailing herb; vegetative parts are rough with spreading hairs, its fruits occur in two forms - the 
bitter and non-bitter forms, which occur mostly in the wild state. It has been established that 
the fruit of C. metuliferus possesses antibacterial activity against S. gallinarum in vitro (Usman 
et al., 2014). The pulp extract of C. metuliferus was shown to have anti-ulcer property 
(Wannang et al., 2009). Glycosides extracted from the fruit pulp of C. metuliferus possess anti-
hyperglycemic activity against alloxan-induced diabetes mellitus in rats (Jimam et al., 2010; 
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Gotep et al., 2011; Tomar et al., 2014). Despite the fact that L. kituiensis and C. metuliferus 
are used in Tanzania for the management of malaria, there is no report on the antimalarial 
activity of the two plants. This paper reports antimalarial activity of methanolic, ethyl acetate 
and chloroform extract of C. metuliferus and L. kituiensis against Plasmodium berghei infected 
in mice. 
3.2 Materials and methods 
3.2.1 Collection and extraction of the plant materials 
Fresh leaves of L.kituiensis and C. metuliferus were collected from Ugweno ward 
within Mwanga District, Kilimanjaro region in Tanzania. Ugweno ward is situated at 3° 39' 0" 
South and 37° 39' 0" East in the Pare Mountains. Herbalists residing in Ugweno ward and a 
taxonomist (Josephat Mboya) were consulted and involved in the identification and collection 
of the plant materials. Voucher specimen coded (Voucher no. 160for C. metuliferus and 161 L. 
kituiensis) ware deposited at the Nelson Mandela African Institution of Science and 
Technology. 
Extraction of the plants: Extraction of the plants: The collected plant leaves were cleaned with 
tap water and dried under shade at room temperature for two weeks and coarsely powdered 
using an electric blender. Total extraction was employed in the extraction process in which 600 
g of the pulverized materials were divided into three portions (200 g each). The three portions 
were soaked with 80% methanol (1600 mL), 100% ethyl acetate (1600 mL) and 100% 
chloroform (1600 mL) for three consecutive days with occasional stirring in Erlenmeyer flask 
for 48 h at room temperature.  
After 48 h, the extracts were separated from the marc (the residue left after the extraction) using 
gauze and further filtered by Whatman filter paper No. 1 (Whatman®, England).  Solvents 
(80% methanol, 100% ethyl acetate and 100% chloroform) were removed through the vacuum 
using a rotary evaporator to obtain 134 g, 136 g and 138 g respectively. The portions of the 
yield were solubilized in 10% DMSO for confirmation of the antimalarial activity and the 
remaining was then kept in a refrigerator at -200C until further use. 
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3.2.2 Experimental animals 
Swiss albino male mice, weighing 25 to 27 g of 6 to 8 weeks old were collected at Sokoine 
University of Agriculture (SUA) and housed at Muhimbili University of Health and Allied 
Sciences (MUHAS) in plastic cages with softwood having and chips as beddings. They were 
exposed to a 12:12 dark-to-light cycle and provided with free access to a pellet diet and clean 
drinking water. All mice were acclimatized to the working environment for one week before 
the beginning of the experiment.  
3.2.3 Malaria parasites and materials 
Chloroquine-sensitive Plasmodium berghei was used for the induction of malaria in 
experimental mice. Blood stage P. berghei parasites used in the study were kindly donated by 
Dr. Lindsay Stewart of the Department of Pathogen Molecular Biology, London School of 
Hygiene and Tropical Medicine, United Kingdom. Materials and reagents: methanol (Okhla 
Industrial, India), Giemsa (Sciencelab, USA), trisodium citrate (Deluxe Scientific Surgico, 
India) and normal saline (Addis Pharmaceuticals Factory, Ethiopia), chloroform (Okhla 
Industrial, India), ethyl acetate (Okhla Industrial, India), Dimethylsulfoxide (DMSO) were 
purchased from Techno-Net Scientific (Dar es Salaam, Tanzania) whereas chloroquine 
diphosphate was purchased from Sigma (Sigma®, Steinheim, Germany) 
3.2.4 Preparation of infected red blood cells suspension 
In-vivo antiplasmodial activity of the crude extract against early P.berghei strain infection was 
carried out according to the method described by Peters et al. (1975). A donor mouse infected 
by chloroquine sensitive P. berghei strain with a rising parasitemia 40-45% was used for 
infecting mice in the 4thday suppressive test procedures. The donor mice were anesthetized by 
diethyl ether blood (parasitized erythrocytes) was collected by cardiac puncture into a test tube 
having 0.5 % trisodium citrate which was added as an anticoagulant. The inoculum was 
prepared by determining percentage parasitemia of the donor mice. According to Waako et al. 
(2005) appropriate inoculum for infecting mice had to be low to 1% by dilution process. In this 
dilution Phosphate Buffered Saline (PBS) 9.77 ml of PBS were required to dilute 0.23 ml of 
blood from the donor mice with 44.40% parasitemia to obtain 10 ml of blood with 1% 
parasitemia, which was used in infecting 50 experimental mice each receiving 0.2 ml of the 
diluted blood through intraperitoneal route containing approximately 1.0 ×107 parasitized cells. 
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3.2.5 Inoculation of parasites and administration of extracts 
Each mouse was infected through the intraperitoneal route with 1 × 107 iRBCs in 0.2 mL 
suspension of 1 × 107 iRBCs per mL. The extracts were solubilized in 10% DMSO and 
Chloroquine was dissolved in normal saline. Three hours post infection the mice were 
randomly allocated into groups, for L. kituiensis extract forty five (45) mice were grouped into 
three groups (chloroform, ethyl acetate and methanol of fifteen mice per group. Each group 
consists of three doses (300, 600 and 1500 mg/kg) having five mice in each dose making a total 
of forty five (45) mice, two females and three males. A similar procedure was repeated for C. 
metuliferus extract that forty five (45) mice were grouped into three groups (chloroform, ethyl 
acetate and methanol of fifteen mice per group. Each group consists of three doses (300, 600 
and 1500 mg/kg) having five mice in each dose making a total of forty five (45) mice, two 
females and three males different sex were separated to avoid physiological interaction like 
mating. Ten mice received a vehicle five as a positive control and five as negative control 
making a total of ninety five mice. The negative control group received 1% DMSO (5 
mL/kg/day), the positive control group received chloroquine 10 mg/kg/day and each mice was 
observed daily for determination of survival time. Treatment started three hours after mice had 
been inoculated with the parasite (Trager & Jensenon, 1976) at day 0 and then continued daily 
for four days from day 0 to day 3. On the 5th day (day 4), thin films were made from the tail 
blood of each mice and smear on to a microscope slide to make a film (Saidu et al., 2000). The 
blood films were fixed with methanol, stained with 10% Giemsa at pH 7.2 and parasitaemia 
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3.2.6 Determination of packed cell volume, mean survival time and body weight 
The cell Packed volume (PCV) of each mouse was measured before infection (D0) and after 
infection (D4). For this purpose, blood was collected from the tail of each mouse in heparinized 
microhematocrit capillary tubes. The tubes were sealed by crystal seal and placed in a 
microhematocrit centrifuge with the sealed ends outwards. The blood was centrifuged at 12 
000 rpm for 5 min. The volume of the total blood and the volume of erythrocytes were 
measured and PCV was calculated according to Mengistie (2012) as given below. 
100
 volumeblood Total
blood of megiven volu ain  eserythrocyt of Volume
XPCV   
3.2.7 Determination of mean survival time and body weight 
Mean survival time (MST) was determined according to Alli et al. (2011) mortality was 
monitored daily, the number of the days from the time of infection up to death was recorded 
for each mouse in the treatment and control groups throughout the follow-up period and the 
MST were calculated for each group by using the following formula. 
100
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The change of body weight of each mouse in all groups was determined before infection (D0) 
and after treatment (D4) by using sensitive electrical balance (ADP 720 L, Adam Equipment) 
(Krettli et al., 2009). Then, body weight change of extract treated groups was compared with 
the control groups. 
3.2.8 Ethical consideration 
Before the experimental work, an ethical clearance with notification number 
NIMR/HQ/R.8a/Vol. IX/2146 was given by the National Health Research Ethics Sub-
Committee (NatHREC) of the National Institute for Medical Research (NIMR) in Tanzania. 
3.2.9 Data analysis 
The data of the study were expressed as mean ±SD (standard deviation of the mean) for each 
group of experiments. Data on the levels of parasitemia, variations in body weight and survival 
times were analyzed using Statistical Analysis System (SAS). Values were considered 
statistically significant at P < 0.05 and more significant at P<0.01. All results were represented 
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asMean ± SD (n = 5) Values with different superscripts were significantly different (P < 0.05) 
and (P<0.01). 
3.4 Results 
3.4.1 In vivo evaluation of the antiplasmodial activity of plant extracts 
The results of in vivo antimalarial activity revealed that C. metuliferus and L. kituiensis extract 
exhibited dose dependent suppression of parasite growth. At a dose of 1500, 600 and 300 
mg/kg/day, of C. metuliferus extract, the highest suppression was obtained from chloroform 
(98%, 70%, and 48%) followed by methanolic (88%, 58% and 36%) and ethyl acetate (84%, 
64% and 30%) respectively as indicated in Table1. In lippia kituiensis extract the highest 
suppression was obtained for ethyl acetate (95%, 70% and 42%) followed by chloroform (93%, 
69% and 46 %) and methanolic extracts (74%, 68% and 35%) respectively as shown in Table 
2. All extracts of C. metuliferus and L. kituiensis leaf reduced parasite growth and the reduction 




Table 1: Antimalarial activities of methanolic, chloroform and ethyl acetate extracts of leaves of C. metuliferus and mean survival time of P. 
berghei infected mice 
Extract C. metuliferus Antimalarial activity on D4 post-infection Mean 
survival time (days) ± SD 
 Dose (mg/kg) % Parasitemia ± SD % suppression± SD 
Methanol 300 30.09±0.78* 36.99±1.64 9±1* 
 600 19.82±0.93** 58.91±1.68 10±2* 
 1500 5.49±0.30** 88.89±0.83 14±0** 
Chloroform 300 25.9±0.39** 45.81±1.22 9±1* 
 600 14.37±0.95** 70.69±2.86 10±1.52* 
 1500 1.10±0.13** 98.55±0.7 14±0** 
Ethyl Acetate 300 34.03±0.98* 30.73±2.73 7.66±0.57* 
 600 17.08±1.68** 64.23±3.53 10.33±1.52* 
 1500 8.95±0.47** 84.39±3.98 14±0** 
CQ 10 0 100 14±0 
NC  47.15±1.74 - 6.0±1 
Key: Values are presented as Mean ± SD; n = 5; DSMO = negative control (1 %); CQ positive control (chloroquine), NC negative control CQ chloroquine (positive control); * = values are 




Table 2:  Antimalarial activities of methanolic, chloroform and ethyl acetate extracts of leaves of L. kintuensis and mean survival time of P. 
berghei infected mice 
Extract L. kentuensis 
Extract antimalarial activity on D4 post-
infection 
Mean 









 Methanol 300 30.08±3.05* 35.94±5.49 9±1* 
 600 14.21±1.95** 68.76±3.34 12±2* 
 1500 12.46±0.52** 74.83±2.35 13±0* 
Chloroform 300 25.61±2.17** 46.38±4.63 9±1* 
 600 14.44±0.20** 69.96±0.50 12±1.52* 
 1500 3.75±0.38** 93.88±2.47 14±0** 
 Ethyl Acetate 300 27.74±3.60* 42.42±8 8±0.57* 
 600 14.64±1.57** 70.14±3.85 10±1.52* 
 1500 2.53±0.13** 95.19±1.11 14±0** 
CQ 10 0 100 14±0** 
NC  47.15±1.74 NC 6±1 
Key: Values are presented as Mean ± SD; n = 5; DSMO = negative control (1 %); CQ positive control (chloroquine), NC negative control CQ chloroquine (positive control); * = values are 
significantly different (p < 0.05) from that of the negative control); ** = values are more significantly different (p < 0.01) from that of the negative control. 
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3.4.2 Effect of extracts on packed cell volume (PCV) 
In the fourth-day suppressive test, packed cell volume (PCV) of P. berghei infected mice were 
measured. The results showed a significant (p < 0.05) reduction in packed cell volume (PCV) 
between day zero (D0-inoculation day) and day four (D4) in mice treated with chloroform, 
methanolic and ethyl acetate extracts of leaves of Lippia kituiensis at dose level of 300 mg/kg. 
Whereas mice treated with a dose level 600 mg/kg and 1500 mg/kg in chloroform, methanolic 
and ethyl acetate extracts did not show a significant reduction (Table 3). In Cucumis 
metuliferus, the mice treated with chloroform, methanolic and ethyl acetate extracts exhibited 
significant reduction (p < 0.05) in packed cell volume (PCV) between day zero (D0-inoculation 
day) and day four (D4) in mice treated at a dose of 300 mg/kg. While the mice treated with 
chloroform, methanolic and ethyl acetate extracts from the two plants at a dose of 600 mg/kg 
and 1500 mg/kg did not show significant (p > 0.05) PCV reduction (Table 4). 
3.4.3 Effect of extract on survival times of mice 
In the four-day suppressive test, 300 mg/kg, 600 mg/kg and 1500 mg/kg extract treated groups 
lived longer than the corresponding negative control. There were significant differences in 
survival times among extract treated groups of C. meturiferus and L. kituiensis in all solvent 
and dose levels as shown in Table 1 and Table 2. 
3.4.4 Effect of extract on body weights of mice 
In the 4-day suppressive test, all extract treated groups prevented body weight except in dose 
level 300 mg/kg of C. metuliferus and L. kituiensis in chloroform, ethyl acetate and methanolic 
extract between day zero (D0) and day four (D4) as compared to the negative control. However, 
there were no significant differences of weight in dose level 600 mg/kg and 1500 mg/kg in all 
extracts when compared with the control as shown in Table 3 and Table 4. 
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Table 3:  Effect of methanolic, chloroform and ethyl acetate extracts of Lippia kintuensis on body weight and PCV of P. berghei infected mice 
Extracts 
Dose (mg/kg) PCV   Body weight 
    D0 D-4  D0 D-4 
Methanol 300 51.23±1.21 43.32±5.6*  29.70±3.21 24.65±2.11* 
 600 50.12±2.32 48.13±1.3  30.11±1.63 28.24±2.12 
 1500 59.31±1.2 57.91±1.2  32.22±1.01 31.90±2.11 
Chloroform 300 51.23±1.50 44.21±2.3*  26.54±2.13 21.44±1.33* 
 600 51.32±2.3 49.23±1.2  29.33±1.55 27.12±1.5 
 1500 50.18±2.1 49.91±1.2  30.45±1.03 29.93±1.02 
Ethyl acetate 300 49.23±1.5 43.32±5.3*  32.12±0.23 25.52±3.23* 
 600 51.34±3.1 48.23±2.1  28.4±2.11 25.23±2.11 
 1500 50.32±1.2 49.32±0.1  28.15±1.23 27.25±2.55 
CQ 10 55.41±1.03 54.66±0.52  30.23±0.44 29.92±0.12 
NC  55.44±1.25 40.45±1.45*  32.17±1.4 25.13±4.35* 
Key: Values are presented as mean ± SD; n = 5; PCV packed cell volume, NC negative control (1% DSMO), CQ chloroquine (positive control); * = the difference between day 0 and day 4 is 
significant (P < 0.05). 
33 
 
Table 4: Effect of methanolic, chloroform and ethyl acetate extracts of Cucumis metuliferus on body weight and PCV of P. berghei infected 
mice 
Extracts 
Dose(mg/kg) PCV   Body weight 
    D0 D-4  D0 D-4 
Methanol      300   48.32±1.61 40.32±5.6*  28.70±3.21 22.65±2.11* 
      600 49.32±2.32 47.13±1.3  30.11±1.63 28.24±2.12 
      1500 51.31±1.2 49.91±1.2  32.22±1.01 31.90±2.11 
Chloroform      300 51.23±1.50 44.21±2.3*  26.54±2.13 20.44±1.33* 
      600 51.32±2.3 49.23±1.2  29.33±1.55 27.12±1.5 
      1500 53.23±2.1 52.32±1.2  30.45±1.03 29.93±1.02 
Ethyl acetate      300 50.23±1.5 40.32±5.3*  32.12±0.23 26.52±3.23* 
      600 51.34±3.1 49.23±2.1  27.14±2.11 25.23±2.11 
      1500 49.32±1.2 48.32±0.1  28.15±1.23 27.25±2.55 
CQ      10 55.41±1.03 54.66±0.52  30.23±0.44 29.92±0.12 
NC  55.44±1.25 40.45±1.45*  32.17±1.4 25.13±4.35* 
  Key:  Values are presented as mean ± SD; n = 5; PCV packed cell volume, NC negative control (1% DSMO), CQ chloroquine (positive control); * = the difference between day 0 and day 4 is 




The emergence of widespread resistance of Plasmodium species to most antimalarial drugs has 
led to a more vigorous and concerted research in traditional medicinal plants for the treatment 
of malaria. Cucumis metuliferus and Lippia kituiensis are two such plants which are 
traditionally used for the treatment of malaria in Tanzania, but for which there is limited 
scientific proof of their efficacies. The results of the present study revealed that Cucumis 
metuliferus and Lippia kituiensis exhibited potent antimalarial activity against Plasmodium 
berghei. Similarly, Odugbemi et al. (2007) reported that the two plants have been traditionally 
claimed to relieve fever and cure malaria 
Parasitemia refers to the level of infection by a particular parasite or the number of parasitized 
cells circulating in the blood (Waako et al., 2005). A decline in parasitemia in a given organism 
is essential for the recovery of symptomatic malaria (Alli et al., 2011). In this study, the 
percentage parasitemia in the negative control group on D4 after infection with Plasmodium 
berghei parasites was 47.15% and Chloroquine had the least parasitemia of 0.00% whilst none 
of the extracts reached this level. For the case of plant extracts, the lowest parasitemia was 
observed in Cucumis metuliferus with 1.1% chloroform extract at dose level 1500 mg/kg and 
in Lippia kituiensis the lowest parasitemia was observed with ethyl acetate 2.53% at a dose 
level of 1500 mg/kg. This result is in agreement with the antimalarial properties reported by 
Renata (2015) and Ajaiyeoba (2005) that support the in vivo activities of C. metuliferus and L. 
kituiensis. 
Chemo-suppression is inversely related to parasitemia, the plant extracts, which have been 
shown to reduce parasitemia to low levels have been shown to have a corresponding high 
chemo-suppression. The study revealed that the highest suppression in Cucumis metuliferus 
extract was observed  from chloroform (98%, 70% and 48%) followed by methanolic (88%, 
58% and 36%) and least was ethyl acetate (84%, 64% and 30%) extracts treated mice at the 
dose levels of 1500 mg/kg, 600 mg/kg and 300 mg/kg, respectively. In the same way, the ethyl 
acetate, chloroform and methanolic extracts of lippia kituiensis extract the highest suppression 
was observed form ethyl acetate (95%, 70% and 42%) followed by chloroform (93%, 69% and 
46 %) and least was methanolic extracts (74%, 68% and 35%) treated mice at the dose levels 
of 1500 mg/kg, 600 mg/kg and 300 mg/kg, respectively.  
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According to Ajaiyeobal and Coweker (2005) in vivo antimalarial activity of plant extracts can 
be categorized as moderate, good and very good if the extract showed 50% or more chemo-
suppression. Hence, the current finding in both plants has very good and good 4-day 
suppressive antimalarial activity in dose level 1500 mg/kg and 600 mg/kg while in the lowest 
dose both plants have low, 4-day suppression antimalarial activity. However, the highest peak 
chemo-suppression was recorded in chloroform extracts of C. meturiferus with 98.53% 
(p<0.05), followed by ethyl acetate of L. kituiensis with 95.19% which was equivalent to that 
induced by chloroquine. This observation was quite interesting since the extract was only a 
crude preparation. The chemo-suppression showed by C. meturiferus and L. kituiensis was in 
agreement with other studies on medicinal plants used for malaria such as Artemisia annua 
(Aduga et al., 2014), Annona senegalensis (Aduga et al., 2014) and Adhathodas chimperian 
(Petros et al., 2012) which showed 90.48%, 96.20%, and 97.80%, respectively. According to 
Zhengming et al. (2009), the antimalarial activity of the plant might be induced by the presence 
of active bioactive compounds. However the observed low antimalarial activity of plant 
extracts could be partly explained by the fact that many antimalarial traditional medicinal plants 
may lack direct antiplasmodial activity to cure the disease but their beneficial role could be in 
their antipyretic, analgesic and immune stimulatory effect as demonstrated in other studies 
(Krettli et al., 2009; Makonnen et al., 2003). 
 According to Abdu et al. (2008) the effectiveness of a given extract can also be influenced by 
the rate of gastrointestinal uptake and the half-life in plasma metabolism of the active 
compound. The difference between the antimalarial activities of extracts of both plants in all 
the three solvents may indicate differences in level and composition of active compounds 
Muregi et al. (2007). In addition to that the difference may also be due to differences between 
the solvents used in terms of polar and nonpolar solvent. Also the administration of plant 
extracts on mice was done orally, due to this, some of the mice may not have taken the whole 
100 mg/kg dosage and this may have affected the parasitemia in the groups. 
Mean survival time is another parameter that evaluates the antimalarial activity of plant extracts 
as indicated in Table 1 and Table 2. Plant materials that can prolong the survival time of 
infected experimental animals compared to the negative controls are considered as active 
agents against malaria (Oliveira et al., 2009; Adugn et al., 2014). In this study, the mice treated 
with 300 mg/kg, 600 mg/kg mg and 1500 mg/kg of extract had significantly lived longer than 
negative control in the four-day suppressive test. This means that the tested extracts contain the 
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anti-malarial compound, which reduces the number of parasites and hence prolong the survival 
time. The current finding was in agreement with other reports on medicinal plants used for 
malaria such as Dodonaeaa ngustifolia seed (Mengistie et al., 2012).  
Body weight is another parameter that can be used to assess the effect of extract in treated mice 
(Taherkhani et al., 2013). In this study, the result showed that there were significant (P < 0.05) 
decrease in body weight between day zero (D0) and day four (D4) of mice treated with 
chloroform, methanolic and ethyl acetate in dose level of 300 mg/kg for both C. metuliferus 
and L. kituiensis and as shown in Table3 and Table 4. This may be due to the depressant action 
on the appetite of the mice and the consequences of disturbed metabolic function and 
hypoglycemic effect of the parasite (Basir et al., 2012). Similar results were reported by Gituaj 
et al. (2012). The reduction of packed cell volume (PCV) values of P. berghei infected mice 
signifies malaria infection. Plasmodium berghei infected mice treated with extracts at 300 
mg/kg exhibited a significant PCV reduction whilst insignificant PCV reduction was recorded 
for infected mice treated with extracts at 600 mg/kg and 1500 mg/Kg. Similar results were 
obtained in studies reported from the same species of A. Remota species used to treat malaria 
(Gupta et al., 2005; Gituaj et al., 2012). 
3.6 Conclusion 
From this study, it can be concluded that the leaf of C. metuliferus and L. kituiensis showed 
good antimalarial activities against Plasmodium berghei infection in mice. The highest 
chemosupression was observed from C. metuliferus chloroform extract of 98.55% and 95% in 
L. kituiensis ethyl acetate extract in dose level of 1500 mg/kg. Accordingly, with the essence 
of further studies this plant could serve as the potential source of new and novel antimalarial 
leads and/or drugs for the treatment and prevention of malaria. However, antimalarial 
compounds from these plants which could significantly contribute to drug discovery remained 







GAS CHROMATOGRAPHY-MASS SPECTROMETRY ANALYSIS OF 
COMPONENTS FROM Cucumis metuliferus AND Lippia kituiensis PLANTS 
Abstract 
Objective: From the recommendations given in the previous chapter, phytochemicals 
evaluation of   the leaf extract of C. metuliferus and L. kituiensis plants was conducted in this 
chapter to reveal the unique chemical classes present in these plants that might be responsible 
for the antiplasmodial effect against P. falciparum. 
Methods: Gas Chromatography-Mass Spectrometry (GC-MS) techniques were used in the 
identification of compounds with low molecular weight of the leaf extracts of C. metuliferus 
and L. kituiensis. The collected samples were dried and extracted with three different polarity 
(chloroform, ethly acetate and methanolic) solvents. 
Result: Preliminary phytochemical analyses of methanol, ethyl acetate and chloroform extracts 
have revealed the presence of steroids, alkaloids, flavonoids, tannins, glycosides, amino acids, 
and phenol compounds. The gas chromatography-mass spectroscopy result revealed the 
presence of 11 major compound  namely Cyclotrisiloxanehexamethyl; Z-Z-6, 28-
Heptatriactontadien-2-one; D-Manitol, 1, 1, 1’-o-1, 16-hexadecanediylbis; Trans, CIS-1, 8-
Dimethylspiro(4, 5)-Decane and  L-(+)-Ascorbic acid 2, 6-dihexadecanoate, 3, 7, 11, 15- 
Tetramethyl-2-Hexadecen-1-ol; Oleyl alcohol tri fluoroacetate; 1-Pentatriacontanol; N-propyl 
11-octadecenoate, fucosterol, Artemiseole compound and other usefully compound. 
Conclusion: The medicinal properties of L. kituiensis and C. metuliferus might therefore due 
to the presence of these groups of phytochemicals. The results of this study offers a base of 
using C. metuliferus and L. kituiensis as an herbal alternative for the synthesis of antimalarial 
agents. 





The uses of medicinal plants as a source of drugs in primary health care have become popular 
universally, particularly in developing countries (Michiels et al., 2012). Plants have been a 
source of the bioactive compound, which serves as a drug (Seyyednejad et al., 2010), these 
bioactive compound work with nutrients and fibers to form an integrated part of a defense 
system against various diseases and stress conditions (Thilagavathi et al., 2015). Several plant 
products have been shown to exert a protective role against the formation of free radicals and 
playing a beneficial role in maintaining disease conditions. Therefore, there is a need for 
screening of bioactive compounds in plant for establishiment of lead compounds which can be 
further developed into potential herbal products for the treatment of several ailments (Bohlin 
& Bruhn, 1999). Gas chromatography coupled to mass spectrometry (GC-MS) has commonly 
been used for the analysis of relatively low molecular weight compounds (Eisenhauer et al., 
2009; Prabhadevi et al., 2012). Taking into consideration of the medicinal importance of these 
compounds, it is essential to thoroughly investigate their composition and hence promote the 
use of such compounds as potential sources of drug templates (Bohlin & Bruhn, 1999).  
Genus Lippia (Verbenaceae, Lamiales Magnoliopsida) includes about 200 species of herbs, 
shrubs and small trees mainly distributed in Central and South America and Africa Tropical 
(Terblanche et al., 1996; Santos et al., 2009). Lippia species have shown a large number of 
important usages in folk medicine for various diseases, particularly in the treatment of cough, 
bronchitis, indigestion, liver, hypertension, dysentery (Pham et al., 1988; Pascual et al., 2001), 
and skin diseases (Matos et al., 1998). ManyLippia species have promising biological 
activities, including antiviral (Abad et al., 1997), antimalarial (Valentin et al., 1995), anti-
inflammatory, analgesic, antipyretic (Forestier et al., 1996: Forestier et al., 1996), 
antimicrobial (Lemons et al., 1990), insecticidal (Lima et al., 2013), and anticonvulsant (Abena 
et al., 1998) properties. Moreover, Lippia species revealed in vitro antitumor activity on 
leukemia (K-562, HL-60, and CEM), colon (HCT-116), breast (MCF-7), glioblastoma (U-
251), and prostate (PC -3) cell lines (Costa et al., 2001; Gonzalez-Guereca et al., 2010).  
Cucumis metuliferus belongs to the family Cucurbitaceae, and is a monoecious, climbing, 
annual vine that can be grown practically anywhere, provided the season is warm (Benzion et 
al., 1993). The fruits are ovoid berries of 8-10 cm long and 4-5 cm in diameter with horn-like 
spines (hence the name horned cucumber), yellow-orange skin and a lime green jelly-like flesh 
when ripe (Wanning et al., 2008). This plant is used by traditional medical practitioners in 
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different place to treat diseases such as peptic ulcer, diabetes mellitus, hypertension and 
HIV/AIDS (Wanning et al., 2008). It was also discovered through personal interaction with 
poultry farmers and other individuals in the Plateau state of Nigeria, that the fruit pulp is used 
to treat poultry diseases and in the management of Hepatitis B. According to Wanning et al. 
(2007), the fruit pulp is used as a remedy to all diseases hence its local name ‘Kanda’ which 
means ‘stop it before it comes’ or ‘a local vaccine. Moreover, the crude extract of C. metuliferus 
has been shown to possess antiviral properties (Noel et al., 2009). Moreover, the two plants L. 
kituiensis and C. metuliferus have been used in Tanzania for the management of malaria 
(Mzena et al., 2018). Since the crude extract of L. kituiensis and C. metuliferus has been shown 
to possess antimalarial property (Mzena et al., 2018) and it is known that certain constituents 
of a plant can be largely responsible for its medicinal activities, this study, therefore, evaluates 
phytochemical compounds of L. kituiensis and C. metuliferus that are responsible for its 
antimalarial activity.  
4.2 Materials and methods 
4.2.1 Collection of plant and extraction of the plant materials 
Fresh leaves of L. kituiensis and C. metuliferus were collected from Ugweno ward 
within Mwanga District, Kilimanjaro Region in Tanzania. Ugweno ward is situated at 3° 39' 
0" South and 37° 39' 0" East in the Pare Mountains. Herbalists residing in Ugweno ward and a 
taxonomist (Josephat Mboya) were consulted and involved in the identification and collection 
of plant materials. The voucher specimen coded (Voucher no. 160 for C. metuliferus and 161 
L. kituiensis) was deposited at Nelson Mandela African Institution of Science and Technology. 
Extraction of the plants: The collected plant leaves were cleaned with tap water and dried under 
shade at room temperature for two weeks and coarsely powdered using an electric blender. 
Then 200 g of the pulverized materials were soaked with 80% methanol (1600 mL), 100% 
ethyl acetate (1600 mL) and 100% chloroform (1600 mL) until the powder was fully immersed, 
incubated overnight and filtered through a whatmann No.1 Whatman®, England).  The filtrate 
is then concentrated to 1ml by bubbling nitrogen gas into the solution. The extract obtained 
was employed in GC-MS for analysis of different compounds 
4.2.2 Preliminary phytochemical screening 
Preliminary phytochemical screening of chloroform, ethyl acetate and methanol of L. kituiensis 
and C. metuliferus leaf extract was tested for alkaloids, terpenoids, flavonoids, tannins, 
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glycosides, phenol, steroids and saponins. The qualitative results are expressed as (+) for the 
presence and (−) for the absence of phytochemicals.  
(i) Test for alkaloids  
A few drops of Dragendroff’s reagent were added to a test tube containing 1 ml of plant extract 
and a colour change was observed. The appearance of an orange colour was an indication of 
the presence of alkaloids (Firdouse & Alam, 2011).  
(ii) Test for terpenoids 
In this test, about 5 ml of plant extract was added to 2 ml of chloroform and 3 ml of concentrated 
sulphuric acid (H2SO4). The presence of terpenoids was indicated by reddish brown colour 
(Edeoga et al., 2005).  
(iii) Test for flavonoids  
About 2 ml of plant extract was treated with few drops of dilute sodium hydroxide (NaOH), 
followed by addition of dilute hydrochloric acid (HCl). A yellow solution with NaOH turned 
colorless with dilute HCl, which indicated the presence of flavonoids (Onwukaeme et al., 
2007). 
(iv) Test for phenols and tannins 
About 2 ml of plant extract was stirred with 2 ml of distilled water and a few drops of ferric 
chloride (FeCl3) solution were added. Formation of dark blue precipitate was an indication of 
the presence of tannins or a blue-green or black coloration indicated the presence of phenols 
and Tannins (Kumar et al., 2007).  
(v) Test for saponin  
About 5 ml of plant extract was shaken vigorously with 5 ml of distilled water in a test tube. 
The formation of stable foam was taken as an indication of the presence of saponins (Parekh 
& Chanda, 2007). 
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(vi) Test for glycosides 
Liebermann’s test- crude extract was mixed with each of 2 ml of chloroform and 2ml of acetic 
acid. The mixture was cooled in ice. Carefully concentrated H2SO4 was added. A colour change 
from violet to blue to green indicated the presence of steroidal nucleus, i.e., glycone portion of 
glycoside. 
(vii) Test for steroid 
Crude extract was mixed with 2 ml of chloroform and concentrated H2SO4 was added sidewise. 
A red colour produced in the lower chloroform layer indicated the presence of steroids. Another 
test was performed by mixing crude extract with 2 ml of chloroform. Then 2 ml of each of 
concentrated H2SO4 and acetic acid were poured into the mixture. The development of a 
greenish coloration indicated the presence of steroids 
4.2.3 GC-MS analysis 
The GC-MS analysis was carried out using Agilent 6890N GC connected to the Agilent 5975 
MS (Agilent Technologies, USA) with a capillary column (HP-5) of 30 meter length, 0.25 mm 
diameter and 0.25 µm film thickness. Helium gas (99.99%) was used as carrier gas at a constant 
flow of 1mL/min and an injection volume of 1 µL was employed. The injector temperature was 
maintained at 250°C, the ion-source temperature was 280°C, the oven temperature was 
programmed at 110°C (isothermal for 2 min), with an increase of 10°C/min to 200°C, then 
5°C/min to 280°C, ending with a 9 min isothermal at 280°C. The mass spectrometer operated 
in electron ionization mode with an ionizing energy of 70 eV and the ion source temperature 
was 230°C. The inlet line temperature was 200ºC and the total GC-MS running time was 36 
minutes. Interpretation of the mass spectrum of GC-MS was done using the database of 
National Institute Standard and Technology (NIST) having more than sixty two thousand 
patterns. The mass spectra of the detected compounds from the C. metuliferus and L. kituiensis 





Figure 3: A Gas Chromatography connected to the Mass Spectrometer instrument used in the 
study 
4.2.4 Identification of phyto components 
Interpretation on mass-spectrum GC-MS was conducted using the database of central 
electrochemical research institute characterization and measurement laboratory having more 
than 62 000 patterns. The spectrum of the unknown components was compared with the 
spectrum of known components stored in the central electrochemical research institute 
characterization and measurement laboratory. The name, molecular weight and structure of the 
components of the test materials were ascertained. 
4.3 Results 
The preliminary phytochemical screening of chloroform, ethyl acetate and methanolic extract 
of L. kituiensis and C. metuliferus plants revealed the presence of major groups of 
phytochemical compounds namely steroids, alkaloids, flavonoids, tannins, glycosides, 
sapponin, and phenol compounds (Table 5). The study revealed that the leaf extracts of Lippia 
kituiensis showed the presence of alkaloids, flavonoids, phenols, tannins, terpenoids and 
saponins in all solvent extract. Glycosides are completely absent in methanolic and 
chloroformic extracts but it is present in ethyl acetate extract. For Cucumis metuliferus 
alkaloids, glycosides, flavonoids, phenols, terpenoids and tannins were present in all solvent 




Table 5:  Preliminary phytochemical screening of L. kituiensis and C. metuliferus methanol, ethyl acetate and chloroform leaf extract 
Plants name Alkaloids Terpanoids Flavonoids Phenol Tannis Sapponin Glycosides Steroids 
Methanol 
L.kituiensis + + + + + + --- --- 
C. metuliferus + + + + + --- + + 
Ethyl acetate 
L.kituiensis + + + + + + + + 
C. metuliferus + + + + + + + + 
Chloroform 
L.kituiensis + + + + + + --- --- 
C. metuliferus + + + + + + + + 
Key: + (Presence of compound), --- (Absence of compound). 
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Furthermore, the volatile phytochemical compounds present in these plants C. metuliferus and 
L. kituiensis were identified by GC-MS technique. The retention time, peak areas, molecular 
formulas, molecular weights and biological activities of these compounds presented in Table 6 
and Table 7, and the structures of the identified compounds are presented in Table 8. The result 
revealed the presence of 11 major compound namely Cyclotrisiloxanehexamethyl; Z-Z-6, 28-
heptatriactontadien-2-one; D-Manitol, 1, 1, 1’-o-1, 16-hexadecanediylbis; Trans, cis-1, 8-
dimethylspiro(4, 5)-Decane and  L-(+)-Ascorbic acid 2, 6-dihexadecanoate, 3, 7, 11, 15- 
Tetramethyl-2-Hexadecen-1-ol; Oleyl alcohol tri fluoroacetate; 1-Pentatriacontanol; N-propyl 
11-octadecenoate, fucosterol, Artemiseole compound. For C. metuliferus plants were: 
Cyclotrisiloxanehexamethyl; Z-Z-6, 28-Heptatriactontadien-2-one; were found in methanolic 
extract and D-Manitol, 1, 1, 1’-o-1, 16-hexadecanediylbis; Trans, CIS-1, 8-Dimethylspiro 
(4,5)-Decane and  L-(+) -Ascorbic acid 2, 6-Dihexadecanoate were found in ethyl acetate 
extract table 5 scheme 1.While the constituents found in L. kituiensis plants were 3, 7, 11, 15- 
Tetramethyl-2-Hexadecen-1-ol; Oleyl alcohol trifluoroacetate; in methanolic extract and 1-
Pentatriacontanol; N-propyl 11-octadecenoate, fucosterol compound were found, in ethyl 
acetate extract while in chloroform extract  Artemiseole was found as showed in Table 7 
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   Table 6:  The antmalarialcompound present in Cucumis metuliferus 
 
RT (min) PA (%) 
Name of Compound 
(Cucumis metuliferus) 









4.989 Z, z-6,28-heptatriactontadien-2-one C37H70O 530 Methanol 
 16.349 2.790 D-Manitol, 1,1’-O-1,16-Hexadecanediylbis C28H58O12 586 Ethyl acetate 
 17.044 1.253 Trans, cis-1,8-dimethylspiro [4.5] decane C12H22 166 Ethyl acetate 
 18.165 24.969 L- (+) -ascorbic acid 2,6-dihexadecanoate C38H68O8 652 Ethyl acetate 
 
   Table 7:  The biomolecules present in Lippia ketuiensis 
 
RT (min) PA (%) 
Name of Compound 
(Lippia ketuiensis) 
M. F M. W Solvent used 
 
17.234 






3.191 Oleyl alcohol, trifluoro acetate C20H35O2F3 364 Methanol 
 19.495 0.978 1-Pentatriacontanol C35H72O 508 Ethyl acetate 
 19.845 14.735 N-propyl 11-octadecenoate C21H40O2 324 Ethyl acetate 
 29.394 40.593 Fucosterol C29H48O 412 Ethyl acetate 
 9.3 1.15 Artemiseole C15H16O 152 Chloroform 
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3, 7,11, 15- Tetramethyl-2-Hexadecen-1-ol; 
 
 



















Other usefully compounds present in both plants C. Metuliferus and L. kituiensis ware, 
Terpineol cis β, β-Tocopherol, Squalene, Vitamin E, n-hexadecanoic acids, Octadecadienoic 
acids, Heneicosane, Santolina epoxide, Tetradecanoic acids, Copaene, Tetratriaicontane, 
Octadecadienoic acid, α-curcumene, α-cubebene, Epizonarene, α-Tocopherol, Stigmastero, 
Tetratriacontane, Oleic aci (Table 9). 
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   Table 9: The biomolecules present in both C. metuliferus and L. kituiensis 
 
RT (min) P A  
(%) 
Name of Compound M. F M. W 
Reported bioactivity 
 11.43 5.73 Terpineol cis β C10H18O 154 Antibacterial 
 31.03 5 β-Tocopherol C28H48O2 416 Antioxidants 
 10.17 3.19 Squalene C30H50 410 Antioxidants, 
 24.07 1.88 Vitamin E C29H50O2 204.35 Antioxidants 
 16.89 1.78 n-hexadecanoic acid C16H32O2 256.42 Antitumor 
 18.88 1.65 Octadecadienoic acid C18H32O2 280.45 Antitumor 
 14.01 1.49 Heneicosane C15H44 296 Antioxidant 
 23.29 1.23 Santolina epoxide C10H16O 152.23 Cardiovascular 
 16.82 1.2 Tetradecanoic acid C14H28O2 228.37 Antitumor 
 33.16 1.89 Tetratriaicontane C34H70 478 Antioxidant 
 18.88 1.65 Ooctadecadienoic acid C18H32O2 280.45 Antitumor 
 8.84 0.61 α-cubebene C15H24 204.35 Antioxidant 
 14.45 0.56 α-Tocopherol C28H48O2 416 Antioxidants 
 21.44 0.52 Stigmastero C29H48O 412 Antimicrobial 
 9.89 0.32 Tetratriacontane C34H70 478 Antioxidant 
 8.52 0.15 Oleic Acids C18H34O2 282 Antioxidant 
   KEY- RT-Retention time, M.F-Molecular formula, M.W-Molecular weight (g/mol) 
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  Table 10: chemical structures found in all extract of C. metuliferus and L. kituiensis 
 
 
Copaene                                       cis-β-Terpineol                                                Terpineol, cis-β- 
 
 













Phenol, 2, 4-bis (1, 1-dimethylethyl)                        Phenol, 2, 5-bis (1, 1-dimethylethyl)- 
 

































The preliminary phytochemical analysis of the crude extract of C. metuliferus and L. kituiensis 
showed the presence of phenolics, flavonoids, tannins, steroidal compounds and saponins. 
Phenolic compounds like flavonoids and tannins are good antioxidant substances that have 
been reported to have biological activities and prevent or control oxidative stress related 
disorders (Naskar et al., 2010). Previous studies indicated that many phenolic and steroidal 
compounds possessed anti-plasmodial activities (Laphookhieo et al., 2009; Beroa et al., 2009). 
Malarial pathogenesis was reported to be associated with free radicals’ formation and decrease 
of antioxidant levels (Kronenberger et al., 2014; Becker et al., 2003; Mulker et al., 2004). This 
suggests that an increase in the body antioxidant can initiate the decrease in parasite number 
and severe infection in the long run (Kronenberger et al., 2014; Wannang et al., 2010). 
Oxidative stress has been implicated in the pathophysiology of malaria (Shahidi et al., 1992). 
The efficacy of antioxidants is usually associated with their ability to inhibit oxidative damage 
by scavenging free radicals. The extract also has phenolic compounds that are antioxidant 
agents that also act as free radical terminators (Shahidi et al., 1992). The phenolic compounds 
found in the extract may be involved in the antimalarial activity exhibited by the C. metuliferus 
and L. kituiensis crude extract. The antimalarial activity of phenolic compounds was reported 
to be due to elevation of red blood cell oxidation, inhibition of parasite’s protein synthesis and 
also by counteracting the oxidative damage induced by the malaria parasite (Wannang et al., 
2010). Plants with antioxidant compounds may ameliorate the progression of malarial infection 
and possibly prevent the development of cerebral complications and other malaria related 
complications. However, the challenge here is that some antimalarial drugs generate free 
radicals to produce their effect suggesting that, their activity may be reduced in the presence of 
antioxidants. The anti-plasmodial activity observed in this study is consistent with the 
traditional use of the C. metuliferus and L. kituiensis as herbal medications against malaria in 
Tanzania. 
Moreover, the crude extract tested positive to alkaloids. Alkaloids are one of the major classes 
of compounds possessing antimalarial activity, and one of the oldest and important antimalarial 
drugs, quinine belongs to these compounds (Dharani et al., 2008). The presence of alkaloids in 
C. metuliferus and L. kituiensis extracts might have contributed to antimalarial activities 
exhibited by the plant extracts. This finding is similar to the findings reported by Ferreira et al. 
(2012) that alkaloids were present in species of Lippia. 
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Additionally the study identified the major 11 compounds using GC-MS analysis namely 
Cyclotrisiloxanehexamethyl; Z-Z-6, 28-heptatriactontadien-2-one; D-Manitol, 1, 1, 1’-o-1, 16-
hexadecanediylbis; Trans, cis-1, 8-Dimethylspiro (4, 5)-Decane and  L-(+)-Ascorbic acid 2, 6-
dihexadecanoate, 3, 7, 11, 15- Tetramethyl-2-Hexadecen-1-ol;  Oleyl alcohol tri fluoroacetate; 
1-Pentatriacontanol; N-propyl 11-octadecenoate, fucosterol, Artemiseole compound. 
According to Sowmiya et al. (2015) several of these compounds were screened in vitro against 
both chloroquines (CQ) sensitive and resistant P. falciparum isolates and were found to exhibit 
antiplasmodial activity. In our study, C. metuliferus was matched with major compounds of 
cyclotrisiloxane hexamethyl and the antiplasmodial activity exhibited by this compound was 
(IC5018.14 μg/ml). 
4.5 Conclusion 
The different polarity solvent (methanol, ethyl acetate and chloroform) extracts of C. 
metuliferus and L. kituiensis were evaluated for phyto chemical compound. The GC-MS results 
revealed unique chemical classes present in the L. kituiensis and C. metuliferus that might be 
responsible for the antiplasmodial effect against Plasmodium berghei observed in previous 
chapter. Further studies are highly warranted for the antiplasmodial activity of identified unique 
chemical classes present in the C. metuliferus and L. kituiensis and also the safety and efficacy 
through animal model studies. However, a detailed experimental analysis of toxicity present in 




In vivo EVALUATION OF ACUTE AND SUB-ACUTE TOXICITY OF 
CHLOROFORM, ETHYLACETATE AND METHANOL EXTRACT OF Lippia 
kituiensis and Cucumis metuliferus EXTRACT IN MICE AND RATS MODELS 
Abstract 
Objective: From the recommendations given in the previous chapter, acute and sub-acute oral 
toxicity of L. kituiensis and C. metuliferus leaf extracts in mice and rats was conducted in this 
chapter to complete the safety profile of this plant extract. Methods: Acute oral toxicity study 
of chloroform, ethyl acetate and methanol extracts of L. kituiensis and C. metuliferus was 
carried out by the administration of 300, 600, 1500, 2500 and 5000 mg/kg body weight to mice 
in the respective groups. The LD50 of the C. metuliferus and L. kituiensis extracts was 
determined to be not greater than 2000 mg/kg body weight. Sub-acute toxicity study was 
conducted by oral administration of the extracts at daily doses of 150, 300 and 500 mg/kg body 
weight in the respective groups of rats for 28 days, and a positive control consisting of 1% 
DMSO and 5 mL was given to each. Results: In the first phase of acute toxicity, all treated 
groups revealed neither mortality nor significant alteration in behavior, body weight, and 
hematology parameters. However, the significance difference was observed in organ weight at 
a dose of 600 mg/kg and 1500 mg/kg of the tested plant extract in both plants. In the second 
phase, all animals in dose level of 5000 mg/kg died within 24hrs while in dose level of 2500 
mg/kg died within 8 days. In sub acute study the result revealed neither mortality nor significant 
alteration in behavior between treated and control. The significant increase (P<0.05) was 
observed in body weight in all doses in both plants while organ weight and haematological 
parameters showed significant difference in dose level 300 mg/kg and 500 mg/kg when 
compared to the control. Moreover, the significant change was observed in biochemical 
parameters of both sexes in a dose of 300 mg/kg and 500 mg/kg body weight of C. metuliferus 
and L. kituiensis extract. A significant histological change was observed in the liver, kidney, 
lungs and spleen in all extractextract of C. metuliferus and L. kituiensis in a dose of 300 mg/kg 
and 500 mg/kg body weight. Conclusion: These plant scan causes’ severe toxicity to animals. 




The search for new drugs which are plant-derived has been receiving renewed interest among 
researchers throughout the world in view of discovering new drugs that possess potency to 
combat the menace of drug resistant agent (About et al., 2000; Pimenta et al., 2003). Plants 
can be useful either in their crude or advanced forms, offering a source of drugs in their pure 
state (Saint et al., 2010; Soejarto et al., 2009). According to the World Health Organization’s 
questionnaire, it is announced that 80% of the population in the world are relying on 
unconventional medicine, mainly in plant sources, in the primary health protection (WHO, 
2015). Recognized for their ability to produce a wealth of secondary metabolites, many of these 
natural products have been shown to present interesting biological and pharmacological 
activities, which could serve as the starting point in the development of modern medicines 
(Abubakar et al., 2010) 
Many drugs such as vinblastine and vincristine (first cures in human cancer) from 
Catharanthus roseus, Quinine (anti-malarial agent) from Cinchon species, Scopolamine 
(sedative) from Datura metel L., and many others that remained in use until the present day 
were developed from plants (Farnsworth & Soejarto, 2009). Although many plants have 
valuable properties, some of them are known to carry toxicological properties as well (Magano 
et al., 2011). Recent studies indicate that although numerous plants are used as food sources, 
some of them may have mutagenic or genotoxic potential (Tülay & Özlem, 2007). Numerous 
research studies have recently focused on both pharmacology and toxicity of medicinal plants 
used by humans (Jimma et al., 2011). This is of high importance to achieve a safe treatment 
with plant products (Parra et al., 2001). The toxicity of the plants may originate from different 
contaminants or from plant chemical compounds that are part of the plant (Balkema et al., 
2003; Martinez et al., 2011). Various assays are used for the research of potential toxicity of 
herbal extracts based on different biological models, such as in vivo assays on laboratory 
animals. Therefore, this study reports the toxicity activity of C. metuliferus and L. kituiensis 
extracts from medicinal plants traditionally used for the treatment of malaria in Tanzania. 
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5.2 Materials and methods 
5.2.1 Plants material and preparation of extract 
The plants (C. metuliferus and L. kituiensis) were collected in September 2016 from 
Ugweno ward within Mwanga District, Kilimanjaro Region in Tanzania. Herbalists residing in 
Ugweno ward and a taxonomist (Mr. Josephat Mboya) were consulted and involved in the 
identification and collection of plant materials. The voucher specimen coded (Voucher no. 160 
and 161) was deposited at Nelson Mandela African Institution of Science and Technology. 
After the extraction process as described in chapter three above the obtained extracts were, 
measured and dissolved in 10% DMSO making a ratio of 1:9. For chloroform extract, 918 mg 
of extract was measured and dissolved in 2.27 ml of DMSO and 28.44 ml of water making a 
total of 30.71 ml. For ethyl acetate extract, 500 mg of extract was measured and dissolved in 
1.01 ml of DMSO and 17.10 ml of water making a total of 18.11 ml. While for methanolic 
extract 1000 mg of extract was measured and dissolved in 3.07 ml of DMSO and 35.64 ml of 
water making a total of 38.71 ml stock solution and stored at 4 ͦ C. 
5.2.2 Experimental animals 
Winstar albino rats weighing 62-96 g for male sex and 45-77 g for female sex and swiss albino 
mice weighing 25–30 g for male sex and 20-27 for female sex from the College of Veterinary 
Medicine and Medical Sciences of Sokoine University of Agriculture (SUA) were used in these 
experiments. All animals were kept in a meshed cage covered with sawdust beddings at room 
temperature 25°C - 30°C. Different sexes were separated to avoid physiological interaction like 
mating and fighting. All experimental animals were exposed to a 12:12 dark-to-light cycle and 
provided with free access to a pellet diet and clean drinking water. All rats were acclimatized 
to the working environment for one week before the beginning of the experiment. 
5.2.3 Acute toxicology assessments 
The acute oral toxicity test of chloroform, ethyl acetate and methanol extracts of L. kituiensis 
and C. metuliferus ware evaluated in swiss albino mice as reported by Muhammad et al. (2015) 
with little modifications that involved two phases. The first phase was conducted as follows. 
For L. kituiensis extract forty five (45) mice were grouped into three groups (chloroform, ethyl 
acetate and methanol) of fifteen mice per group. Each group consist of three doses (300, 600 
and 1500 mg/kg) having five mice in each dose making a total of forty five (45) mice, two 
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females and three males. A similar procedure was repeated for C. metuliferus extract that forty 
five (45) mice were grouped into three groups (chloroform, ethyl acetate and methanol) of 
fifteen mice per group. Each group consists of three doses (300 600 and 1500 mg/kg) having 
five mice in each dose making a total of forty five (45) mice, two females and three males 
different sex were separated to avoid physiological interaction like mating. Five mice received 
a vehicle as a positive control making a total of ninety five mice (95). 
Group 1: Vehicle (1%DMSO) 
Group 2: 300 mg/kg of extract  
Group 3: 600 mg/kg of extract  
Group 4: 1500 mg/kg of extract  
Following an overnight fast, the mice were weighed, and the dose was calculated in reference 
to their body weight. The first phase received 300, 600 and 1500 mg/kg body weight of the 
chloroform, ethyl acetate and methanol extracts of L. kituiensis and C. metuliferus. The positive 
control received 1% of DMSO. The extract was dissolved in 10% DMSO and given via oral 
gavage route. The animals were observed keenly for about 30 min for any signs of toxicity or 
mortality, and further observations were made every 8 h for 24 h after administration of the 
extracts. The general behavior such as urination, food intake, water intake, respiration, 
convulsion, and temperature, changes in eye, skin colors and body weight were observed for a 
period of 14 days post-treatment.  After 14 days other parameters such as body, organ weight 
and hematology were determined. 
The absence of death of any animals in this phase necessitated the conduct of the second phase. 
In the second phase, 24 mice were grouped into six groups of four mice each. The first three 
groups received 2500 and 5000 mg/kg body weight of chloroform, ethyl acetate and methanol 
extracts of L. kituiensis while the other three groups were administered with of chloroform, 
ethyl acetate and methanol extracts of C. metuliferus at a dose of 2500 and 5000 mg/kg body 
weight. The mice were observed for any signs of toxicity or mortality within 24 h. In this phase, 
all animals in dose level 5000 mg/kg died within 24 while the animal in dose level 2500 mg/kg 
died within 8 days 
After the test procedure, the formula employed in the calculation of the LD50 is shown below: 
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                                   LD50= (M0+M1) 
                                                   2 
Where M0 = Highest dose of test substance that gave no mortality, 
             M1 = Lowest dose of test substance that gave mortality 
 
5.2.4 Sub-acute toxicology assessments 
Sub-acute toxicity study (28-day repeated oral toxicity study) was carried out according to 
Muhammad et al. (2015). Both sexes of rats (62-96 g for male sex and 45-77 g for female sex) 
were divided into groups, each comprising 5 animals. The same number of rats was used as in 
acute study first phase ninety five (95) rats was used, the 1st group served as the positive control, 
while 2nd, 3rdand 4thwere considered as tested groups and orally received C. metuliferus and L. 
kituiensis chloroform, ethyl acetate and methanolic extract at dose levels of   150, 300, and 500 
mg/kg. Before dose administration, the body weight of each animal was determined and the 
dose was calculated according to the bodyweight of each animals. The group 1 received 1% 
DMSO vehicle orally at a dose volume of 5 ml/kg body weight and served as a control group. 
All the groups of rats were observed ones a day for mortality, morbidity, bodyweight and other 
clinical signs until the completion of the experiment. Blood samples were collected on the 29th 
day the last day of the experiment from retro orbital plexus of the eye using VITREX NRIS 
soda lime glass 80IU/ml heparinised microhematocrit tubes into EDTA and plain (with clot 
activator tubes) vacutainer tubes for hematological and biochemical laboratory analysis, after 
which the rats were sacrificed and vital organs (liver, lung, kidney and spleen) were collected 
and fixed in 10% buffered formalin for histopathology. 
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5.2.5 Hematological and serum biochemical examination 
On the 29th day of the study, following an overnight fasting, all animals in various groups were 
anesthetized with chloroform and blood samples were collected into heparinized bottles for 
hematological analysis. Red blood cell count (RBC), white blood cell count (WBC), 
hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), lymphocytes 
(LYM), monocytes (MON) and red blood cells distribution width (RDW) were analyzed using 
NS4s auto analyser, Made in Germany. Blood samples without anticoagulant were used for 
serum biochemistry analysis; the samples were placed at room temperature for 1 h and then 
centrifuged at 1500 × g for 10 min to obtain serum. The serum was used for analyzing the 
following parameters, Alanine transaminase (ALT), Alkaline phosphatase (ALP), Aspartate 
transaminase (AST), Albumin (ALB), Total bilirubin (TB), Total protein (TP), Creatinine 
(CREA), urea (UREA), Triglyceride (TG), Total cholesterol (TCHO) and Glucose (GLU). 
5.2.6 Determination of absolute and relative organ weight 
Absolute and relative organ weight of vital organs (liver, kidney, heart, lungs and spleen) of a 
treated animal was determined using an electronic balance and compared with that of a control 
group. Organ-to-body weight ratio was calculated by dividing the weight (g) of each organ by 
the weight (g) of mice before sacrifice as per the given formula.  
            ROW =    Absolute organ weight (g) x100 
                                 Rat’s body weight  
5.2.7 Histopathological examination 
For histopathological examinations, organs were fixed in buffered formalin 10%, before being 
embedded in paraffin. After routine processing, five micrometers of paraffin sections were 
prepared and stained with hematoxylin and eosin before microscopic examination. All the 
sections were examined under a light microscope under 40x magnifications. 
5.2.8 Statistical analysis 
Data collected from the biochemical and hematological analyses were expressed as Mean ± 
SD. One-way ANOVA was used to test the means. Values were considered statistically 
significant at P < 0.05. All results were represented as Mean ± SD (n = 5). 
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5.2.9 Ethical consideration 
Prior to the experimental work, an ethical clearance with notification number 
NIMR/HQ/R.8a/Vol. IX/2146 was given by the National Health Research Ethics Sub-
Committee (NatHREC) of the National Institute for Medical Research (NIMR) in Tanzania. 
5.3 Results 
5.3.1 Acute oral toxicity study 
The acute toxicity effect of chloroform, ethyl acetate and methanolic extract was determined 
as per Muhammad et al. (2015), with little modifications that involved two phases. In the first 
phase no treatment-related toxic symptom or mortality was observed after oral administration 
of the tested plants (C. meturiferus and L. kituiensis) extract at a dose of 300 mg/kg, 600 mg/kg 
and 1500 mg/kg. No change in behavior pattern, body weight, organ weight and hematological 
parameter of the treated animals observed as compared to the control. All the animals given 
the extracts survived for 14 days period of observation. 
5.3.2 Effect of C. meturiferus and L. kituiensis extract on absolute and relative organ 
body weight 
The mean absolute and relative organ weight of male and female mice are shown in Table 11, 
12, 13, 14, 15 and 16. The absolute and relative organ weight of spleen, heart, lungs, liver and 
kidneys in mice treated with chloroform, ethyl acetate and methanolic extract in dose level of 
300 mg/kg, 600 mg/kg and 1500 mg/kg were determined. A significant difference was 
observed in some organs when compared to controls. 
For chloroform extract theof C. metulifures the result showed a significant increase in liver, 
lungs and kidney organs in dose level of 600 mg/kg and 1500 mg/kg for both males and females 
when compared to control (Table 11). For ethyl acetate extract the result reveared significant 
increases in kidney of the male mice treated in dose levels 600 mg/kg and 1500 mg/kg and in 
lungs of the mice treated in dose level 1500 mg/kg when compared to the control.  For female 
mice, the significant increase of kidney, lungs and spleen in mice treated in dose level 600 
mg/kg and 1500 mg/kg was observed when compared to control (Table 12). 
For mice treated with methanolic extract of C. metuliferus, the result revealed significant 
increases of liver, kidney and heart at a dose of 600 mg/kg and 1500 mg/kg and lungs at a dose 
of 1500 mg/kg as compared to control. Female mice the significance increases were observed 
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in dose level 600 mg/kg and 1500 mg/kg body weight of liver, lung and kidney (P > 0.05) when 
compared to control (Table 13). 
For mice treated with L. kituiensis chloroform extract revealed significant reduction of kidney 
and lungs of the male mice treated in a dose of 1500 mg/kg body weight. Female mice, the 
significant reduction were observed in treatement dose level of 600 mg/kg and 1500 mg/kg of 
kidney and lungs when compared to control (Table 14). 
For the mice treated with ethyl acetate extract the result showed significant reductions of liver 
and kidney in mice treated in a dose of 1500 mg/kg when compared to control, while female 
mice, the significant reductions was recorded in tratement dose level 600 mg/kg and 1500 
mg/kg of liver, lungs and spleen when compared to control (Table 15). No significant 
difference was observed at a dose of 300 mg/kg, 600 mg/kg and 1500 mg/kg in both male and 










Table 11:  Effect of chloroform extract of C. meturiferus on absolute (A) and relative organ weight (R %) of mice after 14 days of treatment 
Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg). 
 
Sex   Organ Dose mg/kg      n=5 Sex    Organ Dose mg/kg      n = 5 
 
      300mg/kg 600mg/kg 1500mg/kg 0mg/kg    300mg/kg 600mg/kg 1500mg/kg 0mg/kg 
F A(g) Liver 0.90±0.21 1.50±0.41* 1.89±0.01* 1.30±0.10 M A(g) Liver 1.50±0.03 1.71±0.9* 1.99±0.10* 1.68±0.01 
  Heart 0.11±0.01 0.12±0.01 0.14±0.01 0.13±0.21   Heart 0.15±0.10 0.18±0.10 0.19±0.10 0.18±0.10 
  Kidney 0.41±0.1 0.61±0.01* 0.71±0.01* 0.31±0.01   kidney 0.27±0.11 0.35±0.21 0.54±0.11* 0.28±0.11 
  Lungs 0.33±0.10 0.43±0.10 0.62±0.10* 0.30±0.10   lungs 0.40±0.10 0.55±0.11* 0.74±0.12* 0.21±0.12 
  Spleen 0.44±0.01 0.62±0.01* 0.71±0.01* 0.18±0.01   Spleen 0.16±0.30 0.18±0.12 0.19±0.14 0.18±0.13 
              
 R (%) Liver 1.71±0.01 1.60±0.02 2.43±0.15 1.98±0.13  R (%) Liver 1.84±0.15 1.92±0.11 1.88±0.25 1.98±0.11 
  Heart 0.22±0.14 0.24±0.14 0.28±0.04 0.26±0.05   Heart 0.67±0.12 0.26±0.13 0.29±0.13 0.26±0.12 
  Kidney 0.89±0.15 0.72±0.25 0.91±0.15 0.61±0.15   Kidney 0.42±0.11 0.25±0.10 0.28±0.15 0.28±0.17 
  Lung 0.49±0.01 0.54±0.02 0.72±2.06 0.63±0.03   Lung  0.43±0.20 0.62±0.15 0.69±0.14 0.46±0.18 
  Spleen 0.18±0.07 0.18±0.07 0.18±0.07 0.18±0.07   spleen 0.25±0.14 0.24±0.14 0.18±0.14 0.19±0.17 
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Table 12:  Effect of ethyl acetate extract of C.meturiferus on absolute (A) and relative organ weight (R %) of mice after 14 days of treatment 




Sex Organ Dose mg/kg   n =5 Sex Organ Dose mg/kg   n = 5 
      300mg/kg 600mg/kg 1500mg/kg 0mg/kg    300mg/kg 600mg/kg 1500mg/kg 0mg/kg 
F A(g) Liver 1.28±0.1 1.28.±0.2 1.32±0.01 1.30±0.01 M A(g) Liver 1.68±0.01 1.69±0.20 1.68±0.33 1.68±0.01 
  Heart 0.11±0.10 0.12±0.01 0.14±0.01 0.13±0.21   Heart 0.18±0.13 0.23±0.50 0.35±0.10 0.28±0.10 
  Kidney 0.45±0.01 0.61±0.41* 0.70±0.12* 0.31±0.01   Kidney 0.48±0.10 0.68±0.11* 0.96±0.15* 0.28±0.11 
  Lungs 0.43±0.03 0.45±0.20* 0.51±0.30* 0.30±0.10   Lung 0.38±0.12 0.55±0.12* 0.68±0.22* 0.21±0.12 
  Spleen 0.21±0.01 0.32±0.01* 0.50±0.01* 0.18±0.01   Spleen 0.15±0.13 0.16±0.13 0.17±0.13 0.18±0.13 
              
 R (%) Liver 1.46±0.04 1.58±0.05 1.48±0.33 1.62±0.03  R (%) Liver 1.87±0.25 1.88±0.11 1.98±0.16 1.88±0.01 
  Heart 0.22±0.03 0.22±0.05 0.43±0.02 0.41±0.14   Heart 0.42±0.13 0.42±0.12 0.44±0.16 0.46±0.10 
  Kidney 0.20±0.01 0.62±0.15 0.61±0.15 0.56±0.05   Kidney 0.39±0.15 0.48±0.12 0.45±0.17 0.48±0.11 
  Lung 0.42±0.06 0.66±0.02 0.73±0.02 0.68±0.06   Lung  0.39±0.14 0.43±0.22 0.46±0.15 0.21±0.12 
  Spleen 0.24±0.06 0.19±0.27 0.19±0.05 0.19±0.07   Spleen 0.17±0.11 0.17±0.13 0.18±0.19 0.19±0.13 
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Table 13:  Effect of methanolic extract of C. meturiferus on absolute (A) and relative average organ weight (R %) of mice after 14 days of 
treatment 
Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg).
Sex Organ Dose mg/kg n = 5 Sex Organ Dose mg/kg n = 5 
      300mg/kg 600mg/kg 1500mg/kg 0mg/kg    300mg/kg 600mg/kg 1500mg/kg 0mg/kg 
F A(g) Liver 1.40±0.51 1.58±0.01* 1.97±0.01* 1.30±0.01 M A(g) Liver 1.56±0.09 1.82±0.17* 1.89±0.01* 1.68±0.01 
  Heart 0.13±0.10 0.14±0.31 0.16±0.30 0.13±0.21   Heart 0.33±0.10 0.47±0.12* 0.59±0.10* 0.18±0.10 
  Kidney 0.45±0.31 0.55±0.10* 0.62±0.21* 0.31±0.01   Kidney 0.34±0.20 0.47±0.11* 0.68±0.11* 0.28±0.11 
  Lungs 0.33±0.10 0.43±0.50 0.52±0.10* 0.30±0.10   Lungs 0.25±0.12 0.27±0.12 0.45±0.12* 0.21±0.12 
  Spleen 0.17±0.31 0.18±1.01 0.17±1.10 0.18±0.01   Spleen 0.17±0.23 0.16±0.14 0.16±0.15 0.18±0.13 
 R (%) Liver 1.24±0.06 1.48±0.03 1.76±0.03 1.67±0.03  R (%) Liver 1.63±0.25 1.78±0.12 1.98±0.13 1.98±0.09 
  Heart 0.28±0.14 0.28±0.14 0.25±0.14 0.29±0.04   Heart 0.68±0.11 0.88±0.13 0.79±0.11 0.79±0.10 
  Kidney 0.62±0.35 0.62±0.02 0.62±0.15 0.65±0.03   Kidney 0.27±0.17 0.28±0.17 0.39±0.17 0.28±0.11 
  Lungs 0.06±0.03 0.06±0.16 0.15±0.04 0.07±0.06   Lung  0.45±0.14 0.44±0.12 0.46±0.18 0.44±0.12 
  Spleen 0.19±0.02 0.19±0.03 0.19±0.04 0.18±0.07   Spleen 0.17±0.12 0.18±0.19 0.18±0.19 0.19±0.13 
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Table 14:  Effect of the chloroform extract of L. kituiensis on absolute (A) and relative organ weight (R %) of mice after 14 days of treatment. 
Sex                Organ Dose mg/kg n = 5 Sex Dose mg/kg n = 5 
                 
  
    300mg/kg 600mg/kg 1500mg/kg 0mg/kg   300mg/kg 600mg/kg 1500mg/kg 0mg/kg 
F A(g) Liver 1.10±0.01 0.80±0.01* 0.70±0.01* 1.30±0.10 M A(g) 1.53±0.02 1.45±0.10 1.05±0.09* 1.68±0.01 
  Heart 0.12±0.01 0.12±0.01 0.13±0.01 0.13±0.21   0.16±0.10 0.15±0.20 0.15±0.30 0.18±0.10 
  Kidney 0.33±0.01 0.08±0.01 0.04±0.01* 0.31±0.01   0.16±0.31 0.15±0.21 0.07±0.11* 0.28±0.11 
 
  Lungs 0.33±0.10 0.13±0.20 0.03±0.10* 0.30±0.10   0.09±0.11 0.05±0.22 0.02±1.22* 0.21±0.12 
  Spleen 0.18±0.01 0.18±0.01 0.18±0.01 0.18±0.01   0.16±0.23 0.16±0.23 0.15±0.03 0.18±0.13 
 R (%) Liver 1.24±0.02 1.60±0.03 1.04±0.03* 1.98±0.11  R (%) 1.56±0.04 1.48±0.13 1.28±0.15 1.98±0.11 
  Heart 0.22±0.04 0.23±0.04 0.18±0.04 0.26±0.05   0.27±0.14 0.26±0.16 0.25±0.16 0.26±0.12 
  Kidney 0.77±0.05 0.63±0.05 0.60±0.05 0.61±0.15   0.25±0.17 0.29±0.17 0.38±0.17 0.33±0.17 
  Lungs 0.61±0.02 0.58±0.02 0.60±0.06 0.63±0.03   0.44±0.18 0.45±0.18 0.48±0.18 0.46±0.18 
  Spleen 0.27±0.07 0.18±0.07 0.28±0.07 0.18±0.07   0.26±0.19 0.18±0.19 0.19±0.19 0.19±0.17 
Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg). 
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Table 15:  Effect of ethyl acetate extract of L. kituiensi on absolute (A) and relative organ weight (R %) of mice after 14 days of treatment 
Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg)
Sex          Organ Dose mg/kg n = 5 Sex    Organ                Dose mg/kg n = 5 
     300mg/kg 600mg/kg 1500mg/kg 0mg/kg    300mg/kg 600mg/kg 1500mg/kg 0mg/kg 
F A(g) Liver 1.23±0.11 0.90±0.01* 0.60±0.31* 1.30±0.10 M A(g) Liver 1.52±0.09 1.41±0.02 1.04±0.01* 1.68±0.01 
  Heart 0.14±0.21 0.13±0.40 0.14±0.01 0.13±0.21   Heart 0.16±0.15 0.16±0.10 0.17±0.17 0.18±0.10 
  Kidney 0.40±0.12 0.44±0.01 0.43±0.11 0.31±0.01   kidney 0.28±0.10 0.20±0.21 0.07±0.11* 0.28±0.11 
  Lungs 0.25±0.10 0.04±0.10 0.01±0.10* 0.30±0.10   lung 0.18±0.11 0.28±0.10 0.35±0.13 0.21±0.12 
  Spleen 0.17±0.01 0.12±0.01 0.11±0.01* 0.18±0.01   Spleen 0.17±0.12 0.17±0.13 0.18±0.13 0.18±0.13 
              
 R (%) Liver 1.46±0.03 0.85±0.23 0.79±0.03 1.62±0.01  R (%) Liver 1.69±0.15 1.69±0.13 1.99±0.15 1.88±0.01 
  Heart 0.25±0.02 0.26±0.14 0.48±0.04 0.26±0.10   Heart 0.42±0.16 0.42±0.13 0.42±0.16 0.46±0.10 
  Kidney 0.46±0.05 0.48±0.15 0.48±0.15 0.48±0.11   Kidney 0.58±0.12 0.51±0.11 0.47±0.17 0.48±0.11 
  Lung 0.24±0.06 0.26±0.06 0.26±0.06 0.21±0.12   Lung  0.25±0.12 0.25±0.18 0.23±0.18 0.21±0.12 
  Spleen 0.17±0.07 0.19±0.07 0.19±0.07 0.19±0.13   spleen 0.16±0.19 0.17±0.19 0.18±0.19 0.19±0.12 
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Table 16:  Effect of methanolic extract of L. kituiensis on absolute (A) and relative organ weight (R %) of mice after 14 days of   treatment 
Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control.
Sex Organ Dose mg/kg n = 5 Sex   Organ      Dose mg/kg n = 5 
      300mg/kg 600mg/kg 1500mg/kg 0mg/kg    300mg/kg 600mg/kg 1500mg/kg 0mg/kg 
F A(g) Liver 1.05±0.01 1.05±0.11 1.00±0.01 1.30±0.10 M A(g) Liver 1.05±0.09 1.57±0.01 1.46±0.12 1.68±0.01 
  Heart 0.14±0.21 0.13±0.01 0.12±0.21 0.13±0.21   Heart 0.16±0.11 0.15±0.10 0.15±0.12 0.18±0.10 
  Kidney 0.30±0.01 0.41±0.01 0.21±0.01 0.31±0.01   Kidney 0.19±0.14 0.05±0.13 0.09±0.12 0.18±0.11 
  Lungs 0.28±0.14 0.33±0.12 0.20±0.13 0.30±0.10   Lungs 0.18±0.11 0.09±0.12 0.05±0.12 0.18±0.12 
  Spleen 0.15±0.11 0.16±0.21 0.15±0.01 0.18±0.01   Spleen 0.17±0.12 0.19±0.11 0.13±0.13 0.18±0.13 
              
 R (%) Liver 1.38±0.03 1.16±0.03 1.29±0.03 1.67±0.03  R (%) Liver 1.25±0.25 1.17±0.11 1.18±0.15 1.98±0.09 
  Heart 0.22±0.02 0.25±0.04 0.24±0.04 0.29±0.04   Heart 0.24±0.13 0.21±0.14 0.24±0.16 0.19±0.10 
  Kidney 0.62±0.02 0.61±0.05 0.48±0.05 0.65±0.03   Kidney 0.24±0.12 0.26±0.17 0.29±0.17 0.28±0.11 
  Lung 0.28±0.06 0.33±0.06 0.28±0.06 0.17±0.03   Lung  0.45±0.13 0.38±0.18 0.48±0.18 0.44±0.12 
  Spleen 0.18±0.07 0.18±0.07 0.18±0.07 0.18±0.07   Spleen 0.16±0.19 0.17±0.18 0.18±0.17 0.19±0.13 
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5.3.3 Sub-acute toxicity study 
The sub-acute toxicity study of chloroform, ethyl acetate and methanolic extract of the tested 
plant extract was determined as reported by Muhammad et al. (2015) where the limit dose of 
500 mg/kg was used. No treatment-related toxic symptom or mortality was observed after oral 
administration of the tested plants (C. meturiferus and L. kituiensis) as shown in Table 17. No 
significant change in general behavior of the treated animals and control group was observed. 
None of the two plant extracts produced mortality after giving a dose of 150 mg/kg/, 300 mg/kg 
and 500 mg/kg body weight. All rats given the extracts survived for 28 days period of 
administration and observation and were sacrificed on the 29 days. 
Table 17: General appearance and behavioral observations of sub acute toxicity study for 
control and treated groups of C. meturiferus and L. kituiensis 
PARAMETER 
     
DOSE(mg/kg)       
  Control 300 mg/kg 600 mg/kg 1500 mg/kg 
Lacrimation No No No No 
Salivation No No No No 
Piloerection No No No No 
Drowsiness No No No No 
Tremors No No No No 
Convulsions No No No No 
Fur Normal Normal Normal Normal 
Food intake Normal Normal Normal Normal 
Water taking Normal Normal Normal Normal 
Mortality No No No No 
Breathing Normal Normal Normal Normal 
Temperature Normal Normal Normal Normal 
Sedation Normal No effect No effect No effect 
Diarrhea Normal No present Not present Not present 
Eye color Normal No effect No effect No effect 
Change skin Normal No effect No effect No effect 
Urination Normal No effect No effect No effect 
Coma Not present No effect No effect No effect 
Death No Alive Alive Alive 




5.3.4 General clinical symptom and mortality of rats 
In sub-acute toxicity study of C. metuliferus and L. kituiensis, no mortality and clinical 
symptoms were observed during the experimental period at any of the three doses. No 
differences in general behavior were observed between the control and the treated groups. 
5.3.5 Effect of plants on body weight of rats in the sub-acute study 
The gain in body weight of rats treated with C. metuliferus and L. kituiensis were recorded and 
compared with the control group as shown in Table 18 and Table 19.The mean body weight of 
male and female rats treated with chloroform, ethyl acetate and methanolic extract of both 
plants significantly increases in dose level 150 mg/kg, 300 mg/kg and 500 mg/kg as compared 
to the control. 
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Table 18:  Effect of C. metuliferus extract on body weight in sub-acute study 




  Body weight(g)   Body weight(g)  
Sex Extract Dose 1st day 7th day 14th day 21st 28th Weight gain 
(g) 
 1st day 7th day 14th 
day 
21st 28th Weight gain 
(g) 
F Chloroform 0 65.3±0.2 72.0±0.4 75.00±0.4 79.33±0.4 82.4±0.5 16.91±0.8  65.0±0.2 69.9±0.0 74 ±0.0 79.±0.21 85 ±0.21 19.8±0.1 
  150 66.6±0.4 69.6±0.2 73.8±0.2 78.3±01 84.0±0.1 19.4±0.4*  60.1±0.1 66.3±0.0 72 ±0.1 78.9±0.0 83.4±0.13 25 ±0.1* 
  300 55.9±0.5 62.2±03 66.8±07 74.0±02 79.1±0.2 20.1±0.5*  63.1±0.1 68.0±0.1 74 ±0.3 79.9±0.3 83.9±0.4 20.8±0.4 
  500 52.1±0.3 57.0±0.2 63.7±0.9 68.1±0.1 76.9±0.2 19.8±0.6*  66.1±0.1 68.0±0.1 75 ±0.3 79.9±0.4 83.9±0.5 24.1±0.5* 
 Ethyl acetate 0 65.3±0.2 72.0±0.4 75.0±0.4 79.3±0.4 82.4±0.5 16.1±0.81  65.0±0.2 69.0±0.0 74 ±0.0 79.9±0.1 85.9±0.21 19.8±0.12 
  150 51.9±0.7 57.1±0.1 63.1±0.1 66.1±0.1 70.9±1.2 19.9±0.1*  59.9±0.2 65.09±0.2 71 ±0.1 76.2±0.2 83.9±0.23 24.0±0.9* 
  300 54.8±0.1 59.3±0.1 63.1±0.1 73.1±01 75.2±01 19.04±0.2*  58.9±0.2 66.08±0.2 72 ±0.1 77.2±0.3 84.9±0.24 26.9±0.1* 
  500 50.8±1.2 55.21±04 61.08±01 66.09±03 69.0±04 20.0±0.5*  62.9±0.2 66.05±0.2 73 ±0.1 75.2±0.4 79.9±0.25 25.9±0.1* 
  0 65.3±0.2 72.90±03 75.0±0.4 79.3±04 82.4±0.5 16.1±0.1  65.0±0.2 69.90±0.0 69 ±0.0 81.9±0.1 83.0±0.21 19.3±0.12 
 Methanolic 150 61.9±0.8 67.1±0.1 70.9±0.1 75.2±03 81.9±0.1 19.9±0.2*  64.9±0.9 67.20±0.1 73 ±0.2 75.6±0.23 84.9±0.23 24.7±0.3* 
  300 61.3±0.9 65.1±0.2 72.9±0.2 76.2±0.4 83.7±0.2 22.04±0.1*  65.9±0.1 66.0±0.1 74.0±0.2 78.6±0.2 83.9±0.2 26.7±0.4* 
  500 61.4±0.0 67.01±0.3 73.7±03 76.2±0.5 82.1±0.3 21.1±0.6*  60.1±0.1 68.3±0.1 71.9±0.2 77.7±0.3 84.1±0.3 20.27±0.4 
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Table 19:  Effect of L. kituiensis extract on body weight 
   
  
Body weight(g)  
 
Body weight(g) 
Sex Extract Dose 1st 7th 14th 21st 28th Weight gain (g) 
 




0 65.43±0.6 72.90±0.3 75.00±0.3 79.33±0.4 82.34±0.3 16.91±0.81 M 65.90±0.23 69.90±0.2 74.90±0.5 79.09±0.2 85.09±0.2 19.38±0.12 
  
150 68.56±0.4 71.66±0.9 74.80±0.2 76.30±0.1 82.40±91 20.84±0.44*  61.01±0.13 66.93±0.1 72.09±0.7 76.09±0.0 82.04±0.1 23.03±0.13* 
  
300 57.89±0.5 63.02±0.0 66.88±0.7 72.90±0.2 79.21±0.1 23.31±0.55*  65.01±0.14 68.90±0.1 76.09±0.3 79.09±0.0 83.09±0.3 24.08±0.24* 
  
500 52.31±03 57.90±0.7 62.67±09 68.01±0.1 76.99±0.2 19.68±0.56*  66.01±0.15 68.90±0.1 74.09±0.3 78.09±0.0 83.09±0.3 23.01±0.15* 
 Ethyl acetate 
0 65.43±0.6 72.90±0.3 75.00±0.3 79.33±0.4 82.34±0.3 16.91±0.81*  65.90±0.23 69.90±0.2 74.90±0.0 79.09±0.2 85.09±0.2 19.38±0.12 
  
150 53.09±0.5 59.71±0.1 63.81±90 66.81±0.1 71.09±12 22.90±0.18*  61.09±0.22 65.09±0.1 72.09±0.1 75.22±0.2 82.99±0.2 25.90±0.09* 
  
300 55.98±0.1 58.03±0.1 65.81±0.1 73.01±0.2 75.02±0.1 21.04±0.22*  59.09±0.23 66.08±0.2 70.89±0.1 76.22±0.2 82.99±0.2 23.09±0.10* 
  
500 49.88±1.0 55.21±0.0 64.08±0.1 68.09±0.1 69.90±0.4 23.90±0.25*  63.09±0.24 64.05±0.3 70.09±0.1 75.22±0.2 79.99±0.2 21.9±0.11* 
  
0 65.43±0.6 72.90±0.3 75.00±0.3 79.33±0.4 82.34±0.3 16.91±0.81*  65.90±0.23 69.90±0.4 69.90±0.0 81.09±0.2 83.09±0.2 19.38±0.12 
 Methanolic 
150 61.09±0.7 67.01±0.2 72.09±0.0 75.02±0.2 83.09±0.2 19.09±0.20*  65.09±0.99 69.20±0.1 72.90±0.2 75.66±0.2 84.09±0.2 24.57±0.33* 
  
300 60.03±0.1 65.01±0.1 72.09±0.2 77.02±0.2 82.07±1 21.04±0.11*  67.19±0.10 66.20±0.1 73.90±0.2 76.66±0.2 82.09±0.2 23.37±0.04* 
  
500 61.04±0.8 67.01±0.2 72.07±0.0 75.02±0.2 83.09±0.2 20.09±0.62*   63.09±0.10 68.30±0.1 72.90±0.2 77.66±0.2 84.09±0.2 24.27±0.5* 




5.3.6 Effect of C. meturiferus and L. kituiensis extract on hematological parameters in a   
sub-acute test 
The results of hematological investigations in Table 20, 21, 22, 23, 24 and 25 conducted on 
29th  day for sub-acute toxicity study revealed significant changes in the values of red blood 
cell (RBC), white blood cell (WBC), hemoglobin (Hb), hematocrit (HCT), lymphocytes 
(LYM), neutrophil granulocytes (NEUT), differential count, mean corpuscular volume (MCV) 
mean corpuscular hemoglobin (MCH), mean-corpuscular hemoglobin concentration (MCHC) 
and Red Blood Cells Distribution Width (RDW), of treated groups when compared with the 
respective control rats in dose levels 300 mg/kg and 500 mg/kg. For chloroform extract of C. 
metulifures the result showed a significant increase in WBCs count, RBCs, HCT, MCV, MCH, 
MCHC, RDW, and HB of male rats and female rats WBCs count, HCT, MCV, MCH, MCHC, 
RDW, and HB in a dose of 300 mg/kg and 500 mg/kg (Table 20). 
 
The rats treated with ethyl acetate extract showed a significant increase of WBCs and RBCs 
count, MCV, HCT, MCH, MCHC, HB and RDW in dose level 500 of mg/kg. For female rats, 
the WBCs count raises significantly in a dose level of 500 mg/kg as compared to the control. 
RBCs count and MCV, MCH and MCHC were also significantly increased as compared to 
control in dose level of 500 mg/kg as shown in Table 21. For methanolic extract, a significant 
increase of WBCs and RBCs count in dose levels of 300 mg/kg and 500 mg/kg was observed.  
And all MCV, HCT, MCH, MCHC, RDW and HB were significantly increased in dose level 
of 500 mg/kg with that of the control. For female rats, WBCs count increased significantly at 
a dose of 300 mg/kg and 500 mg/kg as that of the control group. RBCs and HCT, MCV, MCH, 
MCHC and RDW were significant increases as that of control in dose level of 500 mg/kg as 
shown in Table 22.  
For L. kituiensis plant the rats treated with chloroform extract revealed significant increased of 
WBCs, RBCs, MCV, HCT, MCH and MCHC in a dose level 500 mg/kg as compared to the 
with control, and for female rats significantly increased of WBCs, RBCs count and HCT, 
MCV, MCH and MCHC in dose levels 300 mg/kg and 500 mg/kg was observed as compared 
to controls (Table 23). The results obtained in rats treated with ethyl acetate extract showed a 
significant increase of WBC, LYMP, MON, NEU, RBC, MCV, HCT and MCHC in dose levels 
of 300 mg/kg and 500 mg/kg for male rats and WBCs, LYMP, NEU, RBC, MCV, HCT and 
MCHC for female rats in a dose levels of 300 mg/kg and 500 mg/kg when compared with 
control (Table 24). 
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And rats administered with methanolic extract, the hematological result of male and female 
rats’ showed a significant increase of WBC, LYMP, MON, NEU, RBC and HCT in dose levels 








Table 20:  Effect of chloroform extract of C. meturiferus on hematological parameters in rate after 4 weeks of treatment 
Sex Parameter Dose mg/kg n = 5 Sex Dose mg/kg n = 5 
    150mg/kg 300mg/kg 500mg/kg 0mg/kg  150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F WBC 91.43±0.09 97.44±0.12* 109.2±0.1* 88.23±0.01 M 72.12±0.02 85.82±0.02* 90.61±1.2* 75.23±0.02 
 LYMP 66.40±0.02 69.00±0.13* 79.02±0.5* 66.00±0.02  65.02±0.11 68.00±0.01* 71.0±0.12* 62.0±0.50 
 MON 18.00±0.12 20.04±0.14* 21.40±0.10* 16.03±0.08  13.10±0.12 14.80±0.11* 15.60±0.03* 12.20±1.02 
 NEU 7.53±0.02 8.90±0.15* 8.00±0.09* 6.20±0.04  2.00±0.10 3.02±0.05* 3.01±0.12* 1.03±0.03 
 RBC 7.57±0.15 8.72±0.11* 9.90±0.12* 7.37±0.01  6.21±0.04 6.92±0.01* 7.33±0.01* 5.90±0.03 
 MCV 59.70±0.02 63.22±0.17 66.01±0.3* 55.23±0.06  57.11±0.02 60.23±0.07 63.23±1.07* 58.0±0.03 
 HCT 42.7±0.13 43.3±0.12 48.32±0.12* 41.90±0.07  39.13±0.10 41.12±0.01 45.23±0.09* 39.18±0.03 
 MCH 23.4±0.02 26.2±0.19 27.93±0.01* 24.23±08  18.01±0.01 20.21±0.18 19.22±0.00 19.31±0.01 
 MCHC 35.52±0.02 35.04±0.2 38.05±0.90* 32.40±0.01  29.02±0.17 32.21±0.09 34.23±0.03 30.05±0.02 
 RDW 15.34±0.01 17.21±0.21 19.05±0.10* 16.21±1.10  15.0±0.6 18.81±0.10 20.12±1.10* 16.91±0.05 
 HB 15.31±0.01 14.01±0.25 17.13±0.10* 14.23±1.01  15.22±0.09 15.8±0.23 17.12±0.01* 13.34±0.01 
Values are expressed as mean ± SD. P > 0.05 when compared to control group. * = values are significantly different (p < 0.05) from that of the control); White blood cell, red 
blood cell, hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration, lymphocytes, monocytes, 
neutrophil granulocytes, red blood cells distribution width. 
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Table 21:  Effect of ethyl acetate extract of C. meturiferus on hematological parameters in rate after 4 weeks of treatment 
Values are expressed as mean ± SD. P > 0.05 when compared to control group. * = values are significantly different (p < 0.05) from that of the control. White blood cell, red 
blood cell, hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration, lymphocytes, platelet, monocytes, 







Sex Parameter Dos mg/kg n = 5 Sex Dos mg/kg n = 5 
    150mg/kg 300mg/kg 500mg/kg 0mg/kg  150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F WBC 90.40±0.09 93.44±0.12 100.42±0.51* 93.23±0.01 M 75.12±0.02 85.82±0.02* 91.61±1.02* 78.23±0.02 
 LYMP 64.40±0.02 67.00±0.13 72.02±0.15* 65.00±0.02  64.02±0.11 68.00±0.01* 71.00±0.12* 62.0±0.50 
 MON 18.00±0.12 18.04±0.14 20.00±0.10* 16.03±0.08  14.10±0.12 15.80±0.11* 18.60±0.03* 12.20±1.02 
 NEU 8.00±0.02 8.40±0.15 8.02±0.09 6.20±0.04  3.00±0.10 3.02±0.05 4.01±0.12* 1.03±0.03 
 RBC 8.57±0.15 9.32±0.11 9.90±0.12* 7.37±0.01  6.21±0.04 6.92±0.01* 7.33±0.01* 5.90±0.03 
 MCV 60.7±0.02 58.22±0.17 61.1±0.31* 55.23±0.06  57.11±0.02 60.23±0.07 63.23±1.07* 58.0±0.03 
 HCT 44.9±0.13 43.3±0.12 49.32±0.12* 41.90±0.07  39.13±0.10 41.12±0.01 45.23±0.09* 39.18±0.03 
 MCH 21.4±0.02 25.2±0.19 27.23±0.01* 24.23±08  18.01±0.01 20.21±0.18 23.22±0.00* 19.31±0.01 
 MCHC 34.52±0.02 35.04±0.20 39.05±0.90* 32.40±0.01  29.02±0.17 32.21±0.09 35.23±0.03* 30.05±0.02 
 RDW 16.34±0.01 16.21±0.21 20.05±0.10 16.21±1.10  14.0±0.6 16.81±0.10 21.12±1.10* 16.91±0.05 
 HB 16.31±0.01 15.01±0.25 16.13±0.10 14.23±1.01  15.22±0.09 15.8±0.23 19.12±0.01* 13.34±0.01 
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Table 22:  Effect of methanol extract of C. meturiferus on hematological parameters in rate after 4 weeks of treatment 
Values are expressed as mean ± SD. P > 0.05 when compared to control group. * = values are significantly different (p < 0.05) from that of the control); White blood cell, red 
blood cell, hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration, lymphocytes, monocytes, 
neutrophil granulocytes, red blood cells distribution width. 
Sex Parameter Dose mg/kg n = 5 Sex Parameter Dose mg/kg n = 5 
    150mg/kg 300mg/kg 500mg/kg 0mg/kg   150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F WBC 85.40±0.06 99.44±0.12* 102.42±0.51* 93.23±0.01 M WBC 74.12±0.02 85.82±0.02* 89.61±1.02* 75.23±0.02 
 LYMP 58.40±0.02 69.00±0.13* 68.02±0.15* 65.00±0.02  LYMP 64.02±0.11 67.00±0.01* 69.00±0.1* 62.0±0.50 
 MON 20.00±0.12 24.04±0.14 25.00±0.10 20.03±0.08  MON 14.10±0.12 15.80±0.11* 17.60±0.03* 12.20±1.02 
 NEU 7.00±0.02 8.40±0.15 9.02±0.09* 6.20±0.04  NEU 2.00±0.10 3.02±0.05* 3.01±0.12* 1.03±0.03 
 RBC 6.57±0.15 7.72±0.11 9.90±0.12* 7.37±0.01  RBC 6.21±0.04 6.92±0.01 7.53±0.01* 5.90±0.03 
 MCV 58.7±0.02 59.22±0.17 65.01±0.31* 55.23±0.06  MCV 59.11±0.02 60.23±0.07 66.23±1.07* 58.0±0.03 
 HCT 43.9±0.13 43.3±0.12 49.32±0.12* 41.90±0.07  HCT 40.13±0.10 40.12±0.01 45.23±0.09* 39.18±0.03 
 MCH 25.4±0.02 26.2±0.19 29.23±0.01* 24.23±08  MCH 19.01±0.01 22.21±0.18 24.22±0.00* 19.31±0.01 
 MCHC 34.52±0.02 35.04±0.2 38.05±0.90* 32.40±0.01  MCHC 27.02±0.17 33.21±0.09 35.23±0.03* 30.05±0.02 
 RDW 18.34±0.01 18.21±0.21 23.05±0.10* 16.21±1.10  RDW 14.0±0.6 19.81±0.10 22.12±1.10* 16.91±0.05 
 HB 15.31±0.71 16.01±0.25 17.13±0.10 14.23±1.01  HB 15.22±0.09 16.8±0.23 19.12±0.01* 13.34±0.01 
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Table 23:  Effect of chloroform extract of L. kituiensis on hematological parameters in rate after 4 weeks of treatment 
Sex Parameter Dose mg/kg      n = 5 Sex Dose mg/kg        n = 5 
    150mg/kg 300mg/kg 500mg/kg 0mg/kg  150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F WBC 91.40±0.09 97.44±0.12* 99.42±0.51* 93.23±0.01 M 69.12±0.02 80.82±0.02 88.91±1.02* 78.23±0.02 
 LYMP 65.40±0.02 68.00±0.13* 68.02±0.15* 65.00±0.02  55.02±0.11 65.00±0.01 70.00±0.12* 62.0±0.50 
 MON 19.00±0.12 21.04±0.14* 22.00±0.10* 16.03±0.08  12.10±0.12 14.80±0.11 15.60±0.30 12.20±1.02 
 NEU 7.00±0.02 8.40±0.15 9.02±0.09* 6.20±0.04  2.00±0.10 2.02±0.05 3.01±0.12* 2.03±0.03 
 RBC 7.57±0.15 8.72±0.11* 8.90±0.12* 7.37±0.01  6.21±0.04 6.92±0.01 7.93±0.01* 5.90±0.03 
 MCV 53.7±0.02 63.22±0.17* 66.01±0.31* 55.23±0.06  59.11±0.02 60.23±0.07 64.23±1.07* 58.0±0.03 
 HCT 42.9±0.13 46.0±0.12* 49.32±0.12* 41.90±0.07  40.13±0.10 41.12±0.01 46.23±0.09* 39.18±0.03 
 MCH 24.54±0.02 28.72±0.19* 30.83±0.01* 24.23±08  19.01±0.01 20.21±0.18 22.22±0.0* 19.31±0.01 
 MCHC 33.52±0.02 37.04±0.2* 38.05±0.90* 32.40±0.01  30.02±0.17 33.21±0.09 36.23±0.03* 30.05±0.02 
 RDW 13.34±0.01 18.21±0.21 19.05±0.10* 16.21±1.10  13.0±0.6 14.81±0.10 15.12±1.10 16.91±0.05 
 HB 14.31±0.01 15.01±0.25 15.13±0.10 14.23±1.01  13.22±0.09 14.8±0.23 14.12±0.01 13.34±0.01 
Values are expressed as mean ± SD. P > 0.05 when compared to control group. * = values are significantly different (p < 0.05) from that of the control): White blood cell 
(WBC), red blood cell (RBC), hematocrit (HCT), hemoglobin (HGB), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
concentration (MCHC), lymphocytes (LYM), monocytes (MON), neutrophil granulocytes (NEUT), red blood cells distribution width (RDW). 
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Table 24:  Effect of ethyl acetate extract of L. kituiensis on hematological parameters in rate after 4 weeks of treatment 
Sex Parameter Dose mg/kg n = 5 Sex Parameter Dose mg/kg n = 5 
  150mg/kg 300mg/kg 500mg/kg 0mg/kg   150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F WBC 92.40±0.09 98.74±0.12* 105.52±0.51* 93.23±0.01 M WBC 80.16±0.02 90.82±0.02* 99.81±1.02* 78.23±0.02 
 LYMP 65.40±0.02 70.00±0.13* 75.02±0.15* 65.00±0.02  LYMP 72.06±0.11* 70.07±0.01* 74.00±0.12* 62.0±0.50 
 MON 19.07±0.12 20.76±0.14 22.40±0.10 16.03±0.08  MON 14.10±0.12 17.80±0.11* 18.60±0.03* 12.20±1.02 
 NEU 8.00±0.02 8.70±0.15* 8.80±0.09* 6.20±0.04  NEU 3.00±0.10* 3.02±0.05* 3.01±0.12* 2.03±0.03 
 RBC 7.07±0.15 7.92±0.11* 8.40±0.11* 7.37±0.01  RBC 5.21±0.04 6.92±0.01* 7.93±0.01* 5.90±0.03 
 MCV 58.7±0.02 60.22±0.17* 65.01±0.31* 55.23±0.06  MCV 56.11±0.02 59.93±0.07 63.93±1.07* 58.0±0.03 
 HCT 44.9±0.13 44.3±0.12* 49.37±0.12* 41.90±0.07  HCT 40.13±0.13 44.12±0.01* 47.23±0.09* 39.18±0.03 
 MCH 21.4±0.05 23.2±0.10 25.23±0.51 24.23±08  MCH 20.01±0.01 21.31±0.18 24.22±0.00* 19.31±0.01 
 MCHC 33.52±0.02 36.04±0.2* 38.05±0.90* 32.40±0.01  MCHC 31.02±0.17 34.21±0.07 35.83±0.03* 30.05±0.02 
 RDW 14.34±0.03 15.21±0.21 16.05±0.10 16.21±1.10  RDW 12.0±0.60 13.81±0.10 14.12±1.10 16.91±0.05 
 HB 16.31±0.01 15.01±0.25 16.13±0.10 14.23±1.01  HB 13.22±0.06 15.8±0.23 16.12±0.01 13.34±0.01 
Values are expressed as mean ± SD. P > 0.05 when compared to control group. * = values are significantly different (p < 0.05) from that of the control): White blood cell 
(WBC), red blood cell (RBC), hematocrit (HCT), hemoglobin (HGB), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
concentration (MCHC), lymphocytes (LYM), monocytes (MON), neutrophil granulocytes (NEUT) red blood cells distribution width (RDW). 
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Table 25: Effect of methanolic extract of L. kituiensis on hematological parameters in rate after 4 weeks of treatment 
Values are expressed as mean ± SD. P > 0.05 when compared to control group. * = values are significantly different (p < 0.05) from that of the control): White blood cell 
(WBC), red blood cell (RBC), hematocrit (HCT), hemoglobin (HGB), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular 
hemoglobin concentration (MCHC), lymphocytes (LYM), monocytes (MON), neutrophil granulocytes (NEUT)and red blood cells distribution width (RDW) 
Sex Parameter Dose mg/kg n = 5 Sex Parameter Dose mg/kg n = 5 
   150mg/kg 300mg/kg 500mg/kg 0mg/kg   150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F WBC 95.70±0.09 99.64±0.12* 103.2±0.51* 93.23±0.01 M WBC 79.32±0.04 89.72±0.02* 99.91±1.02* 75.23±0.02 
 LYMP 67.70±0.02 71.60±0.13* 71.02±0.15* 65.00±0.02  LYMP 61.02±0.11 71.00±0.01* 78.00±0.42* 62.0±0.50 
 MON 20.00±0.12 20.04±0.14 22.00±0.10* 16.03±0.08  MON 15.30±0.12 16.70±0.11 18.90±0.06* 12.20±1.02 
 NEU 8.00±0.02 8.40±0.15 8.02±0.09 6.20±0.04  NEU 1.00±0.70 3.02±0.05* 3.01±0.12* 1.03±0.03 
 RBC 7.57±0.15 8.72±0.11* 9.90±0.12* 6.3±0.01  RBC 6.71±0.04 7.92±0.01* 8.33±0.01* 5.90±0.03 
 MCV 58.07±0.2 63.82±0.17* 65.41±0.31* 55.23±0.06  MCV 59.81±0.02 60.83±0.07 63.93±1.07* 58.0±0.03 
 HCT 41.9±0.13 44.3±0.12* 48.32±0.12* 41.90±0.07  HCT 40.13±0.10 43.12±0.01* 46.23±0.09* 39.18±0.03 
 MCH 20.4±0.02 23.2±0.19 26.23±0.01* 24.23±08  MCH 19.91±0.01 21.81±0.18 23.22±0.0* 19.31±0.01 
 MCHC 31.52±0.02 33.04±0.2 36.05±0.90* 32.40±0.01  MCHC 28.02±0.17 30.21±0.09 33.23±0.03* 30.05±0.02 
 RDW 12.34±0.01 13.21±0.21 16.05±0.10 16.21±1.10  RDW 12.0±0.6 13.81±0.10 14.62±1.10 16.91±0.05 
 HB 14.31±0.01 14.01±0.25 16.13±0.10 14.23±1.01  HB 12.72±0.09 12.48±0.23 14.12±0.01 13.34±0.01 
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5.3.7 Effect of C. meturiferus and L. kituiensis extract on absolute and relative organ 
body weight in the sub-acute study 
At the end of the study, data on the weights of vital organs (heart, lungs, liver, kidneys, and 
spleen) were assessed. The mean absolute and relative organ weights of male and female rats 
(spleen, heart, lungs, liver and kidneys) treated with   chloroform, ethyl acetate and methanolic 
extract in dose levels of 150 mg/kg, 300 mg/kg and 500 mg/kg were determined as shown in 
Table 26, 27, 28, 29, 30 and 31. 
The liver and heart inmale rats treated with chloroform extract of C. metuliferus showed 
significant different dose levels of 300 mg/kg and 500 mg/kg while kidney and lungs in a dose 
level of 500 mg/kg when compared with control.  For female rats, the organ weights of liver, 
heart, kidney, and lungs showed significantly increase in dose levels of 300 mg/kg and 500 
mg/kg when compared with the controls as shown in Table 26. 
For rats treated with ethyl acetate extract the organ weights of the liver and lungs of male rats 
showed significant increased in dose level of 500 mg/kg and kidney in dose levels of 300 mg/kg 
and 500 mg/kg. For female rats, the significant increase of liver, kidney and spleen in dose 
level of 500 mg/kg and lungs in a dose of 300 mg/kg and 500 mg/kg was observed as shown 
in Table 27. 
While the rats treated with methanolic extract, the mean organ weights of male and female rats 
are shown in Table 28. For male treated rats, the significant increase of liver, heart, kidney and 
lungs in dose level 500 mg/kg was observed as compared to the control. While female rats, the 
results shows a significant increase of liver and heart in dose level 300 mg/kg and 500 mg/kg, 
kidney, and spleen in dose level 500 mg/kg as compared to the control. 
For L. kituiensis plant the rats treated with chloroform extract revealed significant reduction of 
liver, lungs and kidney weight in dose level of 500 mg/kg in male rats and in female rats, the 
significant reduction of liver in a dose of 300 mg/kg and 500 mg/kg was observed while lungs 
and kidney the significant reduction was recorded in dose level 500 mg/kg as compared to the 
control group (Table 29). 
For the rats treated with ethyl acetate extract, showed significantly reduced of vital organ, 
kidney, lungs and spleen in dose level 500 mg/kg in male rats and female rats significant 
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reduced of kidney and lungs in dose level 300 mg/kg, and 500 mg/kg and liver in dose level 
500 mg/kg was observed when compared with the control group (Table 30).  
While the rats treated with methanolic extract, showed the significant reduction of liver, kidney 
and lungs weight in dose level 500 mg/kg for male and female rats when compared with the 




Table 26:  Effect of chlorofom extract of C. metuliferus on absolute (a) and relative organ weight R (%) of mice after 28 days of treatment 
Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg). 
Sex Organ Dose mg/kg n = 5 Sex Organ Dose mg/kg n = 5 
   150mg/kg 300mg/kg 500mg/kg 0mg/kg    150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F A(g) Liver 5.85±0.05 7.96±0.31* 8.93±0.11* 6.51±0.01 M A(g) Liver 5.70±0.01 7.77±0.09* 8.53±0.06* 5.98±0.02 
  Heart 0.65±0.21 0.89±0.41* 0.96±0.01* 0.75±0.21   Heart 0.71±0.01 1.55±0.10* 1.80±0.11* 0.85±0.13 
  Kidney 1.03±0.11 1.70±0.21* 1.87±0.31* 1.35±0.11   kidney 1.05±0.31 0.95±0.14 1.73±0.06* 1.20±0.21 
  Lungs 1.53±0.15 1.73±0.15* 1.95±0.10* 1.60±0.14   lungs 1.50±0.01 1.36±0.12 1.69±0.12* 1.32±0.02 
  Spleen 0.35±0.05 0.24±0.07 0.07±0.01 0.35±0.51   Spleen 0.46±0.10 0.50±0.12 0.50±0.13 0.59±0.14 
 R (%) Liver 5.79±0.56 6.10±0.06 6.35±0.03 5.89±0.03  R (%) Liver 6.30±0.25 6.02±0.11 6.92±0.14 6.99±0.13 
  Heart 1.44±0.02 1.46±0.40 1.47±0.24 1.47±0.04   Heart 1.42±0.14 1.52±0.15 1.63±0.16 1.53±0.12 
  Kidney 2.06±0.01 2.48±0.15 2.53±0.25 2.57±0.05   Kidney 1.40±0.17 1.77±0.16 1.61±0.14 1.60±0.17 
  Lung 1.52±0.06 1.60±0.11 1.63±0.01 1.60±0.06   Lung  1.77±0.18 1.87±0.14 1.65±0.11 1.75±0.02 
  Spleen 0.16±0.07 0.17±0.07 0.17±0.07 0.18±0.07   spleen 0.55±0.14 0.43±0.15 0.74±0.15 1.16±0.15 
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Table 27:  Effect of ethyl acetate extract of C. metuliferus on absolute (a) and relative organ weight R (%) of rats after 28 days of treatment 
Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg). 
Sex Organ Dose mg/kg n=5 Sex Organ Dose mg/kg n=5 
   150mg/kg 300mg/kg 500mg/kg 0mg/kg    150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F A(g) Liver 5.50±0.05 6.84±0.31 7.90±0.11* 6.51±0.01 M A(g) Liver 5.40±0.01 6.10±0.09 7.03±0.06* 5.98±0.02 
  Heart 0.67±0.21 0.65±0.41 0.77±0.01 0.75±0.21   Heart 0.71±0.01 0.80±0.20 0.80±0.12 0.82±0.12 
  Kidney 1.25±0.11 1.38±0.11 1.67±0.31* 1.35±0.11   kidney 1.45±0.11 1.75±0.14* 1.93±0.06* 1.20±0.21 
  Lungs 1.61±0.19 1.80±0.15* 1.92±0.10* 1.60±0.14   lungs 1.30±0.01 1.33±0.12 1.75±0.12* 1.32±0.02 
  Spleen 0.35±0.05 0.34±0.07 0.67±0.01* 0.35±0.51   Spleen 0.44±0.10 0.50±0.12 0.60±0.13 0.59±0.14 
 R (%) Liver 5.89±0.56 6.20±0.06 6.09±0.03 5.89±0.03  R (%) Liver 5.30±0.25 5.02±0.11 6.32±0.14 6.99±0.13 
  Heart 1.04±0.02 1.21±0.04 1.09±0.24 1.47±0.04   Heart 1.12±0.14 1.32±0.15 1.63±0.16 1.53±0.12 
  Kidney 1.06±0.01 1.38±0.15 1.23±0.25 1.57±0.05   Kidney 1.50±0.17 1.67±0.16 1.01±0.14 1.60±0.17 
  Lung 1.46±0.06 1.30±0.11 1.34±0.01 1.60±0.06   Lung 1.67±0.18 1.87±0.14 1.25±0.11 1.75±0.02 
  Spleen 0.18±0.07 0.18±0.07 0.18±0.07 0.18±0.07   spleen 0.52±0.19 0.42±0.15 0.71±0.15 1.18±0.19 
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Table 28:  Effect of methanolic extract of C. metuliferus on absolute (a) and relative organ weight R (%) of rats after 28 days of treatment 
Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg) 
Sex Organ Dose mg/kg n=5 Sex Organ Dose mg/kg n=5 
   150mg/kg 300mg/kg 500mg/kg 0mg/kg    150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F A(g) Liver 6.55±0.05 7.90±0.31* 8.43±0.11* 6.51±0.01 M A(g) Liver 5.40±0.01 5.70±0.09 7.83±0.16* 5.98±0.02 
  Heart 0.97±0.21 1.08±0.41* 1.12±0.01* 0.75±0.21   Heart 0.71±0.01 0.80±0.20 1.30±0.12* 0.82±0.12 
  Kidney 1.03±0.11 1.58±0.11 1.93±0.31* 1.35±0.11   kidney 0.65±0.11 1.48±0.14 1.93±0.06* 1.20±0.21 
  Lungs 1.53±0.19 1.80±0.15 1.90±0.10 1.60±0.14   lungs 1.33±0.01 1.26±0.12 1.94±0.12* 1.32±0.02 
  Spleen 0.35±0.05 0.97±0.07* 0.99±0.01* 0.35±0.51   Spleen 0.46±0.10 0.20±0.12 0.90±0.13 0.59±0.14 
 R (%) Liver 5.89±0.56 5.20±0.06 4.69±0.03 5.89±0.03  R (%) Liver 5.40±0.25 6.02±0.11 6.92±0.14 6.99±0.13 
  Heart 1.04±0.02 1.01±0.40 1.09±0.24 1.47±0.04   Heart 1.52±0.14 1.52±0.15 1.63±0.16 1.53±0.12 
  Kidney 1.36±0.01 1.48±0.15 1.53±0.25 1.57±0.05   Kidney 1.60±0.17 1.67±0.16 1.61±0.14 1.60±0.17 
  Lung 1.42±0.06 1.50±0.11 1.47±0.01 1.60±0.06   Lung 1.77±0.18 1.77±0.54 1.85±0.11 1.75±0.02 
  Spleen 0.18±0.07 0.18±0.07 0.18±0.07 0.18±0.07   spleen 0.42±0.19 0.42±0.15 0.11±0.15 1.18±0.19 
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Table 29:  Effect of chloroform extract of L. kituiensis on 5absolute (A) and relative organ weight R (%) of rats after 28 days of treatment 
Sex Organ Dose mg/kg n = 5 Sex Organ Dose mg/kg n = 5 
      150mg/kg 300mg/kg  500mg/kg 0mg/kg    150mg/kg 300mg/kg  500mg/kg 0mg/kg 
F A(g) Liver 5.50±0.07 4.00±0.02* 3.10±0.01* 6.51±0.01 M A(g) Liver 5.30±0.02 5.20±0.01 3.04±0.20* 5.98±0.02 
  Heart 0.70±0.01 0.54±0.01 0.44±0.01 0.75±0.21   Heart 0.77±0.15 0.77±0.10 0.78±0.12 0.82±0.12 
  Kidney 1.30±0.01 1.00±0.01 0.60±0.01* 1.35±0.11   kidney 1.30±0.13 1.00±0.11 0.70±0.13* 1.20±0.21 
  Lungs 1.30±0.06 1.30±0.10 1.00±0.10* 1.60±0.14   Lung 1.33±0.12 1.28±0.12 0.69±0.12* 1.32±0.02 
  Spleen 0.38±0.05 0.33±0.15 0.33±0.01 0.35±0.51   Spleen 0.50±0.13 0.51±0.13 0.67±0.12 0.59±0.14 
 R (%) Liver 6.10±0.03 6.20±0.01 6.98±0.01 6.89±0.03  R (%) Liver 5.90±0.12 7.96±0.15 7.56±0.13 6.99±0.13 
  Heart 1.20±0.02 1.42±0.02 1.89±0.04 1.47±0.04   Heart 1.44±0.12 1.34±0.12 1.55±0.16 1.53±0.12 
  Kidney 1.89±0.02 2.10±0.02 2.68±0.05 2.57±0.05   Kidney 1.40±0.13 1.50±0.11 1.90±0.17 1.60±0.17 
  Lung 1.60±0.03 1.85±0.01 1.87±0.6 1.90±0.06   Lung  1.66±0.13 1.78±0.13 1.98±0.18* 1.76±0.02 
  Spleen 0.71±0.04 0.66±0.12 0.76±0.13 0.18±0.07   spleen 0.70±0.11 0.71±0.14 1.31±0.18 1.18±0.19 
                                 Values are expressed as mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg). 
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Table 30:  Effect of ethyl acetate extract of L. kituiensis on absolute (A) and relative organ weight R (%) of rats after 28 days of treatment 
Sex Organ Dose mg/kg n = 5 Sex Organ Dose mg/kg n = 5 
   150mg/kg 300mg/kg 500mg/kg 0mg/kg    150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F A(g) Liver 5.50±0.07 5.20±0.02 3.80±0.01* 6.51±0.01 M A(g) Liver 5.80±0.02 4.80±0.01 3.04±0.20* 5.98±0.02 
  Heart 0.74±0.01 0.68±0.01 0.64±0.01 0.75±0.21   Heart 0.77±0.35 0.59±0.10 0.28±0.12* 0.82±0.12 
  Kidney 1.30±0.01 0.80 ±0.1* 0.60±0.21* 1.35±0.11   kidney 1.320±0.13 1.00±0.11 0.50±0.13* 1.20±0.21 
  Lungs 1.50±0.06 0.90±0.10* 0.63±0.10* 1.60±0.14   lung 1.23±0.12 1.00±0.12 0.72±0.12* 1.32±0.02 
  Spleen 0.35±0.05 0.33±0.15 0.23±0.01 0.35±0.51   Spleen 0.50±0.13 0.41±0.13 0.27±0.12 0.59±0.14 
 R (%) Liver 6.10±0.03 6.20±0.01 6.98±0.01 5.89±0.03  R (%) Liver 5.60±0.12 5.96±0.15 6.66±0.13 6.99±0.13 
  Heart 1.21±0.02 1.32±0.02 1.39±0.04 1.47±0.04   Heart 1.44±0.12 1.54±0.12 1.55±0.16 1.53±0.12 
  Kidney 2.39±0.02 2.10±0.02 2.68±0.05 2.57±0.05   Kidney 1.70±0.13 1.60±0.11 1.70±0.17 1.60±0.17 
  Lung 1.60±0.03 1.85±0.01 1.87±0.60 1.90±0.06   Lung 1.67±0.13 1.77±0.13 1.88±0.18 1.76±0.02 
  Spleen 0.61±0.04 0.67±0.12 0.86±0.13 0.18±0.07   spleen 0.50±0.11 0.61±0.14 1.41±0.18 1.28±0.19 
Values are expressed as mean± SD. A: absolute organ weig`ht (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg). 
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Table 31:  Effect of methanolic extract of L. kituiensis on absolute (A) and relative organ weight R (%) of rats after 28 days of treatment 
Sex  Organ Dose mg/kg n = 5 Sex      Organ Dose mg/kg n = 5 
      150mg/kg 300mg/kg 500mg/kg 0mg/kg    150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F A(g) Liver 6.50±0.02 5.30±0.02 4.10±0.01* 6.51±0.01 M A(g) Liver 5.50±0.12 4.90±0.21 3.44±0.20* 5.98±0.02 
  Heart 0.70±0.01 0.74±0.01 0.74±0.01 0.75±0.21   Heart 0.75±0.15 0.70±0.10 0.68±0.12 0.82±0.12 
  Kidney 1.30±0.01 0.98±0.01 0.80±0.02* 1.35±0.11   kidney 1.30±0.13 0.85±0.11 0.30±0.13* 1.20±0.21 
  Lungs 1.50±0.06 1.50±0.10 0.64±0.10* 1.60±0.14   lung 1.33±0.12 1.68±0.12 0.79±0.12* 1.32±0.02 
  Spleen 0.35±0.15 0.34±0.25 0.35±0.11 0.35±0.51   Spleen 0.50±0.13 0.51±0.13 0.47±0.12 0.59±0.14 
 R (%) Liver 6.20±0.03 6.50±0.01 6. 74±0.01 5.89±0.03  R (%) Liver 5.80±0.22 5.66±0.15 5.56±0.13 6.99±0.13 
  Heart 1.30±0.02 1.32±0.02 1.39±0.04 1.47±0.04   Heart 1.54±0.12 1.00±0.12 0.95±0.16 1.53±0.12 
  Kidney 1.89±0.02 2.10±0.02 2.68±0.05 2.57±0.05   Kidney 1.45±0.13 1.70±0.11 1.80±0.17 1.60±0.17 
  Lung 1.62±0.13 1.85±0.01 1.86±0.60 1.90±0.06   Lung  1.66±0.23 1.58±0.13 1.98±0.18 1.76±0.02 
  Spleen 0.01±0.24 0.16±0.12 0.16±0.13 0.18±0.07   spleen 0.80±0.11 0.81±0.14 1.91±0.18 1.18±0.19 
Values are expressed as Mean± SD. A: absolute organ weight (g); R: relative organ weight (%). * P< 0.05 compared with the control (0mg/kg) 
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5.3.8 Effect on biochemical parameters of C. metuliferus and L. kituiensis in sub-acute 
study 
The results on the biochemical tests of experimentally treated animals are summarized in Table 
32, 33, 34, 35, 36 and 37. Oral administration of C. metuliferus and L. kituiensis extact revealed 
significant changes in serum biochemical parameters such as Alanine transaminase (ALT), 
Alkaline phosphatase (ALP), Aspartate transaminase (AST), Albumin (ALB), Total bilirubin 
(TB), Total protein (TP), Creatinine (CREA), urea (UREA), Triglyceride (TG), Total 
cholesterol (TCHO) and Glucose (GLU) in dose level 300 mg/kg and 500 mg/kg . 
The administration of chloroform, ethyl acetate methanolic extract of  C. metuliferus revealed 
significant  increases in serum aspartate aminotransferase (AST), alkaline phosphatase (ALP) 
and Alanine aminotransferase (ALT) activities (P < 0.05) in a dose-dependent level 300 mg/kg 
and 500 mg/kg for both male and female when compared to the control as shown in Table 32, 
33  and 34. 
Chloroform, ethyl acetate methanolic extract of  L. kituiensis revealed a significant  decrease 
in serum aspartate aminotransferase (AST), alkaline phosphatase (ALP) and Alanine 
aminotransferase (ALT) activities (P < 0.05) in a dose-dependent level 300 mg/kg and 500 
mg/kg for both male and female when compared to the control as shown in Table 35, 36 and  
37. 
The result in kidney parameters (blood urea) of rats treated with chloroform extract of C. 
metuliferus revealed a significant increase in dose level 500 mg/kg in male rats, while in dose 
level 150 mg/kg and 300 mg/kg remain normal as control. And in female rats’ significant 
increase was observed in dose level 150 mg/kg, 300 mg/kg and 500 mg/kg as shown in Table 
32. For the rats treated with ethyl acetate extract revealed significant increases in dose level 
500 mg/kg both male and female rats as shown in Table 33. Methanolic extract the result 
revealed a significant increase in dose level of 300 mg/kg and 500 mg/kg when compared with 
control both female and male rats as shown in Table 34. 
For the rats treated with chloroform extract of L. kituiensis revealed significant increase at a 
dose of 500 mg/kg of male and female rats significantly increase was observed at 300 mg/kg 
and 500 mg/kg when compared to control as shown in Table 35. The rats treated with ethyl 
acetate extract, the significant increase was observed in dose level 500 mg/kg in both male and 
female as shown in Table 36, and the rats treated with methanolic extract the significant 
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increase was observed in a dose of 300 mg/kg and 500 mg/kg in male and female as compared 
to control as shown in Table 37. 
Creatinine is another kidney parameter, the rats treated with chloroform extract of C. 
metuliferus revealed significant increases in dose level 500 mg/kg and 300 mg/kg both males 
and females as compared to control as shown in Table 32. And the rats treated with ethyl acetate 
extract significantly increases of creatinine was observed in all dose levels in male and female 
rats as shown in Table 33. While the rats treated with methanolic extract revealed significant 
increase in dose level 500 mg/kg in male and 300 mg/kg and 500 mg/kg in female as compared 
with the control as shown in Table 34. The rats treated with chloroform extract of L. kituiensis 
in dose level 300 mg/kg and 500 mg/kg in Table 35, while in males no significant changes 
were observed as compared to control. The rats that treated with ethyl acetate extract revealed 
a significant increase in dose level 300 mg/kg and 500 mg/kg in male and 150 mg/kg, 300 
mg/kg and 500 mg/kg in female rats as shown in Table 36. While the rats treated with 
methanolic extract revealed a significant increase in dose level 500 mg/kg in male and female 
as compared with the control as shown in Table 37.  
Albumin blood serum is another kidney parameter tested in this study, for the rats treated with 
chloroform extract  of C. metuliferus revealed significant decreases in dose level of 500 mg/kg 
for male and female when compared with control as shown in Table 32. No significant change 
observed in male and female rats treated with ethyl acetate when compared to the control as 
shown in Table 33. For the rats treated with methanolic extract, the significant decrease was 
observed in dose level 300 mg/kg and 500 mg/kg body weight for male and female when 
compared to the control group as shown in Table 34. For rats treated with L. kituiensis 
chloroform, ethyl acetate and methanolic extract significant decrease was observed in dose 
level 500 mg/kg for male and female respectively when compared with the control group as 
shown in Table 35, 36 and  37. 
Moreover, the study tested for lipid parameters, for triglyceride level the animal treated with 
chloroform, ethyl acetate and methanolic extract of C. metuliferus revealed significant decrease 
in dose level 150 mg/kg, 300 mg/kg and 500 mg/kg when compared with control. The 
cholesterol level of treatment dose150 mg/kg, 300 mg/kg and 500 mg/kg decreases 
significantly in rats treated with chloroform, ethyl acetate and methanolic extract when 
compared to control both male and female rats as shown in Table 32, 33 and 34. And total 
protein the animal treated with chloroform extract revealed no significant change in male while 
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in the female the significant decrease was observed in dose level 300 mg/kg and 500 mg/kg as 
shown in Table 32. No significant change was observed in animals treated with ethyl acetate 
and methanolic extract as shown in Table 33 and Table 34. For the rats treated with L. kituiensis 
the rat’s male and female treated with chloroform, ethyl acetate and methanolic extract shows 
a significant decrease of triglyceride level in dose level 150 mg/kg, 300 mg/kg and 500 mg/kg 
as compared to control. The cholesterol level of treatment dose150 mg/kg, 300 mg/kg and 500 
mg/kg showed significant decreases in rats treated with chloroform, ethyl acetate and 
methanolic extract as compared to the control in the male and female rat as shown in Table 35, 
36 and 37. Total protein was another parameter tested in this study, the rats treated with 
chloroform extract revealed no significant change in male while in the female the significant 
decrease was observed in dose level 300 mg/kg and 500 mg/kg as shown in Table 35. While 
the animal treated with ethyl acetate and methanolic extract, revealed significant decrease in a 
dose of 500 mg/kg body weight as shown in Table 36 and Table 37. 
Glucose level is another parameter tested and the animal treated with chloroform extract of C. 
metuliferus revealed a significant increase in dose 500 mg/kg both for male and female rats 
(Table 32). The animal treated with ethyl acetate extract revealed significant increases in dose 
500 mg/kg for male rats and 300 mg/kg and 500 mg/kg for female rats as compared to control 
Table 33. While the rats treated with methanol extract significant increases were observed at 
dose level 500 mg/kg in male rat and 150 mg/kg, 300 mg/kg and 500 mg/kg in females as 
compared to control as shown in Table 34. For animals treated with chloroform extract of L. 
kituiensis in dose level 500 mg/kg in both male and female as shown in Table 35. The rats 
treated with ethyl acetate extract shows a significant increase in treatment dose 500 mg/kg in 
male and 300 mg/kg and 500 mg/kg in females as compared to control Table 36. While the 
animal treated with methanolic extract significant increase were observed in dose level 500 
mg/kg in male and 300 mg/kg and 500 mg/kg in female when compared to the control as shown 
in Table 37. 
Lastly total bilirubin was tested the animal treated with chloroform extract of C. Metuliferus 
revealed a significant increase in dose 500 mg/kg both male and female as compared to control 
(Table 32). While the animal treated with ethyl acetate extract revealed, significantly increases 
in the treatment dose 500 mg/kg in dose level 500 mg/kg for male and 300 mg/kg and 500 
mg/kg for females as compared to control as shown in Table 33. And the rats treated with 
methanol extract, a significant change was observed at a dose of 300 mg/kg and 500 mg/kg 
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both for male and female when compared to the control group as shown in Table 34. The 
animals treated with chloroform extract of L. kituiensi revealed a significant increase in dose 
level 500 mg/kg in both male and female as shown in Table 35. The rats treated with ethyl 
acetate extract, the treatment dose 500 mg/kg significantly increases in male and 300 mg/kg 
and 500 mg/kg in females as compared to the control group as shown in Table 36. While the 





Table 32:  Effect of the chloroform extract of C. meturiferus in biochemical parameters in rate after 4 weeks of treatment 
Sex 
Parameter Dose mg/kg n = 5 Sex Dose mg/kg n = 5 
  150mg/kg 300mg/kg 500mg/kg 0mg/kg  150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F ALP(U/L) 44.5±1.50 64.5±1.02* 77.9±1.01* 46.8±1.10 M 62.3±1.10 68.5±0.7* 78.4±1.01* 59.6±1.0 
 AST(U/L) 49.40±0.1 53.3±1.01* 55.3±1.11* 48.5±0.01  45.7±1.01 66.6±0.1* 75.7±1.0* 55.3±0.13 
 TP(g/L) 7.40±0.21 6.80±0.41* 5.9±0.01* 7.40±0.21  6.18±0.11 6.29±0.11 6.38±0.11 6.40±0.15 
 ALB (U/L 2.70±0.10 2.60±0.40 3.20±1.1* 2.80±0.30  3.00±0.50 2.80±0.4 2.40±0.10* 3.20±0.50 
  ALT(U/L) 33.6±0.21 43.6±0.01* 56.4±0.21* 31.10±0.1  34.9±0.10 39.5±1.10* 43.4±0.15* 35.4±0.9 
 GLU (mmoI/L 53.5±0.80 58.8±1.10 59.2±1.01* 54.8±1.00  55.20±0.9 58.2±1.10 61.5±0.15* 57.0±0.12 
 CREA (µmol/L 33.3±0.20 35.5±0.12* 39.2±0.02* 25.7±0.90  25.4±1.10 28.5±0.13 37.7±0.40* 28.4±0.15 
 TCHO (mmol/L 93.3±0.16* 90.0±0.08* 83.8±1.3** 117.2±2.9  66.3±0.16* 48.0±0.1** 31.5±1.50** 96.1±0.80 
 TG (mmol/L 76.3±1.10* 71.50±1.5* 57.6±0.90** 94.1±1.60  74.4±0.01* 61.3±0.01* 53.5±0.01** 94.0±2.40 
 UREA (µmol/L 24.57±0.4* 21.6±1.01* 17.18±1.0* 28.06±0.2  23.04±0.6 25.4±0.9 19.29±0.1* 29.73±0.4 
 TB (mg/dl) 0.60±0.10 0.70±0.10 0.90±0.10* 0.70±0.10  0.50±0.20 0.80±0.14 1.60±0.23* 0.70±0.20 
Values are expressed as mean± SD, * = values are significantly different (p < 0.05) from that of the control); from that of the control. Alanine transaminase (ALT), Alkaline phosphatase (ALP), 
Aspartate transaminase (AST), Albumin (ALB), Total bilirubin (TB), Total protein (TP), Creatinine (CREA), urea (UREA), Triglyceride (TG), Total cholesterol (TCHO) and Glucose (GLU). 
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Table 33:  Effect of ethyl acetate extract of C. meturiferus on biochemical parameters in rate after 4 weeks of treatment 
Sex Parameter Dose mg/kg n = 5 Sex Parameter Dose mg/kg n = 5 
  150mg/kg 300mg/kg 500mg/kg 0mg/kg   150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F ALP(U/L) 53.6±1.85* 54.6±1.02* 54.7±1.06* 46.8±1.0 M ALP (U/L) 68.3±1.10* 70.3±0.70* 71.20±1.0* 59.6±1.0 
 AST(U/L) 44.7±0.10 47.10±1.0 53.7±1.10* 48.5±0.01  ASP (U/L 58.7±0.06 62.9±0.10* 65.4±1.10* 55.3±0.13 
 TP(g/L) 7.10±0.01 6.81±0.01 5.11±0.01* 6.41±0.01  TP (g/L 6.54±0.10 6.30±0.13 6.18±0.11 6.40±0.15 
 ALB (U/L 2.70±0.70 3.0±0.60 3.80±0.50* 2.80±0.30  ALB (U/L) 3.50±0.50 3.20±0.40 3.80±0.10 3.20±0.50 
 ALT(U/L) 44.3±1.60* 45.0±1.01* 47.9±0.01* 31.1±1.0  ALT (U/L) 38.9±0.09 43.9±1.01* 48.9±1.10* 35.4±0.90 
 GLU (mmoI/L 52.3±1.0 57.1±1.15* 63.8±1.71* 54.80±1.0  GLU (mmoI/L) 56.20±0.90 58.2±1.90 62.5±0.15* 57.7±0.12 
 CREA (µmol/L 25.9±0.20* 35.9±0.10* 44.5±0.02* 25.7±0.90  CREA (µmol/L 33.40±1.10* 42.4±0.3** 48.6±0.4** 28.4±0.15 
 TCHO (mmol/L 97.8±0.16* 88.8±1.10* 62.5±1.30* 117.2±2.9  TCHO (mmol/L) 68.60±0.70* 58.2±0.90* 45.8±1.02* 96.1±0.8 
 TG (mmol/L 83.2±1.5* 74.2±1.4* 58.1±0.90* 94.1±1.60  TG (mmol/L 82.10±0.01* 74.90±1.5* 62.20±0.9* 94.0±2.4 
 UREA (µmol/L 32.95±1.4 25.60±84 23.00±0.1* 28.06±0.2  UREA (µmol/L 28.55±0.90 26.34±0.6 22.60±0.1* 29.73±0.4 
 TB (mg/dl) 0.60±0.10 1.70±0.10* 1.80±0.20* 0.70±0.01  TB (mg/dl) 0.70±0.10 0.70±0.1 1.30±0.20* 0.70±0.20 
Values are expressed as mean± SD, * = values are significantly different (p < 0.05) from that of the control); ** = values are more significantly different (p < 0.01) from that 
of the control. Alanine transaminase (ALT), Alkaline phosphatase (ALP), Aspartate transaminase (AST), Albumin (ALB), Total bilirubin (TB), Total protein (TP), Creatinine 
(CREA), urea (UREA), Triglyceride (TG), Total cholesterol (TCHO) and Glucose (GLU). 
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Table 34:  Effect of methanolic extract of C. meturiferus on biochemical parameters in rate after 4 weeks of treatment 
Sex Parameter Dose mg/kg n = 5 Sex Parameter Dose mg/kg n = 5 
  150mg/kg 300mg/kg 500mg/kg 0mg/kg   150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F ALP(U/L) 37.5±1.20* 49.3±1.05* 55.5±1.02* 46.8±1.0 M ALP (U/L) 53.3±1.10 58.4±0.10 65.3±1.0* 59.6±1.0 
 AST(U/L) 44.6±0.70 52.6±0.06* 55.8±1.10* 48.5±0.01  AST (U/L 57.2±0.90 62.1±0.10* 68.9±1.0* 55.3±0.13 
 TP(g/L) 0.13±0.01 0.11±0.01 0.01±0.01 0.11±0.01  TP (g/L 0.18±0.11 0.18±0.11 0.18±0.11 0.18±0.11 
 ALB (U/L 2.60±0.20 2.00±0.40* 1.70±1.10* 2.80±0.30  ALB (U/L) 3.20±0.50 2.6±0.10* 2.4±0.10* 3.2±0.50 
 ALT(U/L) 52.9±0.70* 54.6±0.60* 57.0±0.50* 31.1±0.09  ALT (U/L) 35.1±1.50 39.4±0.70* 43.3±0.10* 35.4±0.9 
 GLU (mmoI/L 59.5±0.8* 62.8±1.50* 69.0±1.07* 54.8±1.0  GLU (mmoI/L) 59.2±0.9 60.8±1.1 68.4±0.15* 57.0±0.12 
 CREA (µmol/L 31.0±0.50* 32.6±0.12* 34.7±0.02* 25.7±0.9  CREA (µmol/L 25.2±1.10 29.5±0.15* 33.7±0.40* 28.4±0.15 
 TCHO (mmol/L 72.7±0.16* 65.4±0.6** 52.8±1.3** 117.2±2.9  TCHO (mmol/L) 97.4±0.12 77.1±0.9* 65.1±0.50* 96.1±0.8 
 TG (mmol/L 65.5±1.14* 53.9±1.4** 46.2±0.9** 94.1±1.6  TG (mmol/L 85.5±0.01* 84.0±1.50* 78.3±0.10* 94.0±2.4 
 UREA (µmol/L 28.44±0.4 24.39±1.0* 20.58±1.0* 28.06±0.2  UREA (µmol/L 22.58±0.6* 21.67±0.9* 18.29±0.8* 29.73±0.4 
 TB (mg/dl) 0.8±0.1 0.8±0.10 0.9±0.1 0.7±0.0  TB (mg/dl) 0.60±0.20 0.8±0.1 0.80±0.20 0.70±0.20 
Values are expressed as mean± SD, * = values are significantly different (p < 0.05) from that of the control); ** = values are more significantly different (p < 0.01) from that of the control. Alanine 
transaminase (ALT), Alkaline phosphatase (ALP), Aspartate transaminase (AST), Albumin (ALB), Total bilirubin (TB), Total protein (TP), Creatinine (CREA), urea (UREA), Triglyceride (TG), 
Total cholesterol (TCHO) and Glucose (GLU) 
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Table 35:  Effect of chloroform extract of L. kituiensis in biochemical parameters in rate after 4 weeks of treatment 
Sex Parameter Dose mg/kg n=5 Sex Dose mg/kg n=5 
  150mg/kg 300mg/kg 500mg/kg 0mg/kg  150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F ALP(U/L) 42.6±1.1 38.9±0.01* 35.4±1.0* 46.8±1.1 M 55.6±0.1 58.3±0.09 59.6±1.0 59.6±0.1 
 AST(U/L) 45.6±0.1 36.1±1.0* 34.9±0.9* 48.5±0.1  38.9±1.1* 31.2±1.10* 28.9±0.9* 55.3±0.10 
 TP(g/L) 7.10±0.01 7.31±0.01 6.98±0.1* 7.40±0.01  6.40±0.11 6.2±0.11 5.2±0.11* 6.40±0.11 
 ALB (U/L 2.8±0.10 2.7±0.40 2.1±0.8* 2.8±0.30  3.1±0.7 2.9±0.20 2.1±0.80* 3.2±0.50 
 ALP (U/L) 2.2±0.11 1.8±0.41 1.5±0.9* 2.8±0.40  3.1±0.8 3.8±0.3* 4.3±0.90* 3.2±0.60 
 GLU (mmoI/L 64.3±1.1 66.8±1.0* 74.6±1.0* 54.8±0.02  54.6±1.4 63.2±1.1* 66.8±1.01* 57.0±0.60 
 CREA (µmol/L 28.4±1.0 31.8±1.0* 34.2±1.7* 25.7±0.90  25.4±1.1 24.6±0.6 21.7±0.01 28.4±1.0 
 TCHOL (mmol/L 97.3±1.1* 67.9±0.9** 57.2±1.5** 117.2±2.9  96.5±1.5 83.2±0.1* 81.3±0.80* 96.1±0.30 
 TG (mmol/L 75.3±0.05* 53.1±0.7** 34.6±0.3** 94.1±1.60  88.9±0.1* 83.3±0.8* 54.2±0.10** 94.8±0.17 
 UREA (µmol/L 24.31±0.1 24.36±0.8 26.25±1.5 28.06±0.2  28.19±0.7 25.64±0.9 23.29±1.0* 29.06±0.2 
 TB (mg/dl) 0.8±0.1 0.9±0.1 1.5±0.4* 0.7±0.01  0.4±0.1 0.8±0.1 1.3±0.01* 0.7±0.20 
Values are expressed as mean± SD, * = values are significantly different (p < 0.05) from that of the control); ** = values are more significantly different (p < 0.01) from that of the control. Alanine 
transaminase (ALT), Alkaline phosphatase (ALP), Aspartate transaminase (AST), Albumin (ALB), Total bilirubin (TB), Total protein (TP), Creatinine (CREA), urea (UREA), Triglyceride (TG), 
Total cholesterol (TCHO) and Glucose (GLU). 
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Table 36:  Effect of ethyl acetate extract of L. kituiensis in biochemical parameters in rate after 4 weeks of treatment 
Sex Parameter Dose mg/kg n = 5 Sex Parameter Dose mg/kg n = 5 
  150mg/kg 300mg/kg 500mg/kg 0mg/kg   150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F ALP(U/L) 45.8±0.9 38.4±0.01* 36.5±1.0* 46.8±1.1 M ALP (U/L) 54.3±0.10 48.0±0.07 42.3±1.0* 59.6±0.1 
 AST(U/L) 45.8±0.1 53.8±1.0* 58.9±0.9* 48.5±0.1  AST (U/L 48.3±1.10* 45.7±1.10* 43.9±0.9* 55.3±0.10 
 TP(g/L) 7.70±0.01 7.10±0.91 6.11±0.1* 7.4±0.01  TP (g/L 6.50±0.1 6.0±0.01* 5.81±0.1* 6.40±0.15 
 ALB (U/L 2.7±0.50 2.6±0.50 2.0±0.40* 2.8±0.3  ALB (U/L) 3.4±0.20 3.2±0.20 2.3±0.80* 3.2±0.50 
 ALP (U/L) 2.8±0.11 1.9±0.41* 1.8±0.9* 2.8±0.4  ALP (U/L) 3.10±0.80 2.5±0.30* 2.10±0.9* 3.2±0.60 
 GLU (mmoI/L 56.7±1.1 58.8±1.0* 65.5±1.0* 54.8±0.02  GLU (mmoI/L) 55.3±1.4 59.8±1.1 69.8±1.2* 57.0±0.6 
 CREA (µmol/L 30.5±1.0* 32.5±1.0* 35.3±1.7* 25.7±0.9  CREA (µmol/L 29.5±1.2 31.06±0.6* 35.4±0.1* 28.4±1.0 
 TCHO (mmol/L 88.4±1.1* 71.9±0.9* 65.4±1.5** 117.2±2.9  TCHO (mmol/L) 81.7±1.5* 74.5±1.1* 53.1±0.5** 96.1±0.3 
 TG (mmol/L 77.5±1.0* 71.6±0.7* 68.2±1.5** 94.1±1.6  TG (mmol/L 64.8±0.1** 61.3±0.9** 42.6±0.1** 94.18±0.7 
 UREA (µmol/L 27.16±1.0 25.31±0.8 18.7±1.0* 28.6±0.2  UREA (mmol/L 29.51±0.7 25.93±0.9 21.22±1.0* 29.06±0.2 
 TB (mg/dl) 0.6±0.1 0.7±0.1 0.9±0.4 0.7±0.0  TB (mg/dl) 0.7±0.20 0.9±0.10 1.5±0.01* 0.70±0.20 
Values are expressed as mean± SD Values are expressed as mean± SD, * = values are significantly different (p < 0.05) from that of the control);** = values are more significantly different (p < 
0.01) from that of the control, Alanine transaminase (ALT), Alkaline phosphatase (ALP), Aspartate transaminase (AST), Albumin (ALB), Total bilirubin (TB), Total protein (TP), Creatinine 
(CREA), urea (UREA), Triglyceride (TG), Total cholesterol (TCHO) and Glucose (GLU), 
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Table 37:   Effect of methanolic extract of L. kituiensis in biochemical parameters in rate after 4 weeks of treatment 
Sex Parameter Dose mg/kg n = 5 Sex Parameter Dose mg/kg n = 5 
    150mg/kg 300mg/kg 500mg/kg 0mg/kg   150mg/kg 300mg/kg 500mg/kg 0mg/kg 
F ALP(U/L) 54.7±1.10* 65.3±1.01* 68.6±1.0* 46.8±1.1 M ALP (U/L) 54.6±0.10* 60.6±0.09* 68.9±1.01* 59.6±0.1 
 AST(U/L) 48.3±0.10 55.5±1.0* 58.4±0.9* 48.5±0.1  AST (U/L 53.4±1.10 62.4±1.10* 68.4±0.90* 55.3±0.10 
 TP(g/L) 7.26±0.10 6.88±0.61* 6.08±0.1* 7.4±0.21  TP (g/L 6.34±0.41 6.06±0.21 5.21±0.61* 6.18±0.11 
 ALB (U/L 3.3±0.200 2.60±1.10 1.40±0.4* 2.8±0.30  ALB (U/L) 3.10±0.20 2.90±0.20 2.10±0.80* 3.2±0.50 
 ALT (U/L) 32.4±0.11 45.3±0.41* 48.5±0.9* 31.1±0.9  ALT (U/L) 32.4±0.80 35.8±0.90 39.3±0.60* 35.4±0.90 
 GLU (mmoI/L 54.4±1.10 58.7±1.2* 63.6±1.5* 54.8±0.2  GLU (mmoI/L) 54.3±1.40 57.0±1.17 63.10±1.0* 57.0±0.60 
 CREA (µmol/L 25.4±1.01 29.4±1.09* 32.2±1.4* 25.7±0.90  CREA (µmol/L 24.9±1.10 28.9±0.60 35.6±0.10* 28.4±1.01 
 TCHO (mmol/L 85.2±1.10* 72.3±0.90* 67.3±1.50* 117.2±2.9  TCHO (mmol/L) 65.4±1.50* 58.0±0.10* 43.3±0.80* 96.1±0.31 
 TG (mmol/L 77.5±1.01* 66.0±0.70* 54.2±0.30** 94.1±1.60  TG (mmol/L 79.3±0.90* 72.6±0.80* 60.9±0.10** 94.0±0.17 
 UREA (µmol/L 23.31±0.1 22.25±0.8* 18.74±0.9* 28.06±0.2  UREA (mmol/L 27.07±0.8 25.86±0.9* 18.81±1.0* 29.06±0.2 
 TB (mg/dl) 0.5±0.1 0.8±0.1 1.9±0.40* 0.7±0.01  TB (mg/dl) 0.60±0.10 0.70±0.10 1.8±0.01* 0.70±0.20 
Values are expressed as mean± SD, Values are expressed as mean± SD, * = values are significantly different (p < 0.05) from that of the control); from that of the control 
Alanine transaminase (ALT), Alkaline phosphatase (ALP), Aspartate transaminase (AST), Albumin (ALB), Total bilirubin (TB), Total protein (TP), Creatinine (CREA), urea 
(UREA), Triglyceride (TG), Total cholesterol (TCHO) and Glucose (GLU). 
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5.3.9 Histopathological examination 
The results of histopathological examination of liver, kidney, lungs, and spleen section in rats 







Figure 3: Photomicrograph of kidney section of rats treated with chloroform extract of C. 
metuliferus (male and female) 40x magnifications 
The results of histopathological examination of kidney section in rats treated with chloroform 
extract of C. metuliferus are shown in Fig. 3. The kidney in rats administered with 300 mg/kg 
body weight presented the distracted glameli red arrow and normal of tubules (Fig. 3B). For 
the kidney in rats administered with 500 mg/kg body weight shows mild tubular necrosis (green 
arrow), the distraction of glomerula and Bowman capsule as shown in Fig. 3C (red arrow). 
While the female rats treated with 500 mg/kg body weight showed shrinkage of glomerula, 
inflammations black arrow and degeneration of tubular cells as shown in Fig. 3A when 
compared to control (Fig. 3D). 










Figure 4: Photomicrograph of kidney section of rats treated with methanolic extract of C. 
metuliferus male and female 40x magnifications 
Photomicrographs of the kidney section of rats administered with methanolic extract at a dose 
of 300 mg/kg, 500 mg/kg body weight are shown in Fig. 4. The kidney in rat’s adiministed 
with   300 mg/kg bodyweight of methanolic extract of C. metuliferus showed distraction of 
bowman capsule and tubules (Fig. 4A) red arrow as compared to controls (Fig. 4D). While the 
rats administered with 500 mg/kg body weight showed mild tubular necrosis Fig. 4C green 
arrow and distraction of glomerula and bowman capsule (Fig.4B) red arrow as compared to the 
control. And the kidney in rat’s adimistered with dose level 500 mg/kg showed shrinkage of 







A-500 mg/kg                   B-500 mg/kg                      C-0 mg/kg                      D-300 mg/kg 
Figure 5:  Photomicrograph of kidney section of rats treated with chloroform extract of L. 
kituiensis (male and female) 40x magnifications 
A-300 mg/kg              B-500 mg/kg                 C-500 mg/kg                     D-0 mg/kg 
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The results of histopathological examination of kidney section in rats treated with chloroform 
extract of L. kituiensis are shown in Fig. 5. The kidney in rats administered with 300 mg/kg 
showed degeneration of tubular cells and intact glomerula (Fig. 5A & D). For the kidney in 
rats administered with chloroform extract in a dose of 500 mg/kg body showed the distraction 
of glomerula and bowman capsule red arrow and congestion yellow arrow (Fig. 5B). While 
500 mg/kg body weight showed shrinkage of glomerula, inflammations, and degeneration of 






    A- 300 mg/kg                B-500 mg/kg                    C-500 mg/kg             D-0 mg/kg             
Figure 6: Photomicrograph of kidney section of rats treated with ethyl acetate extract of L. 
kituiensis (male and female) 40x magnifications 
The photomicrograph of the kidney section in rats administered with ethyl acetate at a dose of 
300 mg/kg showed degeneration of tubular and tubular necrosis (Fig. 6A) -green arrow. The 
kidney in rats treated with 500 mg/kg body weight showed mild tubular necrosis, destruction 
of glomerular and bowman's capsule (Fig. 6C) red arrow. And the rat administered with 500 
mg/kg body weight shrinkage of Bowman capsule space, degeneration of tubular cells, mild to 
moderate necrosis and blood congestion yellow arrow was observed in Fig. 6B as compared to 









Figure 7: Photomicrograph of liver section of rats treated with chloroform extract of C. 
metuliferus (male and female) 40x magnifications. 
The results of histopathological examination of the liver section in rats treated with chloroform 
extract of C. metuliferus are shown in Fig. 7. The liver in rats administered with dose level 300 
mg/kg in all extract showed mild necrosis, portal congestion and vacuolation as shown in Fig. 
7C. For the liver in rats administered with 500 mg/kg body weight showed hepatic necrosis, 
bile lakes and shrinkage of cell in the liver was observed in both male and female and 
vacuolation (Fig.7D). While the liver in rats treated with dose level 500 mg/kg body weight 
showed bile duct hyperplasia in the portal triad, moderate hepatic necrosis, and portal 






     A- 300 mg/kg                   B-500 mg/kg                    C- 0 mg/kg                 D-500 mg/kg 
Figure 8: Photomicrograph of liver section of rats treated with methanolic extract of C. 
metuliferus (male and female) 40x magnifications. 
 
A – 500 mg/kg               B-0 mg/kg                           C -300 mg/kg             D-500 mg/kg 
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The results of histopathological examination of the liver section in rats treated with chloroform 
extract of C. metuliferus are shown in Fig. 8. The liver in rats administered with 300 mg/kg 
body weight showed mild necrosis, congestion yarrow arrow and vacuolation black arrow. 
While the liver in rats treated with dose level 500 mg/kg body weight showed bile duct 
hyperplasia in the portal triad green arrow, moderate hepatic necrosis red arrow, and portal 
congestion as shown in Fig. 8A as compared to control (Fig. 8B). And the rats administered 
with dose level, 500 mg/kg showed severe necrosis (Fig. 8D). 
 
A -500 mg/kg              B-0 mg/kg                       C -300 mg/kg                        D-300 mg/kg 
Figure 9: Photomicrograph of liver section of rats treated with chloroform extract of L. 
kituiensis (male and female) 40x magnifications. 
The results of histopathological examination of the liver section in rats treated with chloroform 
extract of L. kituiensis are shown in Fig. 9. The liver in rats administered with 300 mg/kg for 
28 days presented the normal portal triad with vacuolation black arrow and mid necrosis as 
shown in Fig. 9D. For the liver in rats administered with 500 mg/kg body weight showed mild 
hepatic necrosis red arrow, vacuolation black arrow and normal portal triad as shown in Fig. 











Figure 10: Photomicrograph of liver section of rats treated with methanolic extract of L. 
kituiensis (male and female) 40x magnifications. 
The results of histopathological examination of the liver section in rats treated with methanolic 
extract of L. kituiensis are shown in Fig. 10. The liver in rats administered with 300 mg/kg of 
methanolic extract showed normal portal triad and mid necrosis as shown in Fig. 10C red 
arrow. For the liver in rats administered with 500 mg/kg body weight of methanolic extract 
showed mild hepatic necrosis, vacuolation black arrow and normal portal triad as shown in Fig 
10D, while 500 mg/kg body weight showed hepatic necrosis red arrow and congestion and bile 







Figure 11: Photomicrograph of lungs section of rats treated with chloroform extract of C. 
metuliferus (male and female) 40x magnifications 
The results of histopathological examination of the lung section in rats treated with chloroform 
extract of C. metuliferus are shown in Fig. 11. The lungs in rats administered with 300 mg/kg 
A-500 mg/kg                    B- 0 mg/kg                   C 300 mg/kg                    D 500 mg/kg 
A-500 mg/kg                     B-0 mg/kg                 C- 300-mg/kg                D- 500 mg/kg 
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body weight of chloroform extract showed thickened alveolar wall, narrow respiratory ducts 







Figure 12: Photomicrograph of lung section of rats treated with ethyl acetate extract of L. 
kituiensis (male and female) 40x magnifications. 
The results of histopathological examination of the lungs section in rats treated with ethyl 
acetate extract of L. kituiensis are shown in Fig. 12. The lungs in rats administered with 300 
mg/kg and 500 mg/kg body weight of ethyl acetate extract showed thickened alveolar wall and 
narrow respiratory ducts red arrow, hemorrhage (green arrow) and congestion (black arrow) 
(Fig.12A, B & C) as compared to control (Fig. 12D). 
 
 
Figure13: Photomicrograph of spleen section of rats treated with chloroform extract of C. 
metuliferus (male and female) 40x magnifications 
 
A-500 mg/kg                     B-500 mg/kg                          C- 300 mg/kg                D- 0 mg/kg 




The results of histopathological examination of the spleen section in rats treated with 
chloroform extract of C. metuliferus are shown in Fig. 13. The spleen in rats administered with 
300 mg/kg showed mid distraction of red and white pulp and 500 mg/kg body weight of 
chloroform extract showed distraction of red and white pulp appearance (Fig. 13A, B & C) as 







     0 mg/kg A                         A500 mg/kg B                  300 mg/kg C         500 mg/kg D 
Figure14: Photomicrograph of spleen section of rats treated with methanolic extract of L. 
kituiensis (male and female) 40x magnifications 
The results of histopathological examination of the spleen section in rats treated with 
methanolic extract of C. metuliferus were shown in Fig. 14. The spleen in rats administered 
with 300 mg/kg and 500 mg/kg body weight of methanolic extract showed the distraction of 
red and white pulp appearance (Fig. 14B, C & D) red arrow as compared to control (Fig. 14A) 
purple. 
5.4 Discussion 
Toxicity is an expression of being poisonous, indicating the state of adverse effects led by the 
interaction between toxicants and cells (Das et al., 2015). The acute toxicity study of C. 
meturiferus and L. kituiensis extract was carried out as per Muhammad et al. (2015). The single 
oral dose administration of C. meturiferus and L. kituiensis in albino rats at a dose of 300 mg/kg, 
600 mg/kg and 1500 mg/kg  revealed  neither  mortality nor clinical signs, like changes in fur 
and skin, drowsiness, tremors, Lacrimation, salvation, temperature, diarrhea, eyes, respiratory 
rate were observed. No significant reduction in feed and water intake of the treated rats in either 
sex through the 14-day study; this is a pointer to the fact that the diet and water were well 
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accepted by the animals, suggesting that the extracts did not interfere with the metabolism of 
in the treated animals. This report is in agreement with the work reported by Akhila et al. 
(2007) and therefore this supports the traditional usage of the plant by the oral route. 
Insignificant difference in the bodyweight gain of all the animals treated with chloroform, ethyl 
acetate and methanolic extract of C. meturiferus and L. kituiensis in all doses 300 mg/kg, 600 
mg/kg and 1500 mg/kg were observed. This suggests that extracts did not interfere the normal 
body metabolism of the animals as the increment in food and water intake is synonymous with 
an increase in body weight. This result is in agreement with the findings reported by Raza and 
Al-shabanah (2002). The assessment of blood hematology provides an insight into possible 
damage brought about by the extract in the hematopoietic system (Rasekh et al., 2008). No 
significant change was observed in organ weight and  hematological parameters white blood 
cell (WBC), red blood cell (RBC), hematocrit (HCT), hemoglobin (HGB), mean corpuscular 
hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
concentration (MCHC), lymphocytes (LYM), monocytes (MON), neutrophil granulocytes 
(NEUT), Red blood cells distribution Width (RDW) in rats treated with chloroform, ethyl 
acetate and methanolic extract of C. meturiferus and L. kituiensis in all doses 300 mg/kg, 600 
mg/kg and 1500 mg/kg body weight. This report is in agreement with the work reported by 
Clarke et al. (2011). The LD50 value was established to be not greater than 2000 mg/kg, 
throughout the repeated dose 28-day administration of C. meturiferus and L. kituiensis no 
morbidity or mortality no clinical signs, like changes in fur, skin were observed in the extract 
treated rats. This result align with the findings reported by Olorunnisola (2012). In addition to 
that no significant reduction in feed and water intake of the treated rats in male and female sex 
was observed; this is a pointer to the fact that the diet and water were well accepted by the rats, 
suggesting that the extracts did not alter the metabolism processes. This may also signify that 
the nutritional status of weight gain and appetite stability of the animal did not adversely affect 
by the extracts. This corroborates the traditional usage of the plant by the oral route. 
The body weight changes may reflect the general health status of animals (Michael et al., 2015). 
However, the body weight gain witnessed in all the animals treated with C. metuliferus and L. 
kituiensis in dose level 150 mg/kg, 300 mg/kg and 500 mg/kg of chloroform, ethyl acetate and 
methanolic extract suggests that the extracts did not interfere with normal body metabolism of 
the animals as the increment in food and water intake is synonymous with an increase in body 
weight. This result corroborates with the findings reported by Sireeratawong (2008), and this 
supports the traditional usage of this plants. 
111 
 
Organ weight is one of the most sensitive drug toxicity indicators (Yano et al., 2007). Based 
on the results, the toxicant present in the plant greatly affects the heart, liver, kidney and spleen, 
which were presented with an absolute difference. The rats treated with chloroform, ethyl 
acetate and methanolic extract of C. meturiferus shows a significant increase in heart, liver, 
kidney and spleen in dose level 300 mg/kg and 500 mg/kg body weight. This result is in 
agreement with the findings reported by Sireeratawong (2010). While the rats treated with 
chloroform, ethyl acetate and methanolic extract of L. kituiensis revealed a significant decrease 
in heart, liver, kidney and spleen in dose level 300 mg/kg and 500 mg/kg body weight. The 
alteration of organ weight provides an insight into possible damage of organs brought by the 
extract in the hepatic and renal functions. The alterations in liver weight may suggest treatment-
related changes including hepatocellular hypertrophy (enzyme induction or peroxisome 
proliferation or lipidosis) however; elevation of liver weight signifies enzyme-induction, which 
is one marked activity of a terpene. Changes in kidney weight may reflect renal toxicity. Spleen 
is one of the histopathological indicators for possible immune toxicity; the depressing weight 
of spleen suggests cell depletion and is viewed as a potentially immunotoxic effect but still 
requires more definitive testing (Firenzuoli et al., 2008).  
Blood parameters analysis is relevant to risk evaluation as the hematological system has a 
higher predictive value for toxicity in humans when assay involves animals (Olson et al., 2000). 
Blood is an important index of physiological and pathological status in both animals and 
humans and the parameters usually measured are red blood cell count (RBC), white blood cell 
count (WBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
platelets (PLT), lymphocytes (LYM), and monocytes (MON). In this study, the rats treated 
with chloroform, ethyl acetate and methanolic extract of C. meturiferus and L. kituiensis shows 
a significant increase in in the above-mentioned blood parameters in dose level 300 mg/kg and 
500 mg/kg body weight. From this result, it is possible that the extract contains agents that 
stimulate the bone marrow to produce neutrophils and release them into the blood. Neutrophils 
are the major granulocytes to be activated when the body is invaded by bacteria and they 
provide the first line of defense against invading microorganisms. The granules of the 
neutrophil contain many enzymes, which makes it a powerful and effective killing machine. 
This effect on neutrophil count may be partly responsible for the claim that C. metuliferus and 
L. kituiensis have antibacterial actions.  
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The study also revealed a significant rise in lymphocytes which signify the potential usefulness 
of the plant as immune system stimulant, a factor that may justify the use of the plant in the 
treatment of cancer (Hoffmann, 2003). In addition, the significant increase in lymphocytes in 
the tested animals suggests that the extract may have immune stimulating properties (Bruneton, 
1995; Govid et al., 2012; Hoffmann, 2003). According to Lissoni (2006) the plants that show 
anticancer chemotherapies tend to raise lymphocyte numbers by producing interleukine2 that 
modulates cytokines that promote differentiation of lymphocyte precursor cells into mature 
lymphocytes, due to that these two plants may have anticancer effects that triggered the rise of 
WBC (Lissoni et al., 2006; Lisson et al., 1999). In general, this result suggests that the extract 
did not change the hemopoietic sites that produce white blood cells in treated groups. 
Moreover, red blood cell distribution width (RDW) is a measure of erythrocyte size variability; 
it has been used as a good indicator of renal disease (Solak et al., 2014). The RDW is a change 
in RBC shapes, caused by several factors like nutrition, heart diseases, iron deficiency and 
chemotherapy, in humans. In this study, C. metuliferus showed a significant increase of RDW 
in rats treated with chloroform, ethyl acetate and methanolic extract; this increase may be 
associated with renal impairment (Yakubu et al., 2007; Tekce et al., 2014).  
The assessment of clinical biochemistry provides an insight into possible damage brought 
about by the extract in the hepatic and renal functions. In toxicity studies, assessment of liver 
and kidney functions is germane because both organs are essential for the survival of an 
organism (Olorunnisolaet al., 2012). In this study Alanine transaminase (ALT), Alkaline 
phosphatase (ALP), Aspartate transaminase (AST), Albumin (ALB), Total bilirubin (TB), 
Total protein (TP), Creatinine (CREA), urea (UREA), Triglyceride (TG), Total cholesterol 
(TCHO) and Glucose (GLU) were measured. Alanine aminotransferase (ALT), aspartate 
transaminase (AST), and alkaline phosphatase (ALP) are sensitive enzymes used in assessing 
the severity of liver damage (Ramaiah et al., 2011). Elevated activities of these enzymes are 
associated with liver or heart damage (Wasan et al., 2001; Brawtbar et al., 2002). The rats 
treated with Chloroform, ethyl acetate and methanolic extract of C. metuliferus in 300 mg/kg 
and 500 mg/kg showed significant increases in ALT and AST of the treated animals in both 
sexes compared with control. This could suggest that C. metuliferus may have hepatotoxic 
effect, while the increase of ALP might suggest obstruction of the biliary tract which may be 
present in the liver. An elevation in the activity of liver enzymes (ALT, AST and ALP) is 
conventionally an indicator of liver injury. This result aligns with findings reported by Tarkang 
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(2010) on the sub acute and subchronic toxicity of the aqueous and ethanol leaf extracts of 
Carica papaya in Wistar rats.  
While the rats treated with L. kituiensis revealed a significant reduction of ALT, AST and ALP 
in dose level 300 mg/kg and 500 mg/kg, this could suggest that L. kituiensis that may not have 
a hepatotoxic effect. Measurement of blood urea and creatinine concentration reflects the 
likelihood of renal problems or dysfunction (Lameire et al., 2005). Creatinine is a by product 
of muscle cellular metabolism for energy production and is removed by kidneys to a level that 
can be accommodated by the body (BioSystems, 2016). The results in this study reveal a 
significant increase of blood urea to the rats treated with chloroform, ethyl acetate and 
methanolic extract of C. metuliferus and L. kituiensis in dose level 300 mg/kg and 500 mg/kg. 
Destruction of the glomeruli causes a significant decrease in the glomerular filtration rate and 
that results to increase in blood urea and creatinine resulting in chronic renal failure. Creatinine 
is not supposed to be reabsorbed but all creatinine that is filtered in the glomerular filtrate 
passes on through the tubular system and is excreted in the urine. In this situation, creatinine is 
reabsorbed rather than excreted in the urine. The abnormal values of kidney parameters such 
as blood urea nitrogen (BUN) and creatinine suggest that sub-acute administration of C. 
metuliferus and L. kituiensis can course damage to the kidney. The result of this study is 
consistent with the findings of Builders et al. (2011). 
Albumin is a big part of the serum protein produced from the liver and excreted through the 
kidneys (Townsed et al., 1990). In this study the rats treated with chloroform, ethyl acetate and 
methanolic extract of C. meturiferus and L. kituiensis shows a significant decrease in dose level 
300 mg/kg and 500 mg/kg body weight. A reduction in albumin is an indication of impaired 
hepatocellular function (Thapa et al., 2008). However, a significant difference in the serum 
level of these parameters upon prolonged administration of C. metuliferus and L. kituiensis, 
when compared with the control further, corroborates the fact that the extracts destroy the 
secretory functions of the liver. Therefore, a decrease of albumin can directly be linked to liver 
damage and kidney disfunction (Thapa & Walia, 2007). 
Triglycerides and Cholesterol make up the body lipids, in this study the results showed a 
significant decrease in dose level 300 mg/kg and 500 mg/kg in both plants as compared to the 
control group. This result signifies that the two plants may have hypolipidemic effects, and this 
result is in agreement with that reported by Khanna et al. (2010). In addition to that, 
abnormalities in the concentration of major lipids like cholesterol (TCHO) and triglycerides 
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(TG) can give useful information on the lipid metabolism as well as the predisposition of the 
animals to atherosclerosis and its complications.  
In this study, total protein was also tested, the results of total protein revealed a significant 
decrease in rats treated with chloroform, ethyl acetate and methanolic extract of C. metuliferus 
and L. kituiensis in dose level 300 mg/kg and 500 mg/kg. The observed a decrease in total 
protein in tested rats compared to controls might be due to liver and kidney malfunction 
because of this extract, so the organs failed to produce the required amount of protein (Burtis 
et al., 2008). This is also confirmed with slides that show abnormality in liver cells and kidney 
glomeruli that may hinder protein synthesis and elimination (Ozer et al., 2008; Burtis et al., 
2008; Yaqub et al., 2013). 
Glucose level is another parameter measured; the significant increase was observed in rats 
treated with chloroform, ethyl acetate and methanolic extract of C. metuliferus and L. kituiensis 
in treatment dose 300 mg/kg and 500 mg/kg body weight. The increase in glucose level in the 
blood signifies that the extract had an influence on the metabolism of carbohydrates into 
glucose. Glucose level increases are normally observed in animals that are suffering from 
impairment of pancreas function that leads to the production of inadequate or dysfunctional 
insulin. In this study, the extracts reduce the ability of insulin to act on peripheral tissues like 
skeletal, adipose and liver tissues (Goji et al., 2009). The result of this study is consistent with 
the findings reported by Pieme (2006). 
Bilirubin is a yellow pigment that is produced after the breakdown of the erythrocyte 
hemoglobin in the liver resulting in protein separating into globin and heme, heme is further 
broken to biliverdin that is reduced into bilirubin, this occurs in the reticular endothelial system 
of the liver, spleen and bone marrow (Kakadiya, 2009). The result revealed significant 
increases in rats treated with C. metuliferus and L. kituiensis in dose level 300 mg/kg and 500 
mg/kg body weight. Elevated bilirubin levels are an indication of distorted liver functions and 
a small elevation is an important indicator of liver damage in laboratory animals or could be a 
sign of biliary duct obstruction. In order to assess the synthetic capacity of the liver, 
determination of plasma proteins like albumin is required and decrease in plasma proteins, 
therefore, tend to reflect chronic damage (Burtis et al., 2008).  
Histopathological studies provide supportive evidence for biochemical and hematological 
observations. The above-mentioned biochemical investigations were in correlation with the 
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histopathological studies. Liver section of rats administered with 300 mg/kg and 500 mg/kg 
body weight of chloroform, ethyl acetate and methanolic extracts revealed inflammation, 
necrosis, and duct hyperplasia in the portal triad, moderate hepatic necrosis, and portal 
congestion in both plants. And kidney section of rats administered with 300 mg/kg and 500 
mg/kg body weight revealed that shrinkage of glomerula, inflammations, degeneration of 
tubular cells and distraction of glomeruli were observed indicating that C. metuliferus and L. 
kituiensis extract causes kidney damage. However, animals in the control group had intact 
hepatocytes, portal vein, glomeruli and intact tubules. The occurrence of lymphocytic 
infiltration in organs has been attributed to the presence of glycosides as reported by Adedapo 
(2003). The result of this study is consistent with the findings of Builders (2012) who 
investigated the toxicity of Parkiabiglobosa stem bark extracts in rats. 
The lungs of the rats treated with chloroform, ethyl acetate and methanolic extract of C. 
metuliferus at a dose of 300 mg/kg and 500 mg/kg revealed thickened alveolar wall and narrow 
respiratory ducts and congestion. While rats treated with chloroform, ethyl acetate and 
methanolic extract L. kituiensis at a dose of 300 mg/kg and 500 mg/kg showed thickened 
alveolar wall and narrow respiratory ducts and hemorrhage as compared to control. While the 
micrograph for histological sections of the spleen showed normal, red and white pulp 
appearance with the appearance of extramedullary hemopoiesis in male and female spleen of 
C. metuliferus and L. kituiensis, this may indicate damage of spleen as compared to control. 
The result of this study is consistent with the findings of Pudoe et al. (2010). It was reported 
that the toxicity of some of the herbal medications might be a result of phytochemical 
constituents. Muhammad et al. (2015). It also reported that a large intake of tannins may cause 
kidney and liver damage (Kifayatullah et al., 2015). 
5.5 Conclusion 
The result from this chapter describes the adverse effects or safety of a substance that result 
either from a single exposure or multiple exposures in a short space of time. The results 
obtained in the acute toxicity test showed fluctuations in organ weight over the 14 days of 
survival observation period this maybe suggestive of chronic toxicity. In sub acute study the 
plants showed severe toxic to animals. The study suggest isolation of pure compound should 
be taken as a promising alternative for exploring therapeutic and pharmaceutical interest of C. 




CONCLUSION AND RECOMMENDATIONS 
6.1 General discussion 
This chapter presents the concluding remarks from the obtained findings, research contribution, 
and future research directions. The aim of this study was to evaluate antimalarial activity two 
medicinal plants namely C. metuliferus and L. kituiensis used traditionally to treat malaria in 
Tanzania. Furthermore, the study provided scientific evidence of the efficacy of these plants 
through in vivo-Acute and Sub-acute toxicity in an animal model, that all plant materials 
entailed for medical purposes should be thoroughly tested for their efficacy and safety before 
being approved for human consumption. Additionally, this study established the volatile 
phytochemicals present in the C. metuliferus and L. kituiensis leaf extract. The major findings, 
outcomes and recommendations are summarized in this chapter. 
The results of this study showed that the leaves of C. metuliferus and L. kituiensis possess 
highly antimalarial activity. Comparatively, the extracts of C. metuliferus exhibited higher 
antimalarial activity than extracts of L. kituiensis. This result has established the rationale for 
the traditional use of the plants in the treatment of malaria and showed that medicinal plants 
which have reputations for antimalarial properties can be screened to ascertain their efficacy 
and determine their potentials as sources of new antimalarial drugs. 
The phytochemical screening of methanolic, chloroform and ethyl acetate of C. metuliferus and 
L. kituiensis showed the presence of steroids, alkaloids, flavonoids, tannins, glycosides, amino 
acids, and phenol compounds. The gas chromatography-mass spectroscopy result revealed the 
presence of  11 major compound  namely Cyclotrisiloxanehexamethyl; Z-Z-6, 28-
Heptatriactontadien-2-one; D-Manitol, 1, 1, 1’-o-1,16-hexadecanediylbis; Trans, CIS-1, 8-
Dimethylspiro(4, 5)-Decane and  L-(+)-Ascorbic acid 2, 6-dihexadecanoate, 3, 7, 11, 15- 
Tetramethyl-2-Hexadecen-1-ol; Oleyl alcohol tri fluoroacetate; 1-Pentatriacontanol; N-propyl 
11-octadecenoate, fucosterol, Artemiseole compound and other usefully compound. It is 
thereforepossible that the antimalarial effects observed may be attributed by these compounds 
observed. The antimalarial effects produced by crude extracts of both experimental plants 




Extracts of C. metuliferus and L. kituiensis have been found to be toxic and therefore not safe 
for malaria therapy and perhaps for the treatment of other ailments. The acute administration 
of C. metuliferus and L. kituiensis at the three dose levels showed fluctuations in organ weight 
over the 14 days of survival observation period, this be suggestive that the intake of high doses 
of this plant’s extracts may exhibit organs toxicity in Swiss albino mice. In sub acute study all 
experimental rats were alive and normal for all 28 days of experimentation period. No mortality 
or signs of toxicity were observed. However, at a dose of 300 mg/kg and 500 mg/kg C. 
metuliferus and L. kituiensis caused elevation of body weight, organ weight, hematology, 
biochemical parameters and histopathological changes in target organs of toxicity (liver, 
kidney, lungs and spleen). These plants can cause severe toxic to animals. 
6.2 Conclusion 
Malaria is a major public health problem that presently is complicated by the increasing 
resistance of P. falciparum against the current drugs. This has necessitated the search for novel 
antimalarial agents that have a unique mechanism of action. As a result, a number of medicinal 
plants have been screened for antimalarial activity. In this study, extracts from C. metuliferus 
and L. kituiensis have been established to exhibit antimalarial activity against plasmodium 
berghei. The medicinal properties of L. kituiensis and C. metuliferus observed might therefore 
due to the presence of these groups of phytochemicals. Additionally, the studies provide strong 
evidence that the plant can cause severe toxicity to heath tissue. 
6.3 Recommendations 
Based on these findings the following recommendations are considered: 
(i) Isolation and characterization of antimalarial compounds are recommended in order to 
provide a stepping-stone for further detailed study and development of antimalarial herbal 
products.  
(ii)  The study suggests further pharmacological studies should be carried out in order to 
characterize secondary metabolites with toxic properties for the purpose of suppressing 
toxicity effect.  
(iii)  A similar research work should be conducted on toxicity using extracts of the same 
experimental plants, involving more animal models over a longer period of time to 
determine the safety of these plants.  
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(iv) The study also recommends for evaluation of antioxidants and anticancer compounds. 
(v) Since medicinal plants have been used as alternative drugs for the management of 
malarial, plants have been over-exploited, thus increasing risks of their extinction. 
Therefore, appropriate strategic plans on the proper utilization of medicinal plants should 
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